classic
mannich
reaction
threecompon
condens
structur
divers
substrat
xeh
contain
least
one
activ
hydrogen
atom
aldehyd
compon
gener
r
cho
amin
reagent
lead
class
compound
gener
known
mannich
base
scheme
mannich
base
may
regard
deriv
substrat
obtain
substitut
aminoalkyl
moieti
mannich
reaction
also
known
aminoalkyl
reaction
particular
instanc
formaldehyd
employ
aldehyd
compon
substrat
convert
correspond
mannich
base
aminomethyl
process
although
primari
amin
even
ammonia
form
ammonium
salt
may
employ
amin
reagent
aminomethyl
aminoalkyl
secondari
aliphat
amin
r
nh
commonli
encount
amin
reagent
mannich
reaction
formaldehyd
use
great
extent
aldehyd
compon
mannich
reaction
structur
divers
mannich
base
stem
primarili
miscellan
type
substrat
subject
aminomethyl
secondarili
varieti
amin
reagent
potenti
employ
mannich
reaction
regardless
structur
divers
substrat
activ
function
group
crucial
structur
featur
requir
render
substrat
activ
mannich
reaction
carbonyl
function
keton
phenol
hydroxyl
phenol
termin
carbonecarbon
tripl
bond
alkyn
heteroatom
heterocycl
electronwithdraw
group
substitut
carbon
atom
carboxyl
group
ester
aliphat
carboxyl
acid
common
exampl
pair
activ
group
correspond
substrat
list
far
exhaust
gener
classif
common
type
mannich
base
respect
substrat
deriv
natur
atom
substitut
aminomethyl
function
given
fig
normal
reaction
condit
substitut
substrat
singl
aminomethyl
function
result
monomannich
base
two
aminomethyl
group
may
also
graft
onto
substrat
contain
one
activ
hydrogen
atom
lead
doubl
mannich
base
deriv
dialkyl
keton
alkyl
aryl
keton
phenol
pyrrol
respect
fig
also
aminomethyl
substrat
xeh
amin
reagent
secondari
amin
ammonia
three
reactiv
hydrogen
atom
nitrogen
primari
amin
renh
two
reactiv
hydrogen
atom
nitrogen
may
lead
trismannich
base
bismannich
base
respect
fig
addit
capabl
polyfunct
substrat
aminomethyl
chemoselect
singl
potenti
reaction
site
appropri
reaction
condit
aminomethyl
indiscrimin
multipl
reaction
site
even
undergo
aminomethyl
simultan
ring
closur
contribut
consider
structur
varieti
result
mannich
base
two
excel
albeit
rather
old
review
provid
detail
synthesi
reaction
mannich
base
interest
reader
mannich
base
found
numer
practic
applic
treatment
natur
macromolecular
materi
leather
paper
textil
product
synthet
polym
addit
use
petroleum
industri
product
use
water
treatment
analyt
reagent
cosmet
dye
etc
nonetheless
import
applic
mannich
reaction
lie
field
medicin
chemistri
claim
support
substanti
number
paper
publish
topic
everi
year
first
mannich
base
could
present
interest
biolog
activ
mani
yet
discov
dilig
screen
process
second
aminomethyl
drug
could
use
improv
deliveri
human
bodi
aminomethyl
may
increas
hydrophil
properti
drug
introduct
polar
function
structur
longknown
rolicyclin
one
common
exampl
solubl
water
drug
could
enhanc
quatern
nitrogen
atom
aminomethyl
deriv
convers
ammonium
salt
altern
lipophil
properti
drug
could
tailor
mannich
reaction
appropri
amin
reagent
employ
addit
aminomethyl
drug
could
act
prodrug
releas
activ
substanc
control
hydrolyt
condit
via
deaminomethyl
deamin
spite
tremend
potenti
mannich
base
medicin
chemistri
wealth
inform
studi
concern
structureeact
relationship
sar
involv
mannich
base
use
aminomethyl
drug
prodrug
appear
inspir
mani
recent
literatur
review
consequ
best
knowledg
present
review
fill
void
provid
comprehens
coverag
relev
develop
medicin
chemistri
mannich
base
gener
exclus
aminomethyl
inform
order
accord
report
biolog
activ
due
larg
number
articl
publish
topic
coverag
review
limit
last
decad
anticanc
properti
cytotox
keton
mannich
base
emphasi
mannich
base
type
deriv
acetophenon
structur
relat
bunsatur
keton
review
year
ago
two
group
compound
shown
exert
cytotox
action
alkyl
cellular
thiol
glutathion
cystein
may
use
sensit
tumor
cell
antineoplast
agent
even
revers
drug
resist
therefor
surpris
compound
keton
mannich
base
moieti
activ
unsatur
carbonecarbon
doubl
bond
structur
exampl
mannich
base
chalcon
consid
candid
evalu
sequenti
cytotox
theori
theori
hypothes
success
releas
two
cytotox
agent
result
increas
toxic
malign
tissu
rather
normal
cell
addit
mannich
base
enon
easili
access
alkyl
aryl
keton
one
synthet
step
also
demonstr
mark
toxic
toward
numer
cancer
cell
line
furthermor
orthophenol
mannich
base
undergo
deamin
easili
yield
orthoquinon
methid
mannich
base
chalcon
deriv
either
phenol
aldehyd
keton
class
compound
structur
prototyp
examin
also
cytotox
agent
last
decad
quest
potent
anticanc
agent
amongst
four
gener
type
cytotox
mannich
base
fig
steadili
continu
cytotox
keton
mannich
base
type
variou
substitut
pattern
aromat
ring
type
deriv
studi
detail
gul
et
al
shown
structur
modif
singl
mannich
base
r
r
h
deriv
acetophenon
secondari
aliphat
amin
doubl
mannich
base
fig
gener
result
increas
cytotox
mous
renal
carcinoma
renca
transform
human
tlymphocyt
jurkat
cell
line
extent
doubl
mannich
base
cytotox
refer
drug
melphalan
cytotox
singl
doubl
mannich
base
respect
revers
compound
use
brine
shrimp
bioassay
presum
due
fast
deamin
doubl
mannich
base
could
reach
target
also
keton
mannich
base
dimethylamino
amin
moieti
featur
either
unsubstitut
various
monosubstitut
phenyl
ring
thiophen
ring
evalu
respect
cytotox
toward
jurkat
cell
androgenindepend
prostat
cancer
cell
cytotox
compound
higher
standard
addit
mannich
base
type
deriv
shown
display
moder
cytotox
properti
toward
murin
cell
well
human
molt
cem
tlymphocyt
number
compound
possess
remark
potenc
toward
seven
human
colon
cancer
cell
line
use
primari
aliphat
amin
mannich
reaction
lead
reaction
product
divers
structur
fig
aminomethyl
acetophenon
use
methylamin
amin
reagent
afford
bismannich
base
r
ch
piperidinol
r
ch
evalu
cytotox
toward
jurkat
cell
show
bismannich
base
gener
potent
correspond
piperidinol
monomannich
base
besid
abil
alkyl
cellular
glutathion
compound
r
ch
may
exert
cytotox
action
inhibit
dna
topoisomeras
correspond
piperidinol
gener
devoid
dna
topoisomeras
inhibitori
action
author
tent
attribut
activ
bismannich
base
linear
structur
possibl
format
hydrogen
bond
dna
nucleotid
hand
aminomethyl
acetophenon
use
isopropylamin
nbutylamin
amin
reagent
yield
secondari
monomannich
base
r
ch
ch
ch
ch
whose
cytotox
evalu
hepatoma
cell
human
jurkat
rat
skelet
muscl
deriv
myoblast
cell
compar
refer
drug
compound
cytotox
toward
hepatoma
cell
cytotox
toward
human
jurkat
cell
cytotox
toward
cell
aminomethyl
acetophenon
use
phenethylamin
amin
reagent
could
led
care
control
reaction
condit
either
monomannich
base
r
ch
ch
c
h
correspond
piperidinol
r
ch
ch
c
h
cytotox
compound
toward
androgenindepend
prostat
cancer
cell
rang
mm
wherea
best
compound
seri
averag
valu
dna
topoisomeras
interfer
approxim
anticanc
activ
keton
mannich
base
compar
deriv
carbonyl
function
fig
seri
azin
keton
mannich
base
design
bifunct
cytotox
agent
activ
toward
jurkat
cell
cell
less
potent
best
case
equipot
parent
keton
mannich
base
hand
hydrazon
consist
cytotox
correspond
keton
mannich
base
noteworthi
contribut
gul
et
al
understand
mechan
cytotox
action
compound
group
provid
evid
connect
anticanc
activ
keton
mannich
base
variou
structur
piperidinol
abil
alkyl
glutathion
wherea
compound
mix
effect
thioredoxin
glutaredoxin
heat
shock
protein
limit
number
exampl
mannich
base
bunsatur
keton
type
cytotox
action
avail
recent
public
small
seri
mannich
base
fig
evalu
cytotox
agent
use
human
molt
cem
tlymphocyt
well
murin
leukem
cell
compar
parent
bunsatur
keton
mannich
base
consist
potent
half
maxim
inhibitori
concentr
ic
valu
mm
rang
furthermor
mannich
base
deriv
aromat
aldehyd
substitut
chlorin
carboxyl
methoxi
cinnamoyloxi
group
exhibit
signific
potenc
toward
human
tumor
cell
line
emphasi
antileukem
effect
instanc
compound
prepar
studi
demonstr
select
toxic
differ
cell
enhanc
potenti
util
addit
compound
simpler
mannich
base
deriv
synthes
evalu
cell
line
prove
mannich
base
cytotox
correspond
show
growthinhibit
properti
ic
approxim
mm
potent
refer
drug
melphalan
nmyristoyltransferas
express
larger
quantiti
tumor
normal
cell
enzym
consider
molecular
target
cancer
howev
substanti
high
ic
valu
mm
toward
nmyristoyltransferas
repres
compound
seri
candid
suggest
inhibit
enzym
play
import
role
mechan
cytotox
activ
compound
sever
compound
also
test
murin
cancer
cell
sensit
cytotox
agent
resist
cytotox
agent
demonstr
high
cytotox
latter
also
normal
murin
cell
hand
mannich
base
show
activ
point
import
doubl
bond
conjug
carbonyl
function
explor
possibl
mechan
cytotox
action
compound
reveal
compound
may
interfer
number
essenti
cellular
mechan
alkyl
thiol
enzym
protein
disrupt
mitochondri
electron
transport
creat
hole
cell
membran
thu
promot
atp
leakag
final
mannich
base
high
cytotox
activ
two
human
breast
cancer
cell
line
cell
human
leukemia
cell
show
glutathion
bind
abil
exhibit
inhibitori
action
glutathionestransferas
p
wherea
analogu
obtain
hydrogen
doubl
carbonecarbon
bond
slightli
less
activ
natur
dialkylamino
group
seem
affect
cytotox
activ
compound
substitut
aromat
ring
methyl
select
increas
cytotox
effect
breast
cancer
cell
immort
mammari
epitheli
cell
literatur
report
anticanc
activ
mannich
base
type
even
scarcer
given
signific
antineoplast
properti
compound
novel
seri
substitu
r
phenyl
ring
care
select
view
impart
varieti
physicochem
properti
design
synthes
sinc
gradual
releas
mannich
base
niosom
improv
bioactiv
vivo
amino
alcohol
fig
may
slowli
undergo
dehydr
yield
desir
mannich
base
also
examin
cytotox
agent
final
order
explor
hypothesi
cytotox
would
retain
even
thiol
liber
synthesi
adduct
carri
compound
fig
evalu
human
widr
colon
cancer
cell
human
foreskin
fibroblast
ic
valu
lesser
mm
obtain
compound
evalu
toward
human
widr
colon
cancer
cell
correspond
candid
also
ic
valu
low
micromolar
rang
hand
convers
mannich
base
correspond
adduct
led
reduct
potenc
addit
compound
demonstr
preferenti
cytotox
cancer
cell
compar
normal
fibroblast
studi
show
compound
cytotox
toward
larg
number
human
tumor
cell
line
two
import
featur
mani
compound
lethal
effect
toward
promyelocyt
leukem
cell
select
toxic
aforement
cancer
cell
line
select
index
diverg
mechan
action
requir
drug
candid
develop
tumorspecif
spare
normal
tissu
noteworthi
repres
mannich
base
caus
apoptosi
activ
cell
cell
cytotox
phenol
mannich
base
chalcon
analogu
type
fig
well
repres
recent
literatur
one
strategi
avail
synthesi
type
mannich
base
consist
aminomethyl
chalcon
analogu
deriv
least
either
phenol
aldehyd
phenol
keton
line
strategi
seri
five
monomannich
base
fig
obtain
mannich
reaction
chalcon
analogu
deriv
employ
piperidin
amin
reagent
despit
use
excess
paraformaldehyd
piperidin
doubl
mannich
base
analog
isol
evalu
compound
androgeneindepend
prostat
cancer
cell
line
show
although
three
potent
parent
chalcon
analogu
cytotox
mannich
base
less
potent
refer
drug
base
correl
cytotox
hammet
constant
one
hand
cytotox
partit
coeffici
hand
author
hypothes
increas
gener
hydrophob
molecul
would
result
enhanc
cytotox
therefor
novel
seri
mannich
base
design
incorpor
dibenzylaminomethyl
residu
replac
piperidinomethyl
group
everi
attempt
obtain
doubl
mannich
base
vari
reaction
condit
fail
monomannich
base
could
isol
evalu
androgeneindepend
prostat
cancer
cell
line
compound
consist
display
lower
cytotox
parent
chalcon
analogu
unexpectedli
cytotox
seri
mannich
base
dibenzylaminomethyl
residu
also
much
lower
correspond
mannich
base
seri
contain
piperidinomethyl
motif
thu
invalid
hypothesi
put
forth
author
previou
studi
furthermor
adduct
ethanethiol
repres
mannich
base
could
detect
h
wherea
incub
ethanethiol
correspond
parent
chalcon
analogu
condit
result
format
small
amount
adduct
author
conclud
activ
cyclohexadienon
speci
form
follow
potenti
deamin
mannich
base
introduct
dibenzylaminomethyl
group
reduc
abil
chalcon
moieti
undergo
thiol
addit
view
explor
effect
variat
dialkylamino
moieti
cytotox
phenol
mannich
base
chalcon
analogu
candid
synthes
aminomethyl
three
chalcon
analogu
deriv
divers
secondari
aliphat
amin
equimolar
ratio
reactant
afford
monomannich
base
type
evalu
hepatocellular
carcinoma
human
lung
carcinoma
human
breast
cancer
cell
line
mannich
base
residu
exhibit
reduc
cytotox
toward
three
line
cancer
cell
wherea
candid
residu
activ
seri
less
cytotox
refer
drug
ellipticin
respect
substitut
pattern
b
phenyl
ring
mannich
base
fig
deriv
r
h
r
cl
r
och
r
h
consist
activ
deriv
r
h
r
och
screen
identifi
five
compound
whose
ic
valu
cell
line
lower
mgml
wherea
cytotox
compound
r
h
r
cl
nr
ic
valu
lower
mgml
three
cancer
cell
line
use
studi
larger
librari
phenol
mannich
base
chalcon
analogu
featur
dialkylaminomethyl
moieti
either
ring
ring
b
chalcon
system
synthes
claiseneschmidt
condens
appropri
substitut
mannich
base
phenol
aldehyd
keton
heterocycl
keton
aldehyd
respect
use
substrat
mannich
reaction
yield
mixtur
deriv
isomer
deriv
former
major
reaction
product
case
adept
tailor
ratio
substrat
formaldehyd
morpholin
mannich
reaction
result
select
prepar
either
singl
doubl
mannich
base
substrat
hand
afford
mixtur
deriv
deriv
morpholinylmethyl
deriv
even
equimolar
ratio
reagent
use
isovanillin
underw
aminomethyl
posit
morpholin
piperidin
amin
reagent
employ
exampl
phenol
aldehyd
substrat
mannich
reaction
help
intermedi
sever
small
seri
mannich
base
heterocycl
chalcon
analogu
fig
synthes
evalu
cytotox
activ
four
human
cancer
cell
line
name
nasopharyng
carcinoma
kb
resist
nasopharyng
carcinoma
kbvin
rich
divers
within
librari
compris
structur
relat
entiti
allow
interest
insight
cytotoxicityestructur
relationship
first
presenc
two
phenol
group
ring
seem
enhanc
cytotox
activ
proven
candid
type
r
h
het
potent
entir
librari
four
type
cancer
cell
line
presenc
methoxi
group
seri
r
ch
appear
gener
prefer
ethoxi
isopropoxi
wherea
comparison
cytotox
similar
compound
type
type
usual
favor
candid
latter
seri
aminomethyl
group
para
phenol
hydroxyl
analysi
cytotox
within
seri
candid
type
demonstr
sixmemb
heterocycl
particularli
residu
prefer
five
member
heterocycl
ring
b
moieti
observ
valid
inspect
anticanc
activ
compound
seri
howev
presenc
second
morpholinylmethyl
group
appear
detriment
cytotox
activ
candid
shuffl
hydroxi
morpholinylmethyl
group
mannich
base
led
compound
seri
gener
less
cytotox
counterpart
deriv
chalcon
analogu
substitu
ring
select
high
cytotox
cell
line
display
compound
seri
featur
morpholinylmethyl
moieti
ring
b
chalcon
system
overal
mannich
base
librari
mannich
base
heterocycl
chalcon
analogu
cytotox
ic
mgml
four
member
librari
highli
cytotox
ic
mgml
four
cell
line
four
least
three
cell
line
usual
sensit
kb
kbvin
cell
line
later
novel
mannich
base
type
ar
evalu
sever
cancer
cell
line
candid
show
cytotox
low
micromolar
rang
toward
promyelocyt
leukem
cell
oral
squamosa
cell
carcinoma
wherea
ic
valu
nonmalign
gingiv
fibroblast
pulp
cell
periodont
ligament
fibroblast
higher
tumor
select
mannich
base
may
result
proven
abil
cleav
poli
adpribos
cell
gingiv
fibroblast
cell
addit
cytotox
activ
mannich
base
chalcon
analogu
aminomethyl
moieti
b
ring
structur
similar
panel
breast
cancer
melanoma
renal
cancer
cell
line
describ
patent
compound
activ
potent
mostli
toward
first
two
cancer
cell
line
seri
mannich
base
bichalcon
analogu
fig
two
chalcon
unit
link
bi
aminomethyl
function
gener
use
bifunct
amin
reagent
piperazin
also
synthes
evalu
cancer
cell
line
aminomethyl
acetovanillon
piperazin
afford
bismannich
base
subsequ
led
compound
claiseneschmidt
condens
variou
aldehyd
surprisingli
compound
ar
select
cytotox
human
tongu
squamou
carcinoma
human
pharyng
squamou
carcinoma
fadu
cell
line
wherea
phenyl
analogu
cytotox
compound
toward
cell
line
substitut
phenyl
ring
ar
c
h
methoxi
group
strip
mannich
base
cytotox
toward
cell
line
wherea
decreas
cytotox
activ
induc
presenc
chlorin
substitu
drastic
replac
phenyl
led
compound
select
cytotox
one
cell
line
substitut
methyl
fivememb
heterocycl
render
devoid
cytotox
line
despit
notabl
exampl
select
result
obtain
collect
compound
encourag
suggest
incorpor
second
chalcon
unit
enhanc
cytotox
mannich
base
deriv
chalcon
analogu
cytotox
activ
mannich
base
bichalcon
analogu
explor
use
candid
modifi
design
synthet
strategi
compris
synthesi
monophenol
mannich
base
start
acetovanillon
substrat
employ
phenyl
ethanon
amin
reagent
bichalcon
unit
gener
claiseneschmidt
condens
acetyl
function
aromat
aldehyd
mannich
base
bichalcon
analogu
featur
pyridinyl
moieti
candid
fig
activ
toward
prostat
cancer
nonsmal
cell
lung
cancer
ileocec
hct
nasopharyng
carcinoma
kb
cell
line
ic
valu
mm
compound
ic
valu
greater
mm
compar
compound
mannich
base
singl
chalcon
unit
less
activ
ic
mm
explor
mechan
action
compound
suggest
compound
like
act
via
apoptosi
signal
pathway
ferul
acid
deriv
provid
anoth
exampl
type
substrat
contain
bunsatur
system
activ
electronwithdraw
group
similar
phenol
chalcon
analogu
phenol
mannich
base
synthes
grow
bodi
evid
suggest
deoxythymidin
azt
known
antivir
also
possess
anticanc
activ
spark
studi
aim
cytotox
evalu
seri
conjug
azt
ferul
acid
deriv
thu
propargyl
ester
npropargylamid
ferul
acid
chemoselect
underw
aminomethyl
ortho
phenol
hydroxyl
variou
secondari
aliphat
amin
result
phenol
mannich
base
x
nh
react
termin
alkyn
moieti
azt
via
cu
catalyz
click
chemistri
process
afford
correspond
evalu
cytotox
mannich
base
fig
relat
human
breast
adenocarcinoma
lung
adenocarcinoma
colon
adenocarcinoma
cell
line
show
compound
cytotox
despit
presenc
structur
ident
scaffold
compris
phenol
mannich
base
moieti
activ
carbonecarbon
doubl
bond
motif
deem
respons
cytotox
effect
mannich
base
correspond
inact
eight
mannich
base
propargyl
ester
ferul
acid
report
studi
three
inact
three
line
rest
weak
moder
cytotox
activ
candid
ic
mgml
mannich
base
x
pyrrolidinylmethyl
moieti
except
mannich
base
x
nh
piperidinylmethyl
moieti
other
candid
deriv
npropargylamid
ferul
acid
inact
aminomethyl
phenol
cytotox
activ
report
besid
phenol
mannich
base
chalcon
analogu
unfortun
wide
structur
divers
phenol
substrat
phenol
mannich
base
origin
lack
systemat
comprehens
search
structureecytotox
activ
relationship
within
particular
type
phenol
substrat
undermin
effort
discov
good
lead
compound
develop
drug
phenol
substrat
subject
mannich
reaction
view
obtain
novel
cytotox
agent
includ
simpl
complex
structur
exampl
illustr
structur
simpl
phenol
substrat
whose
mannich
base
piperidin
exhibit
growthinhibitori
effect
toward
panel
carcinoma
cell
line
includ
hela
cervic
epithelioid
carcinoma
cell
mammari
gland
adenocarcinoma
cell
skhep
hepatocellular
carcinoma
cell
esophag
carcinoma
cell
although
cytotox
effect
aminomethyl
naphthol
deriv
known
time
mechanist
studi
present
aforement
report
show
phenol
mannich
base
induc
apoptosi
activ
caspasedepend
pathway
furthermor
upon
addit
copper
ion
compound
dramat
stimul
product
reactiv
oxygen
speci
activ
variou
kinas
group
enzym
known
import
oxid
stressmedi
cell
death
candid
fig
potent
small
seri
concentr
cell
growth
inhibit
mm
valu
decreas
mm
presenc
mm
copper
detail
studi
structureecytotox
activ
relationship
within
class
compound
show
either
replac
sulfonyl
function
methylen
group
replac
piperazin
ring
ethylenediamino
moieti
compound
fig
led
signific
increas
cytotox
activ
cell
line
use
studi
exhibit
select
sensit
toward
differ
mannich
base
appear
modul
natur
arylsulfonyl
group
part
molecul
substitut
posit
quinolin
motif
especi
nitro
group
benefici
effect
wherea
replac
phenol
led
decreas
cytotox
activ
cytotox
enantiomericallyenrich
mannich
base
fig
deriv
aromat
aldehyd
either
r
h
acetyl
counterpart
r
coch
murin
leukem
human
lymphoblast
molt
cem
cell
line
examin
anoth
studi
compound
moder
cytotox
ic
valu
middl
micromolar
rang
also
less
potent
refer
drug
melphalan
substitut
aryl
group
r
result
seri
compound
whose
cytotox
potenti
estrogenrespons
human
breast
cancer
cell
found
compar
tamoxifen
howev
remov
moieti
mannich
base
led
benzylnaphthol
enhanc
cytotox
cell
like
due
bind
antagonist
effect
human
estrogen
receptor
alpha
flavon
repres
anoth
type
phenol
substrat
cytotox
mannich
base
synthes
flavon
chrysin
bear
structur
resembl
androgen
mannich
base
fig
design
inhibitor
human
aromatas
enzym
convert
androgen
estrogen
therefor
repres
key
target
treatment
hormonedepend
tumor
includ
breast
cancer
sever
singl
doubl
mannich
base
chrysin
found
inhibit
human
aromatas
effect
refer
drug
aminoglutethimid
addit
mannich
base
r
oh
r
h
r
aminomethyl
apigenin
fig
prepar
aliphat
primari
secondari
amin
via
chemoselect
aminomethyl
benzopyran
ring
system
antiprolif
activ
mannich
base
four
human
cancer
cell
line
name
human
cervic
hela
human
liver
human
lung
human
breast
cancer
cell
determin
use
standard
bromid
mtt
assay
pyrrolidin
mannich
base
apigenin
promis
compound
seri
inhibit
cell
prolifer
greater
four
cell
line
concentr
mgml
mani
natur
synthet
carbazol
either
simpl
condens
heterocycl
pyridocarbazol
indolocarbazol
pyranocarbazol
pyrrolocarbazol
etc
report
anticanc
agent
recent
studi
examin
cytotox
seri
oxazinocarbazol
major
product
aris
mannich
reaction
nsubstitut
primari
amin
fig
appropri
reaction
condit
yield
oxazino
c
carbazol
wherea
led
mixtur
regioisomer
oxazino
carbazol
oxazino
carbazol
use
allylamin
benzylamin
amin
reagent
afford
major
product
isom
major
compon
mixtur
employ
addit
small
moder
yield
bismannich
base
isol
nsubstitut
respect
employ
amin
reagent
evalu
antiprolif
action
compound
cem
cell
leukemia
jurkat
acut
cell
leukemia
raji
burkitt
lymphoma
breast
cancer
cell
colorect
cancer
use
colorimetr
assay
show
primari
screen
mm
bismannich
base
less
activ
oxazinocarbazol
seri
compound
best
antiprolif
effect
observ
candid
either
allyl
prenyl
group
carbazol
nitrogen
atom
allyl
group
oxazin
nitrogen
atom
thu
jurkat
raji
cell
line
major
candid
exhibit
signific
antiprolif
action
mm
compound
r
activ
toward
jurkat
raji
cell
line
ic
mm
aminomethyl
deriv
hydroxycarbazol
also
mention
differ
studi
describ
synthesi
small
seri
phenol
mannich
base
fig
obtain
b
along
vitro
anticanc
evalu
nation
cancer
institut
nci
use
inhous
develop
screen
panel
approxim
cell
line
deriv
nine
differ
type
cancer
one
mannich
base
r
coc
h
activ
parent
benzocarbazoledion
compar
analysi
reveal
mechan
action
novel
resembl
known
mechan
action
standard
anticanc
drug
candid
select
studi
concern
interact
dna
relat
report
phenol
mannich
base
indol
found
inact
similar
screen
quinon
class
compound
wide
investig
anticanc
agent
besid
anthracyclin
antibiot
natur
hydroxyquinon
plumbagin
juglon
lapachol
deriv
report
exhibit
signific
cytotox
mannich
base
anoth
natur
phenol
quinon
name
lawson
pt
ii
complex
fig
synthes
shown
highli
cytotox
toward
six
cancer
cell
line
melanoma
promyelocyt
leukemia
colon
brain
ovari
prostat
ligand
complex
long
alkyl
chain
r
nheptyl
ndecyl
activ
complex
actual
cytotox
cisplatin
wherea
neutral
complex
x
cl
gener
cytotox
correspond
charg
complex
x
h
nh
examin
mechan
action
complex
shown
aqua
complex
effici
inhibitor
ethidium
bromid
intercal
dna
amino
complex
candid
r
ch
ch
x
h
effici
cisplatin
aqua
complex
also
induc
dna
strand
break
correspond
amino
complex
ineffect
abil
complex
inhibit
topoisomeras
also
examin
chlorido
amino
complex
activ
refer
drug
camptothecin
dna
relax
assay
caus
major
unwind
dna
except
complex
r
ndecyl
x
cl
addit
cellular
platinum
accumul
shown
increas
increas
length
alkyl
chain
amino
moieti
mannich
base
ligand
chlorido
pt
ii
complex
oxid
correspond
chlorido
pt
iv
complex
cytotox
new
complex
compar
cytotox
parent
pt
ii
complex
presum
owe
rapid
reduct
pt
iv
complex
enter
cancer
cell
furthermor
miscellan
aminomethyl
phenol
structur
divers
substrat
report
anticanc
agent
fig
thu
small
seri
seven
phenol
mannich
base
synthes
aminomethyl
natur
occur
antibiot
lasalocid
simultan
elimin
carboxyl
group
neighbor
phenol
hydroxyl
antiprolif
effect
mannich
base
evalu
human
breast
adenocarcinoma
human
lung
adenocarcinoma
human
colon
carcinoma
murin
leukemia
use
either
mtt
sulforhodamin
b
srb
assay
four
candid
cytotox
toward
cell
line
anticanc
drug
cisplatin
candid
also
present
higher
select
toward
cancer
cell
toward
normal
murin
embryon
fibroblast
hlmec
human
lung
microvascular
endotheli
cell
line
lack
activ
three
mannich
base
attribut
aralkyl
long
alkyl
chain
amin
moieti
compound
camptothecin
anoth
natur
occur
phenol
substrat
lead
compound
plethora
cytotox
substanc
convert
oxazino
deriv
fig
mean
mannich
reaction
use
primari
aliphat
aromat
amin
evalu
novel
hexacycl
camptothecin
deriv
toward
nine
human
cancer
cell
line
kb
use
mtt
assay
camptothecin
topotecan
refer
compound
show
exhibit
cytotox
toward
sever
cell
line
superior
compar
topotecan
candid
present
cytotox
compar
camptothecin
candid
r
c
h
nc
h
potent
antiprolif
agent
seri
presenc
small
alkyl
group
nitrogen
oxazin
moieti
seem
prefer
high
cytotox
seri
oxazino
deriv
r
ch
fig
also
prepar
gtocotrienol
primari
amin
via
mannich
reaction
wherea
dtocotrienol
afford
condit
mixtur
oxazino
deriv
r
h
former
major
compon
reaction
occur
secondari
amin
use
instead
two
phenol
mannich
base
obtain
indirectli
correspond
oxazino
deriv
candid
librari
thirti
compound
greater
antiprolif
activ
highli
metastat
sa
mous
mammari
epitheli
cancer
cell
parent
tocotrienol
ic
mm
seven
candid
ic
valu
nanomolar
rang
mannich
base
less
activ
correspond
oxazino
deriv
nci
standard
panel
cell
line
suggest
oxazin
ring
essenti
pharmacophor
cytotox
activ
tocotrienol
deriv
gener
oxazino
deriv
dtocotrienol
activ
correspond
isom
deriv
gtocotrienol
long
alkyl
chain
nitrogen
atom
prefer
termin
hydroxyl
group
prove
benefici
antiprolif
activ
conclus
drawn
evalu
structureeantimigratori
activ
relationship
use
highli
metastat
breast
cancer
cell
line
novel
gquadruplex
ligandalkyl
hybrid
structur
fig
obtain
tether
naphthalen
diimid
core
gquadruplex
recogn
properti
phenol
mannich
base
use
flexibl
spacer
assess
cytotox
effect
compound
n
correspond
methiodid
human
embryon
kidney
cell
line
mtt
assay
suggest
length
spacer
core
phenol
mannich
base
moieti
modul
cytotox
candid
twocarbon
atom
onecarbon
atom
spacer
activ
ic
mm
respect
wherea
mannich
base
threecarbon
atom
spacer
less
activ
cytotox
compound
parallel
abil
alkyl
dna
graft
alkyl
mannich
base
moieti
central
core
contribut
enhanc
gquadruplex
fold
induct
stabil
similar
gquadruplex
ligandalkyl
hybrid
structur
shown
significantli
slow
growth
melanoma
cell
caus
telomer
dysfunct
downregul
telomeras
express
suggest
hybrid
could
possibl
candid
develop
novel
target
anticanc
therapi
connect
methiodid
doubl
mannich
base
fig
quinazolin
core
also
shown
crosslink
linear
dna
concentr
low
mm
inhibit
dna
transcript
almost
complet
mm
phenol
mannich
base
norvisnagin
fig
prepar
direct
aminomethyl
abil
interact
dna
evalu
use
qualit
bind
assay
colorimetr
microassay
base
displac
methyl
green
dna
three
candid
r
diethylamino
methylamino
show
moder
dna
bind
affin
could
potenti
cytotox
also
mannich
base
r
h
fig
display
moder
good
cytotox
lung
cancer
tongu
squamosa
cell
carcinoma
liver
cancer
hepatocarcinoma
gastric
carcinoma
urinari
bladder
carcinoma
mtt
assay
sever
report
mannich
base
indol
cytotox
agent
also
avail
recent
literatur
cytotox
indol
mannich
base
deriv
piperazin
fig
evalu
liver
breast
colon
cancer
cell
line
use
srb
assay
compound
ic
valu
lower
micromolar
rang
compound
r
cytotox
toward
three
cancer
cell
line
fare
better
refer
drug
hand
nmannich
base
inhibit
growth
cancer
cell
high
ic
valu
spite
fact
subsequ
studi
dedic
exclus
investig
cytotox
novel
seri
nmannich
base
type
cancer
cell
line
broaden
natur
substitu
posit
piperazin
prove
favor
sever
compound
report
later
studi
present
cytotox
activ
compar
refer
drug
comparison
morpholog
featur
cancer
cell
apoptosi
induc
either
select
nmannich
base
paclitaxel
suggest
compound
r
ch
paclitaxel
share
mechan
action
design
novel
cytotox
mannich
base
indol
substrat
aminomethyl
also
revisit
use
extend
panel
piperazin
amin
reagent
aminomethyl
novel
candid
prove
cytotox
toward
cancer
cell
line
howev
cytotox
observ
candid
electronwithdraw
group
benzoyl
acetyl
substitu
posit
piperazin
cmannich
base
indol
deriv
claim
potent
inhibitor
isoprenylcystein
carboxyl
methyltransferas
imct
enzym
play
import
role
posttransl
modif
protein
involv
regul
cell
growth
therefor
repres
potenti
therapeut
target
oncogenesi
among
small
molecul
inhibitor
imct
discov
far
promis
appear
cysmethynil
deriv
impair
growth
factor
signal
induc
cell
cycl
arrest
autophagi
cysmethynil
suffer
poor
water
solubl
strong
bind
plasma
protein
ration
modif
hit
compound
expect
yield
potent
imct
inhibitor
improv
bioavail
replac
acetamid
function
cysmethynil
variou
aminomethyl
moieti
led
compound
r
dialkylamino
inhibitori
effect
icmt
gener
potent
parent
inhibitor
evalu
effect
candid
viabil
human
breast
cancer
cell
use
colorimetr
tetrazolium
assay
confirm
result
icmt
inhibit
thu
compound
fig
found
cytotox
ic
mm
cysmethynil
ic
mm
modif
lead
compound
r
diethylamino
either
preserv
potenc
candid
eg
shuffl
methyl
group
phenyl
ring
result
potenc
decreas
eg
replac
noctyl
prenyl
howev
replac
mtolyl
moieti
polar
heteroaromat
ring
led
submicromolar
ic
valu
icmt
inhibit
assay
ic
valu
antiprolif
assay
breast
prostat
cell
line
lower
fig
cytotox
indol
azaindol
mannich
base
lead
r
diethylamino
compound
fig
potent
compound
seri
present
seri
improv
druglik
profil
cysmethynil
good
solubl
water
accept
permeabl
artifici
membran
limit
tendenc
form
light
scatter
aggreg
use
naphtho
scaffold
seri
deriv
synthes
four
candid
evalu
antiprolif
agent
standard
panel
human
cancer
cell
line
nci
compound
r
primari
secondari
aliphat
amin
residu
r
oh
fig
less
potent
doxorubicin
cell
line
multidrug
resist
breast
cancer
cell
found
sensit
doxorubicin
addit
mannich
base
show
potenc
cancer
cell
line
otherwis
resist
anticanc
drug
pglycoproteinposit
sublin
leukemia
cell
sublin
colon
carcinoma
cell
line
replac
phenol
hydroxyl
group
r
r
dimethylamino
moieti
led
mix
result
potenc
improv
cell
line
declin
other
sensit
multidrug
resist
breast
cancer
cell
modifi
candid
complet
lost
furthermor
candid
r
r
oh
shown
inhibit
topoisomeras
imedi
relax
dna
suppress
topoisomeras
activ
presum
lead
although
probabl
factor
contribut
cytotox
mannich
base
naphtho
preobrazhenskaya
et
al
also
shown
seri
singl
doubl
mannich
base
r
h
dialkylaminomethyl
maleimid
fig
structur
relat
rebeccamycin
staurosporin
highli
cytotox
toward
cell
line
cytotox
correl
well
abil
either
inhibit
protein
kinas
ca
constrain
activ
multipl
drug
resist
mannich
base
indol
isoster
name
pyrimidin
design
inhibitor
lipid
kinas
modul
activ
downstream
effector
akt
mtor
sinc
consequ
biolog
activ
akt
includ
tumor
progress
prolifer
surviv
growth
invas
angiogenesi
metastasi
repres
attract
target
develop
anticanc
drug
although
aminomethyl
pyrrolopyrimidin
fig
effici
inhibitor
ic
nm
show
good
select
mtor
compound
exhibit
low
cytotox
toward
cancer
cell
addit
analogu
mannich
base
found
even
weaker
inhibitor
lead
compound
isatin
nowaday
well
recogn
privileg
scaffold
design
cytotox
anticanc
compound
sever
isatincontain
substrat
name
isatin
analogu
correspond
imin
deriv
obtain
sulfadiazin
sulfadoxin
trimethoprim
hydrazon
deriv
isoniazid
aminomethyl
use
gatifloxacin
amin
reagent
result
mannich
base
test
nci
standard
panel
cell
line
use
srb
assay
compound
fig
emerg
effici
anticanc
agent
gener
potent
refer
drug
etoposid
cell
line
panel
anoth
librari
mannich
base
deriv
isatin
isatin
schiff
base
evalu
cytotox
effect
three
breast
cancer
cell
line
use
srb
assay
introduct
halogen
substitu
posit
isatin
mannich
base
led
increas
cytotox
modif
isatin
schiff
base
follow
aminomethyl
result
mannich
base
enhanc
cytotox
candid
compound
fig
potent
seri
ic
mm
potent
refer
drug
cisplatin
cytotox
normal
cell
low
far
mechan
action
concern
compound
induc
cell
cycl
arrest
phase
concentr
similar
observ
cell
growth
inhibit
wherea
compound
furthermor
anoth
collect
mannich
base
isatin
imin
gener
either
evalu
human
breast
adenocarcinoma
cell
line
use
srb
assay
cytotox
compound
moder
ic
mm
inferior
doxorubicin
gener
aminomethyl
schiff
base
isatin
deriv
cytotox
counterpart
deriv
compound
fig
potent
collect
ic
mm
cytotox
mannich
base
isatin
also
design
employ
hybrid
isatin
scaffold
gener
substrat
subject
aminomethyl
cytotox
compound
toward
breast
cancer
cell
line
moder
ic
valu
mm
activ
improv
slightli
seri
correspond
thiosemicarbazon
ic
rang
mm
mannich
base
fig
potent
candid
everi
seri
cytotox
cisplatin
preferenti
inhibit
growth
cancer
cell
normal
cell
studi
use
flow
cytometri
also
suggest
compound
induc
cancer
cell
death
apoptosi
besid
isatin
deriv
sever
class
nhazol
aminomethyl
view
synthes
cytotox
mannich
base
appear
prefer
substrat
within
categori
like
owe
straightforward
prepar
start
methyl
salicyl
good
yield
correspond
oxadiazolethion
mannich
base
fig
obtain
three
step
compound
collect
aris
primari
aromat
amin
divers
substitut
aromat
ring
wherea
mannich
base
deriv
secondari
aliphat
amin
poorli
repres
select
candid
seri
initi
evalu
nci
panel
consist
lung
breast
glioblastoma
cancer
cell
line
use
srb
assay
seven
thirteen
mannich
base
either
chlorin
carboxi
group
substitu
aromat
ring
amin
moieti
reduc
growth
cell
line
less
select
standard
line
panel
assay
compound
r
h
r
h
h
present
higher
cytotox
refer
drug
cyclophosphamid
cancer
cell
line
panel
abil
sever
oxadiazolethion
mannich
base
featur
various
substitut
aromat
ring
posit
oxadiazolethion
ring
r
h
r
oh
ch
r
r
cl
inhibit
growth
tumor
vivo
also
investig
tumor
volum
tumor
weight
mice
inject
ehrlich
ascit
carcinoma
cell
reduc
dose
mg
candid
fig
per
kg
bodi
weight
wherea
similar
dose
refer
drug
inhibit
tumor
format
mannich
base
especi
hydroxyl
methyl
chloro
substitu
phenyl
ring
posit
potent
also
count
red
blood
cell
leukocyt
well
hemoglobin
level
restor
almost
normal
valu
mice
treat
mannich
base
aminomethyl
oxadiazolethion
fig
gener
cytotox
colon
carcinoma
less
cytotox
breast
cancer
cell
use
srb
assay
potent
candid
nr
nhc
h
ch
less
cytotox
refer
drug
doxycyclin
cytotox
seri
mannich
base
fig
norharmaneoxadiazolethion
structur
hybrid
evalu
panel
compris
melanoma
breast
ovarian
resist
nciadr
renal
lung
prostat
ovarian
ovcar
colon
cell
line
use
srb
assay
sever
candid
r
h
n
ch
r
isopropylamino
benzylamino
exhibit
broad
spectrum
cytotox
activ
aminomethyl
parent
oxadiazolethion
significantli
enhanc
cytotox
result
mannich
base
compar
correspond
substrat
furthermor
mannich
base
fluoroquinoloneeoxadiazolethion
hybrid
prepar
use
either
secondari
aliphat
amin
substitut
arylamin
amin
reagent
vitro
evalu
cytotox
cancer
cell
use
mtt
assay
show
compound
fig
potent
parent
fluoroquinolon
pefloxacin
also
mannich
base
seri
deriv
aliphat
amin
gener
cytotox
deriv
arylamin
candid
r
n
ch
even
potent
refer
drug
bisantren
could
also
act
substrat
prepar
cytotox
nmannich
base
schiff
base
obtain
substitut
aminomethyl
use
either
morpholin
diphenylamin
afford
mannich
base
fig
whose
cytotox
cell
line
evalu
use
mtt
assay
five
test
candid
mannich
base
morpholin
moieti
potent
diphenylamin
moieti
still
less
cytotox
refer
drug
doxorubicin
eleven
dimethylamin
mannich
base
obtain
aminomethyl
schiff
base
deriv
posit
moieti
origin
fluoroquinolon
ofloxacin
screen
cytotox
murin
leukemia
cell
line
human
leukocytoma
cell
line
mannich
base
fig
gener
cytotox
correspond
parent
schiff
base
candid
hydroxyl
group
aromat
ring
azomethin
function
r
oh
cytotox
compound
seri
ic
valu
rang
mm
mannich
base
thiazolidinon
deriv
also
investig
cytotox
agent
caminomethyl
two
use
secondari
aliphat
amin
afford
mannich
base
x
ch
fig
evalu
colon
breast
cancer
cell
line
srb
assay
cytotox
gener
moder
low
ic
valu
mm
addit
naminomethyl
two
r
cl
och
morpholin
piperidin
various
piperazin
yield
mannich
base
fig
investig
nci
standard
line
panel
use
srb
assay
prove
virtual
inact
growth
inhibit
sensit
cell
line
sever
exampl
pmannich
base
deriv
organ
ester
phosphor
acid
disclos
cytotox
agent
avail
literatur
thu
aaminophosphon
synthes
alkyl
phosphit
r
ch
c
h
nc
h
ic
h
nc
h
fluorinesubstitut
benzaldehyd
cytotox
evalu
prostat
melanoma
epidermoid
carcinoma
breast
cancer
cell
use
mtt
assay
mannich
base
fig
exhibit
low
moder
growth
inhibit
cell
cytotox
toward
cell
gener
greater
natur
fluorin
substitu
appear
influenc
cytotox
candid
fluorin
directli
attach
aromat
ring
potent
trifluoromethyl
substitu
improv
cytotox
increas
length
alkyl
residu
r
initi
phosphit
also
note
pmannich
base
r
ch
c
h
ic
h
fig
prepar
use
thieno
aldehyd
compon
mannich
reaction
dialkyl
phosphit
various
substitut
arylamin
major
candid
show
good
cytotox
esophag
cancer
cell
gener
potent
hepatocellular
liver
carcinoma
cell
concentr
mgml
aaminophosphon
fig
obtain
mannichtyp
process
diphenyl
phosphit
various
substitut
anilin
prove
cytotox
hepg
liver
carcinoma
cell
line
ic
mm
breast
adenocarcinoma
cell
line
ic
mm
use
mtt
assay
although
candid
approxim
less
cytotox
refer
drug
doxorubicin
ld
valu
greater
correspond
ic
valu
make
safe
use
aminomethyl
diethyl
phosphit
either
aromat
aldehyd
aromat
diamin
terephthaldehyd
variou
amin
led
bi
aaminophosphon
fig
respect
whose
cytotox
jurkat
tcell
lymphoma
raji
burkit
lymphoma
breast
cancer
cell
line
determin
use
mtt
assay
structur
divers
seri
compound
devoid
cytotox
moder
cytotox
compound
deriv
tryptamin
amin
reagent
mannich
reaction
emerg
potent
seri
cytotox
compar
doxorubicin
furan
belong
categori
electronrich
heterocycl
known
undergo
electrophil
substitut
mannich
reaction
great
eas
exampl
aminomethyl
synthet
lacton
natur
furanditerpen
acid
substrat
use
variou
secondari
aliphat
amin
led
furan
mannich
base
fig
antiprolif
effect
compound
potent
parent
lacton
panel
nine
cancer
cell
line
melanoma
breast
ovarian
express
resist
phenotyp
adryamycin
nciadrr
kidney
lung
nonsmal
cell
prostat
ovarian
colon
erythromyeloblastoid
leukemia
determin
srb
assay
mannich
base
also
equipot
refer
drug
doxorubicin
least
one
mani
cancer
cell
line
often
ic
valu
low
mgml
addit
posit
side
chain
cap
furan
ring
aminomethyl
variou
secondari
aliphat
amin
yield
larg
seri
furan
mannich
base
fig
cytotox
compound
liver
cancer
fibro
sarcoma
cell
establish
use
mtt
assay
result
suggest
substitut
arylamin
moieti
natur
aliphat
amino
residu
aminomethyl
function
signific
influenc
potenc
candid
particular
presenc
group
substitut
pattern
arylamin
moieti
led
high
cytotox
cell
line
level
compar
refer
drug
cisplatin
also
presenc
dimethylamino
moieti
aliphat
amino
residu
aminomethyl
group
mannich
base
appear
result
signific
antiprolif
effect
moieti
drastic
decreas
even
abolish
cytotox
titaniumbas
chemic
entiti
enjoy
reput
tremend
potenti
solid
tumor
recent
number
studi
present
synthesi
cytotox
seri
titanocen
featur
variou
aminomethyl
fivememb
heterocycl
substitu
either
one
cyclopentadien
moieti
thu
titanocen
fig
contain
monoand
bisaminomethyl
pyrrol
respect
titanocen
fig
dimethylaminomethyl
group
posit
indol
respect
well
titanocen
fig
present
aminomethyl
imidazol
ring
screen
pig
kidney
epitheli
cell
human
renal
cancer
cell
found
ic
valu
quit
similar
cisplatin
rang
mm
presenc
least
one
aminomethyl
function
structur
claim
crucial
high
cytotox
titanocen
aminomethyl
group
abl
coordin
titanium
center
could
therefor
stabil
monoor
dicat
form
hydrolysi
either
one
chlorin
atom
insid
cell
result
enhanc
interact
titanocen
dna
lead
cell
death
low
concentr
aminomethyl
termin
alkyn
also
employ
gener
mannich
base
potenti
cytotox
effect
phenothiazin
underw
aminomethyl
secondari
aliphat
amin
give
propargylamin
r
h
cl
cf
fig
first
evalu
cytotox
activ
use
two
hematolog
tumor
cell
line
name
promyelocyt
leukemia
ccrfcem
lymphocyt
leukemia
afterward
test
combin
doxorubicin
abil
revert
activ
correspond
multidrug
resist
variant
although
compound
devoid
signific
antiprolif
effect
sensit
cell
line
highli
cytotox
resist
cell
line
appear
arrest
cell
phase
cell
cycl
unlik
classic
anticanc
agent
furthermor
sever
mannich
base
abl
restor
sensit
doxorubicin
resist
cell
line
effect
concentrationdepend
reach
maximum
mm
propargylamin
seem
induc
apoptosi
activ
caspas
cascad
although
neither
extrins
intrins
pathway
appear
involv
apoptosi
betulin
deriv
bear
ethynyl
function
also
serv
start
materi
acetylen
mannich
base
cytotox
potenti
exampl
propargylamin
fig
obtain
alkyn
prepar
addit
organometal
deriv
acetylen
carbonyl
function
betulon
acid
ester
alkyn
synthes
betulin
sequenc
compris
oxid
primari
alcohol
function
aldehyd
follow
addit
organometal
deriv
acetylen
aldehyd
carbonyl
afford
propargylamin
fig
cytotox
mannich
base
evalu
panel
nine
human
cancer
cell
line
use
srb
assay
result
prove
compound
show
consider
toxic
ic
valu
low
mm
introduct
aminomethyl
group
significantli
improv
cytotox
propargylamin
compar
parent
alkyn
presum
enhanc
solubl
bioavail
highli
hydrophob
steric
hinder
amino
moieti
dicyclohexylamino
dibenzylamino
led
decreas
cytotox
correspond
aminomethyl
alkyn
mannich
base
type
shown
act
trigger
apoptosi
although
complementari
process
autophagi
could
also
involv
attempt
circumv
resist
mechan
develop
cancer
cell
prolong
administr
doxorubicin
address
issu
poor
solubl
short
lifetim
high
toxic
prodrug
doxoform
secondgener
watersolubl
prodrug
doxorubicin
develop
conjug
activ
drug
salicylamid
mean
mannich
reaction
doxorubicinesalicylamid
conjug
doxaliform
fig
halflif
approxim
one
hour
cytotox
doxorubicin
sensit
resist
breast
cancer
cell
furthermor
doxaliform
amen
function
view
provid
site
attach
releas
target
group
might
direct
conjug
specif
receptor
overexpress
cancer
cell
mani
breast
cancer
cell
overexpress
estrogen
receptor
receptor
chosen
target
doxasaliform
tether
hydroxytamoxifen
moieti
prototyp
fig
cytotox
candid
function
length
tether
show
triethylen
glycol
unit
provid
lead
compound
whose
growth
inhibit
four
select
breast
cancer
line
enhanc
rel
doxorubicin
later
work
confirm
uptak
hydroxytamoxifentarget
doxorubicinesalicylamid
conjug
mediat
antiestrogen
bind
site
estrogen
receptor
also
sever
doxorubicineformaldehyd
conjug
tether
nonsteroid
antiandrogen
cyanonilutamid
design
synthes
evalu
androgen
receptortarget
ligand
specif
deliveri
conjug
prostat
cancer
cell
construct
later
use
studi
intend
evid
bind
androgen
receptor
live
prostat
cancer
cell
subsequ
transloc
construct
bound
receptor
nucleu
result
promis
effort
direct
toward
conjug
doxasaliform
cyclic
peptid
nemevrgdf
known
cilengitid
potent
antagonist
v
b
integrin
involv
mani
cellmatrix
recognit
cell
adhes
phenomena
play
import
role
angiogenesi
tumor
metastasi
although
complet
construct
maintain
high
affin
v
b
integrin
ic
growth
inhibit
cell
greater
doxasaliform
poor
result
tent
blame
limit
drug
deliveri
caus
specif
reduc
abund
receptor
type
cell
eventu
doxasaliform
activ
prodrug
doxoform
doxazolidin
line
research
termin
howev
topic
later
revisit
author
report
synthesi
construct
deriv
either
doxorubicinesalicylamid
daunorubicinesalicylamid
deriv
aminotermin
poli
ethylen
glycol
use
vitro
vivo
studi
construct
present
cytotox
compar
parent
drug
lifetim
one
construct
determin
longer
doxorubicin
also
construct
effici
doxorubicin
reduc
weight
xenograft
tumor
cytotox
mannich
base
deriv
miscellan
structur
unrel
substrat
group
last
paragraph
section
fig
show
moder
potent
cytotox
toward
human
lung
adenocarcinoma
sgc
human
gastric
cancer
human
myelogen
leukemia
human
colorect
carcinoma
kbvcr
human
oral
cancer
cell
use
mtt
assay
one
candid
r
c
h
r
ch
cytotox
refer
drug
taxol
cell
line
ic
nm
least
one
mechan
action
appear
inhibit
tubulin
polymer
seri
imidazo
benzothiazol
fig
evalu
antiprolif
activ
hepatocellular
carcinoma
human
breast
human
cervic
hela
cancer
cell
line
use
mtt
assay
mannich
base
inhibit
prolifer
cancer
cell
concentr
lower
mm
arrest
cell
cycl
phase
downregul
cyclin
b
upregul
protein
appear
induc
apoptosi
base
elev
level
r
h
ch
substrat
use
synthesi
mannich
base
fig
high
moder
cytotox
ic
mm
toward
human
prebcel
leukemia
cell
line
chronic
myeloid
leukemia
appear
exert
cytotox
action
least
part
induct
apoptosi
replac
methoxi
substitu
compound
chlorin
led
margin
improv
ic
valu
seri
mannich
base
r
h
ch
x
ch
nr
fig
fuse
pyridazinon
deriv
synthes
test
vitro
use
srb
assay
determin
growth
inhibitori
properti
singl
mm
dose
sixti
differ
human
tumor
cell
line
show
activ
two
candid
moder
inhibit
growth
nonsmal
cell
lung
cancer
ekvx
glioblastoma
cell
line
impress
number
articl
deal
antibacteri
activ
mannich
base
publish
last
decad
structur
point
view
mannich
base
report
studi
deriv
nearli
major
type
substrat
capabl
undergo
aminomethyl
mannich
base
evalu
gramposit
gramneg
bacteria
belong
variou
famili
evalu
antibacteri
activ
perform
use
differ
screen
method
alway
standard
version
complic
interpret
comparison
result
obtain
differ
studi
owe
particular
relev
tuberculosi
report
concern
screen
mannich
base
mycobacterium
speci
present
separ
section
keton
mannich
base
antibacteri
potenti
heart
sever
studi
within
period
time
cover
review
aminomethyl
bunsatur
cyclic
keton
variabl
ring
size
afford
librari
compound
n
fig
deriv
secondari
cyclic
aliphat
amin
aromat
ring
either
substitu
methyl
group
variabl
number
methoxi
group
evalu
antibacteri
activ
mannich
base
panel
gramposit
gramneg
bacteria
use
serial
dilut
method
show
candid
deriv
sevenor
eightmemb
bunsatur
cyclic
keton
least
activ
natur
amin
moieti
number
posit
methoxi
group
aromat
ring
influenc
antibacteri
activ
none
compound
activ
pseudomona
aeruginosa
moder
activ
escherichia
coli
mannich
base
affect
gramposit
bacteria
minimum
inhibitori
concentr
mic
mgml
case
candid
less
potent
refer
antibiot
anoth
set
mannich
base
fig
obtain
benzofus
cyclic
keton
indanon
benzosuberon
test
condit
extend
panel
gramposit
gramneg
bacteria
collect
natur
amin
moieti
alkoxi
substitu
r
influenc
antibacteri
activ
greater
extent
gramposit
bacteria
lesser
extent
gramneg
bacteria
indanon
deriv
activ
class
bacteria
mic
mgml
wherea
tetralon
benzosuberon
deriv
mostli
activ
gramposit
bacteria
presum
due
higher
outer
membran
permeabl
bacteria
also
statist
comparison
antibacteri
activ
mannich
base
mannich
base
show
latter
activ
former
base
oxazolidinon
antibacteri
linezolid
eperezolid
small
seri
mannich
base
r
nhcoch
nhcsch
fig
deriv
cyclohexanon
benzofus
cyclic
keton
synthes
evalu
three
select
gramposit
microorgan
use
standard
serial
dilut
method
compound
acetamido
group
low
antibacteri
activ
replac
group
thioacetamido
restor
activ
level
exhibit
parent
oxazolidinon
antibacteri
modif
r
nhcsnh
produc
candid
whose
antibacteri
activ
superior
linezolid
one
doubl
mannich
base
fig
moder
high
antibacteri
activ
determin
use
disc
diffus
method
concentr
dmso
major
compound
activ
e
coli
deriv
pyrrolidin
diethylamin
dinbutylamin
amin
reagent
show
signific
antibacteri
activ
zone
inhibit
mm
toward
bacteria
compar
refer
drug
gentamycin
zone
inhibit
mm
hand
compound
deriv
nethylmethylamin
inact
inhibit
concentr
higher
mgml
also
structur
divers
type
mannich
base
deriv
acetophenon
monomannich
base
type
r
ch
fig
bismannich
base
type
r
ch
fig
piperidinol
type
r
ch
fig
well
azin
deriv
fig
devoid
antibacteri
activ
wide
rang
humanand
plantpathogen
bacteria
methiodid
fig
dimethylamin
mannich
base
acetophenon
sole
activ
compound
seri
staphylococcu
aureu
diamet
inhibit
zone
measur
mm
compar
cm
case
refer
drug
ofloxacin
mic
mgml
antibacteri
activ
keton
mannich
base
gener
arylamin
aromat
aldehyd
also
investig
sever
group
start
cyclohexanon
set
eleven
compound
obtain
screen
four
common
bacteria
use
serial
dilut
method
show
mani
candid
excel
antibacteri
activ
compar
ceftriaxon
howev
lack
ration
design
systemat
use
aldehyd
amin
compon
use
gener
mannich
base
fig
preclud
logic
conclus
regard
sar
collect
use
four
differ
substitut
acetophenon
sever
parasubstitut
anilin
led
mannich
base
fig
screen
four
common
bacteria
compound
inact
candid
r
r
f
potent
refer
drug
ampicillin
four
microorgan
wherea
anoth
candid
r
r
h
potent
ampicillin
e
coli
aureu
arylamin
mannich
base
fig
obtain
respect
evalu
e
coli
aureu
p
aeruginosa
use
disc
diffus
method
sinc
compound
seri
deriv
acid
expect
least
compound
good
antibacteri
activ
three
candid
r
h
cl
f
antibacteri
activ
compar
refer
drug
streptomycin
rest
almost
inact
seri
candid
provid
one
remark
activ
mannich
base
r
n
ch
rest
compound
benzofuran
moieti
gener
activ
coumarinederiv
candid
arylamino
fig
show
broad
spectrum
activ
gramposit
gramneg
bacteria
highest
degre
growth
inhibit
obtain
aureu
mic
valu
vari
mgml
make
compound
approxim
less
activ
refer
drug
tetracyclin
compound
fig
similar
structur
phenyl
ring
instead
ferrocen
report
possess
moder
high
antibacteri
activ
appear
replac
phenyl
ferrocen
could
respons
substanti
decreas
activ
record
case
compound
aminomethyl
phenol
also
report
antibacteri
activ
mannich
base
fig
obtain
secondari
aliphat
amin
screen
antibacteri
activ
seven
type
bacteria
potenc
rather
low
moder
correspond
copper
ii
complex
fare
better
two
mic
compar
chloramphenicol
mgml
mannich
reaction
deriv
anoth
dihydroxyl
phenol
either
secondari
aliphat
amin
primari
arylamin
afford
compound
fig
whose
zone
inhibit
three
common
bacteria
determin
two
concentr
mgml
use
disc
diffus
method
smaller
observ
refer
drug
ofloxacin
mgml
chemic
modif
natur
antibiot
novobiocin
mean
aminomethyl
hypothes
increas
permeabl
outer
membran
gramneg
bacteria
phenol
mannich
base
fig
design
synthes
evalu
aureu
one
novobiocin
usual
target
francisella
tularensi
e
coli
candid
significantli
less
potent
novobiocin
three
microorgan
antibacteri
activ
potent
compound
almost
time
weaker
novobiocin
thirteen
novel
phenol
mannich
base
fig
deriv
lawson
benzaldehyd
primari
aliphat
amin
togeth
correspond
copper
ii
complex
test
antibacteri
activ
seven
type
bacteria
except
mannich
base
gener
potent
correspond
complex
presum
due
greater
solubl
proligand
two
mannich
base
antibacteri
activ
compar
higher
chloramphenicol
bacillu
subtili
e
coli
aureu
wherea
compound
inhibit
bacteri
growth
concentr
greater
mmoll
antibacteri
activ
fuse
oxazin
obtain
mannich
reaction
phenol
naphthol
primari
amin
also
examin
fig
screen
mgml
three
common
microorgan
use
disc
diffus
method
show
good
growth
inhibitori
activ
toward
aureu
moder
potenc
e
coli
b
subtili
antibacteri
activ
evalu
fig
substitut
chloro
methyl
group
aromat
ring
bi
fig
naphtho
fig
well
naphtho
fig
use
serial
dilut
method
regardless
aliphat
aromat
natur
moieti
nitrogen
atom
compound
especi
naphthoxazin
mic
valu
greater
mg
ml
two
benzoxazin
deriv
aromat
amin
potent
ampicillin
e
coli
wherea
compound
deriv
equipot
gentamycin
aureu
addit
benzoxazin
naphthoxazin
benzazol
moieti
nitrogen
atom
test
four
common
type
bacteria
although
major
compound
inact
antibacteri
activ
candid
greater
refer
drug
tetracyclin
enhanc
activ
candid
associ
presenc
benzimidazol
system
nitrogen
atom
least
one
halogen
phenol
start
materi
contradict
previous
mention
result
number
naphtho
obtain
various
substitut
arylamin
found
quit
activ
antibacteri
agent
toward
e
coli
b
subtili
compound
gener
activ
latter
pathogen
candid
deriv
even
potent
refer
drug
streptomycin
mannich
reaction
phenol
fuse
heterocycl
also
investig
prepar
antibacteri
mannich
base
quatern
heterocycl
nitrogen
atom
bromoacet
acid
ester
superior
alcohol
r
nc
h
nc
h
nc
h
give
compound
x
ch
fig
antibacteri
activ
candid
determin
three
concentr
mgml
use
disc
diffus
method
show
compound
activ
toward
gramposit
gramneg
bacteria
presenc
structur
long
alkyl
chain
rather
aminomethyl
function
like
respons
activ
phenol
mannich
base
r
h
br
fig
evalu
e
coli
bacillu
cirroflagellosu
mgml
use
disc
diffus
method
antibacteri
activ
gener
weak
except
candid
deriv
morpholin
amin
reagent
aminomethyl
deriv
r
oh
fig
also
manifest
antibacteri
activ
variou
degre
activ
candid
mannich
base
deriv
cyclohexylamin
potent
tetracyclin
b
subtili
mic
mgml
mannich
base
deriv
morpholin
antibacteri
activ
ampicillin
aureu
mic
mgml
phenol
mannich
base
deriv
receiv
special
attent
potenti
antibacteri
allomaltol
convert
mannich
base
fig
whose
antibacteri
activ
four
differ
gramposit
bacteria
moder
mic
mgml
hand
antibacteri
activ
mannich
base
fig
deriv
chlorokoj
acid
superior
analog
candid
shown
possess
broad
spectrum
activ
standard
strain
mic
mgml
toward
clinic
drugresist
isol
strike
differ
antibacteri
activ
aminomethyl
deriv
piperidin
amin
moieti
growth
inhibit
gramposit
bacteria
except
enterococcu
faecali
occur
mic
valu
lower
requir
growth
inhibit
gramneg
bacteria
mannich
base
piperazin
amin
moieti
seem
best
compound
seri
activ
consist
lower
refer
antibacteri
drug
subsequ
novel
seri
mannich
base
synthes
time
use
variou
substitut
aryl
piperazin
amin
reagent
compound
collect
weaker
antibacteri
analog
deriv
screen
anoth
novel
set
compound
either
identifi
compound
improv
remark
antibacteri
activ
best
candid
studi
mic
valu
mg
ml
howev
piperazinylsubstitut
fluoroquinolon
employ
amin
reagent
mannich
reaction
substrat
result
hybrid
r
cl
fig
broad
spectrum
highli
activ
panel
compris
gramneg
gramposit
bacteria
gener
aminomethyl
deriv
chlorokoj
acid
r
cl
potent
antibacteri
aminomethyl
deriv
kojic
acid
r
oh
mannich
base
r
cl
deriv
fluoroquinolon
ciprofloxacin
potent
candid
seri
replac
quinolon
scaffold
candid
deriv
norfloxacin
naphthyridon
moieti
mannich
base
deriv
enoxacin
result
decreas
antibacteri
activ
among
bacteria
use
studi
e
coli
klebsiella
pneumonia
sensit
microorgan
hybrid
dock
activ
compound
topoisomeras
ii
dnagyras
activ
site
tradit
target
quinolon
show
mannich
base
deriv
ciprofloxacin
bind
manner
similar
ciprofloxacin
enzym
activ
site
moieti
anchor
addit
hydrogen
bond
within
bind
pocket
thu
increas
stabil
inhibitoreenzym
complex
mannich
base
isatin
deriv
also
investig
antibacteri
agent
aminomethyl
isatin
semicarbazon
hetero
arylamin
afford
mannich
base
fig
whose
antibacteri
activ
moder
toward
e
coli
good
toward
aureu
addit
seri
mannich
base
r
secondari
aliphat
amin
fig
deriv
hydrazon
isatin
incorpor
biolog
relev
moieti
sulfa
drug
azacarbazol
moder
good
antibacteri
activ
previous
mention
microorgan
hydrazidon
obtain
isatin
hydrazid
various
substitut
acet
acid
also
aminomethyl
view
synthes
antibacteri
mannich
base
exampl
mannich
base
deriv
substitut
isatin
morpholin
piperidin
gener
show
poor
antibacteri
activ
two
aforement
type
bacteria
except
compound
r
r
whose
inhibit
determin
disc
diffus
method
approxim
half
refer
drug
gentamycin
anoth
collect
mannich
base
r
gener
substitut
isatin
substrat
morpholin
piperidin
amin
reagent
exhibit
weak
moder
antibacteri
activ
toward
e
coli
aureu
shigella
flemeri
zone
inhibit
mm
compar
norfloxacin
zone
inhibit
mm
schiff
base
gener
isatin
variou
hetero
aromat
amin
repres
anoth
type
isatinderiv
substrat
subject
aminomethyl
obtain
potenti
antibacteri
agent
use
isatin
schiff
base
mannich
reaction
amino
phenylacet
acid
amin
reagent
yield
compound
r
substitut
phenyl
fig
prove
less
potent
refer
drug
ciprofloxacin
array
bacteria
use
gener
schiff
base
isatin
aminomethyl
secondari
aliphat
amin
gave
mannich
base
fig
compound
moder
good
activ
e
coli
aureu
p
aeruginosa
salmonella
typhi
disc
diffus
assay
show
also
moder
good
blactamas
inhibitori
activ
schiff
base
trimethoprim
aminomethyl
give
compound
r
mannich
base
deriv
ciprofloxacin
lomefloxacin
gatifloxacin
amin
reagent
mannich
reaction
least
potent
potent
correspond
parent
fluoroquinolon
larg
panel
bacteria
antibacteri
activ
mannich
base
r
deriv
schiff
base
isatin
isatin
aminotriazolethion
gener
good
four
common
microorgan
size
inhibit
zone
candid
especi
deriv
halogen
isatin
piperidin
morpholin
residu
aminomethyl
group
compar
size
inhibit
zone
refer
drug
ciprofloxacin
recent
mannich
base
fig
obtain
use
schiff
base
deriv
substrat
ciprofloxacin
amin
reagent
shown
gener
less
potent
antibacteri
refer
drug
ciprofloxacin
although
candid
mic
valu
compar
ciprofloxacin
investig
bacteria
larg
number
paper
publish
last
decad
report
antibacteri
activ
mannich
base
structur
point
view
mannich
base
triazolethion
synthes
aminomethyl
report
fall
two
major
categori
relev
inform
studi
ie
substitu
posit
triazol
ring
amin
reagent
use
aminomethyl
microorgan
employ
antibacteri
evalu
present
condens
manner
tabl
seri
compound
natur
amin
moieti
aminomethyl
group
appear
critic
antibacteri
activ
mannich
base
piperazin
consist
potent
mannich
base
arylamin
even
potent
refer
drug
ampicillin
comparison
antibacteri
activ
structur
relat
suggest
replac
substitu
posit
triazol
ring
hydroxybenzylideneamino
enhanc
antibacteri
activ
although
shown
substitut
chlorin
phenyl
posit
triazol
ring
improv
antibacteri
activ
seri
compound
aminomethyl
also
increas
bacteri
growth
mannich
base
compar
parent
triazolethion
candid
substanti
antibacteri
activ
could
singl
two
collect
howev
use
ciprofloxacin
amin
reagent
synthesi
mannich
base
led
substanti
increas
antibacteri
activ
compound
potent
refer
drug
ciprofloxacin
vancomycin
sever
type
bacteria
methicillinresist
aureu
mrsa
respect
mannich
base
diphenylsulfon
moieti
posit
triazol
ring
weak
antibacteri
activ
small
number
mannich
base
especi
halogen
substitu
phenyl
triazol
ring
inhibit
growth
gramposit
bacteria
mannich
base
especi
candid
morpholin
nmethylpiperidin
trifluoromethylphenylpiperazin
aminomethyl
group
good
antibacteri
activ
mic
mgml
wherea
analog
instead
less
potent
inhibit
zone
mm
compar
mm
ampicillin
three
mannich
base
report
studi
gave
interest
result
candid
deriv
inhibit
zone
mm
bacteria
ethylamin
inhibit
zone
mm
microorgan
evalu
potent
refer
drug
ampicillin
wherea
bismannich
base
deriv
piperazin
inact
howev
elabor
compound
abolish
antibacteri
activ
mannich
base
featur
moieti
posit
triazol
ring
gener
poorer
antibacteri
refer
drug
ampicillin
although
isol
exampl
amongst
candid
show
potenc
ampicillin
certain
bacteria
furthermor
replac
substitu
posit
triazol
ring
modif
phenyl
benzyl
substitu
posit
triazol
ring
led
inact
mannich
base
type
mannich
base
featur
moieti
posit
triazolethion
scaffold
show
good
antibacteri
activ
compound
gener
potent
two
candid
actual
mic
valu
compar
refer
drug
ciprofloxacin
mannich
base
continu
next
page
devoid
effect
antibacteri
activ
structur
relat
candid
singular
notabl
except
compound
activ
bacillu
cereu
mannich
base
also
inact
antibacteri
except
candid
potent
p
aeruginosa
refer
drug
ampicillin
everi
member
seri
h
primari
arylamin
diphenylamin
piperazin
aureu
pyogen
mannich
base
activ
test
bacteria
potent
refer
drug
nitrofurazon
addit
natur
substitu
posit
triazol
ring
seri
compound
notic
influenc
antibacteri
activ
data
base
singl
exampl
suggest
presenc
chlorin
aromat
ring
substitu
x
pyrazol
moieti
could
improv
activ
mannich
base
mostli
activ
aureu
b
subtili
candid
deriv
ethyl
gener
potent
deriv
piperazin
note
presenc
halogen
structur
r
enhanc
antibacteri
activ
mannich
base
contrast
substitut
halogen
compound
eg
r
led
potent
candid
seri
antibacteri
activ
compar
refer
drug
ciprofloxacin
use
moieti
posit
triazol
ring
mannich
base
also
produc
candid
good
excel
antibacteri
activ
compound
secondari
aliphat
amin
aminomethyl
group
gener
potent
arylamin
even
anilin
use
aminomethyl
substitut
addit
halogen
atom
although
mannich
base
antibacteri
activ
close
analogu
compound
fig
potent
ampicillin
bacteria
panel
except
aureu
replac
aminomethyl
group
mannich
base
use
substitut
phenyl
r
afford
structur
relat
candid
moder
antibacteri
activ
antibacteri
activ
mannich
base
moder
good
even
potent
compound
seri
moieti
aminomethyl
group
least
less
activ
refer
drug
ciprofloxacin
mannich
base
also
moder
good
antibacteri
activ
inhibit
zone
mm
less
potent
tetracyclin
inhibit
zone
mm
overal
antibacteri
activ
reason
seri
mannich
base
compound
mic
valu
variou
bacteria
close
determin
refer
drug
mannich
base
potent
p
aeruginosa
refer
drug
levofloxacin
amikacin
candid
exhibit
broad
moder
good
antibacteri
activ
evalu
mannich
base
antibacteri
agent
receiv
littl
attent
recent
literatur
small
seri
six
mannich
base
fig
deriv
substitut
hetero
arylidendeamino
synthes
test
seven
type
bacteria
antibacteri
activ
candid
rang
moder
excel
compound
potent
refer
drug
ampicillin
e
coli
p
aeruginosa
candid
r
nr
ethylamino
least
activ
ampicillin
type
bacteria
use
studi
except
aureu
mannich
base
type
fig
deriv
morpholin
piperidin
excel
broad
spectrum
antibacteri
wherea
analogu
either
inact
weak
antibacteri
moder
activ
test
bacteria
singl
mannich
base
fig
moieti
substitu
posit
triazol
ring
synthes
evalu
antibacteri
activ
effect
e
coli
p
aeruginosa
compar
ampicillin
three
mannich
base
moieti
posit
scaffold
analog
compound
deriv
moder
good
activ
bacteria
panel
superior
refer
drug
ampicillin
antibacteri
activ
mannich
base
investig
extens
structur
featur
compound
report
studi
summar
tabl
along
microorgan
use
screen
mannich
base
moder
good
antibacteri
activ
mic
valu
mgml
none
potent
refer
drug
ciprofloxacin
definit
sar
could
infer
biolog
result
growth
inhibit
mannich
base
appear
modul
natur
amin
aminomethyl
residu
thu
candid
deriv
potent
seri
antibacteri
activ
compar
refer
drug
ciprofloxacin
follow
order
mannich
base
deriv
morpholin
case
mannich
base
candid
deriv
secondari
aromat
amin
inact
wherea
remain
compound
less
activ
gram
neg
bacteria
activ
gram
posit
bacteria
mic
valu
lesser
refer
drug
ampicillin
mannich
base
report
studi
moder
good
antibacteri
activ
potent
ampicillin
e
coli
e
faecali
candid
deriv
gener
potent
mannich
base
deriv
ethylamin
case
thiazolecontain
mannich
base
antibacteri
activ
compound
moder
mic
valu
mgml
wherea
compound
two
compound
emerg
effect
antibacteri
especi
gramneg
bacteria
mic
valu
lesser
refer
drug
chloramphenicol
sever
mannich
base
nr
nhc
h
nhc
h
nhc
h
cf
nhc
h
f
antibacteri
activ
compar
refer
drug
penicillin
bacteria
even
compar
refer
drug
streptomycin
mannich
base
nr
equipot
refer
drug
ciprofloxacin
aureu
antibacteri
activ
rest
candid
seri
weaker
ciprofloxacin
test
bacteria
compound
report
studi
includ
mannich
base
claim
exhibit
moder
antibacteri
activ
lack
access
origin
inform
provid
onlin
edit
supplement
materi
miss
make
data
assess
imposs
phenylpiperazinecontain
mannich
base
gener
potent
candid
deriv
ethyl
isonipecot
moder
antibacteri
activ
compar
refer
drug
ampicillin
three
eight
synthes
mannich
base
screen
antibacteri
activ
growth
inhibit
weak
moder
inhibit
zone
mm
compar
refer
drug
chloramphenicol
inhibit
zone
mm
none
synthes
mannich
base
present
antibacteri
activ
maximum
concentr
test
mgml
mannich
base
compound
antibacteri
activ
structur
divers
librari
evalu
studi
effect
moder
best
screen
result
mannich
base
also
disappoint
bare
inhibit
growth
e
coli
concentr
mgml
two
synthes
mannich
base
candid
morpholin
residu
aminomethyl
group
display
excel
antimicrobi
activ
test
microorgan
candid
methylpiperazin
residu
good
moder
activ
bacteria
panel
except
e
coli
k
pneumonia
growth
inhibit
exert
mannich
base
moder
compar
refer
drug
uninfluenc
natur
amin
moieti
aminomethyl
group
nalidix
acidbas
oxadiazolethion
mannich
base
exhibit
weak
antibacteri
activ
mic
valu
mgml
compar
refer
drug
streptomycin
mic
mgml
toward
b
subtili
structur
relat
mannich
base
fig
quit
activ
mic
valu
high
mgml
microorgan
use
studi
final
mannich
base
moieti
posit
ring
fig
inact
aureu
e
coli
p
aeruginosa
bacillu
megaterium
two
studi
present
synthesi
antibacteri
evalu
cmannich
base
thiazolidinon
fig
substitu
posit
candid
alkyl
aryl
group
r
substitu
thiazolidinon
ring
show
antibacteri
activ
panel
eight
bacteria
analogu
unsubstitut
r
h
weak
antibacteri
activ
aureu
mic
valu
mgml
two
mannich
base
r
h
thiazolidinon
featur
moieti
fig
less
potent
typhimurium
nr
diethylamino
less
potent
b
cereu
nr
refer
drug
ciprofloxacin
antibacteri
activ
mannich
base
fig
found
potent
mic
valu
mgml
parent
thiazolidinon
sar
suggest
natur
substitu
r
influenc
significantli
abil
compound
inhibit
growth
variou
bacteria
aminomethyl
substrat
easili
obtain
consider
structur
varieti
simpl
biginelli
reaction
also
investig
relat
antibacteri
activ
result
mannich
base
thu
mannich
base
fig
obtain
use
natur
alkaloid
cytosin
amin
reagent
aminomethyl
evalu
antibacteri
agent
show
potent
growth
inhibitor
aureu
b
subtili
weak
activ
p
aeruginosa
e
coli
doubl
mannich
base
fig
x
good
antibacteri
agent
zone
inhibit
zone
inhibit
refer
drug
streptomycin
e
coli
b
subtili
analog
doubl
mannich
base
x
even
potent
except
candid
moieti
posit
pyrimidin
ring
r
r
h
take
advantag
labil
proton
locat
nitrogen
atom
amid
function
sever
nmannich
base
fig
obtain
either
sulfonamid
common
secondari
amin
amin
reagent
synthes
evalu
antibacteri
activ
panel
bacteria
candid
deriv
sulfonamid
potent
parent
compound
wherea
mannich
base
deriv
morpholin
antibacteri
agent
broad
spectrum
good
activ
nmannich
base
glutarimid
r
h
cc
h
cc
h
h
fig
screen
antibacteri
activ
claim
potent
potent
although
comparison
currentlyinus
antibacteri
avail
compound
deriv
sulfonamid
show
improv
growth
inhibit
activ
test
microorgan
correspond
parent
amin
wherea
analogu
gener
secondari
aliphat
amin
gener
equipot
obtain
sulfonamid
also
nmannich
base
succinimid
r
h
c
h
nr
nhc
h
fig
nmannich
base
phthalimid
weak
moder
antibacteri
e
coli
typhi
b
subtili
wellknown
antibiot
also
subject
aminomethyl
hope
increas
antibacteri
activ
improv
bioavail
hybrid
tetracyclin
sulfonamid
fig
gener
use
mannich
reaction
screen
salmonella
enteritidi
pasturella
multocida
show
antibacteri
activ
higher
parent
sulfonamid
unfortun
comparison
activ
tetracyclin
refer
drug
provid
studi
aminomethyl
one
modif
also
explor
case
vancomycin
ndecylaminoethyl
moieti
introduc
structur
vancomycin
view
restor
antibacteri
activ
vancomycinresist
enterococci
retain
potenc
mrsa
graft
hydrophil
group
consid
way
reduc
overal
lipophil
ndecylaminoethylmodifi
vancomycin
restor
initi
favor
distribut
properti
vancomycin
sever
type
amin
reagent
amino
acid
amino
sugar
phosphon
acid
consid
synthesi
mannich
base
fig
modif
led
candid
activ
vancomycinresist
bacteria
ultim
discoveri
telavancin
lead
compound
improv
absorpt
distribut
metabol
excret
adm
properti
ndecylaminoethylvancomycin
fig
subsequ
screen
larg
number
predominantli
gramposit
isol
develop
antibacteri
resist
show
highli
activ
methicillinresist
staphylococci
mic
mgml
streptococci
mic
valu
mgml
vanbtyp
enterococci
mic
valu
mgml
respect
mechan
action
telavancin
inhibit
latestag
peptidoglycan
biosynthesi
substratedepend
fashion
bound
cell
wall
high
affin
perturb
bacteri
cell
membran
potenti
permeabl
aminomethyl
vancomycin
also
use
first
step
construct
glycopeptideblactam
heterodim
via
linkag
aminomethyl
vancomycin
variou
cephalosporin
core
adip
acid
moieti
heterodim
found
exhibit
excel
potenc
rang
import
gramposit
bacteria
subset
candid
also
demonstr
rapid
bactericid
activ
mrsa
wherea
two
attract
compound
shown
exhibit
vivo
efficaci
fold
greater
vancomycin
final
patent
claim
seri
mannich
base
vancomycin
compound
suitabl
oral
deliveri
enhanc
antibacteri
potenc
antibacteri
activ
mannich
base
deriv
miscellan
substrat
cover
last
paragraph
section
mannich
base
r
ch
oc
h
fig
deriv
either
ethyl
acetoacet
diethyl
malon
substrat
various
substitut
benzaldehyd
aldehyd
compon
benzyl
carbam
amin
reagent
poor
moder
activ
five
type
common
bacteria
hydrazidon
deriv
isoniazid
aminomethyl
posit
ortho
alkoxi
group
give
mannich
base
fig
member
collect
ethoxi
group
demonstr
concentr
mgml
antibacteri
activ
superior
refer
drug
amoxicillin
mgml
wherea
candid
propoxi
group
less
potent
mannich
base
deriv
substitut
aryl
imidazo
pyridin
fig
two
halogen
substitu
phenyl
ring
posit
fuse
heterocycl
system
potent
seri
e
coli
p
aeruginosa
aureu
streptococcu
pyogen
mannich
base
deriv
imidazo
ring
system
fig
show
weak
activ
gramposit
bacteria
moder
activ
vibrio
cholera
growth
inhibit
activ
e
coli
compar
refer
drug
norfloxacin
evalu
antibacteri
activ
mannich
base
deriv
one
show
one
candid
fig
moder
activ
enteritidi
mgml
aureu
mgml
compar
refer
drug
ciprofloxacin
mgml
mgml
respect
mention
microorgan
monomannich
base
r
ch
doubl
mannich
base
gener
sydnon
fig
found
inhibit
moder
growth
four
standard
microorgan
regardless
natur
amin
reagent
use
aminomethyl
use
conclus
regard
sar
seri
could
drawn
develop
also
mannich
base
r
och
weak
moder
activ
gramposit
gramneg
bacteria
except
candid
r
och
nr
potent
refer
drug
ciprofloxacin
ampicillin
gramposit
bacteria
contrast
aminomethyl
anoth
sydnon
deriv
use
variou
primari
secondari
aliphat
amin
report
occur
pyrazolin
ring
give
mannich
base
instead
fig
good
antibacteri
activ
compar
refer
drug
ampicillin
four
common
bacteria
particularli
b
subtili
copper
ii
complex
pyrazol
cmannich
base
fig
inhibit
growth
b
subtili
concentr
low
mm
like
promot
mutagenesi
induc
cell
death
screen
pyrazolon
nmannich
base
fig
variou
bacteria
result
inhibit
zone
compar
refer
drug
ciprofloxacin
mic
valu
candid
ultim
far
greater
ciprofloxacin
acetylen
mannich
base
r
c
h
h
r
c
h
h
fig
antibacteri
activ
compar
refer
drug
ofloxacin
aureu
fewer
show
good
activ
e
coli
one
candid
equipot
ofloxacin
p
aeruginosa
variou
substrat
eg
benzimidazol
one
succinimid
phthalimid
naphthalimid
aminomethyl
use
norfloxacin
amin
reagent
correspond
mannich
base
potent
parent
fluoroquinolon
especi
e
coli
p
aeruginosa
sulfonamid
primari
secondari
aliphat
amin
employ
amin
reagent
aminomethyl
isoniazid
give
mannich
base
fig
candid
antibacteri
activ
superior
parent
sulfonamid
wherea
mannich
base
nr
nhch
potent
compound
seri
aureu
b
anthraci
use
hydantoin
substrat
mannich
reaction
led
deriv
deriv
fig
depend
substitu
imidazol
ring
mannich
base
moder
good
antibacteri
activ
four
common
bacteria
aminomethyl
aminoalkyl
saccharin
use
variou
type
amin
reagent
led
mannich
base
fig
moder
excel
antibacteri
activ
aureu
zone
inhibit
mm
compar
mm
refer
drug
chloramphenicol
note
report
concis
manner
synthesi
antibacteri
activ
mannich
base
fig
deriv
phenothiazin
primari
aromat
amin
compound
studi
potent
broad
spectrum
test
bacteria
monomannich
base
dion
fig
screen
concentr
mgdisc
found
potent
refer
drug
nalidix
acid
concentr
mgdisc
four
common
bacteria
except
proteu
vulgari
moder
good
antibacteri
activ
determin
mannich
base
one
fig
none
candid
potent
refer
drug
amikacin
four
common
bacteria
use
studi
addit
anticanc
activ
evalu
pmannich
base
fig
also
screen
antibacteri
activ
mic
valu
gener
approxim
mgml
regardless
candid
structur
type
bacteria
comparison
refer
drug
provid
studi
paper
claim
synthesi
smannich
base
secondari
aliphat
amin
fig
also
report
antibacteri
activ
weak
moder
potent
candid
less
potent
refer
drug
ciprofloxacin
four
type
bacteria
tuberculosi
chronic
diseas
whose
magnitud
graviti
glean
studi
world
health
organ
state
alon
million
new
case
tuberculosi
report
million
death
caus
tuberculosi
million
peopl
infect
human
immunodefici
viru
mycobacterium
continu
rise
number
report
case
drugresist
latent
tuberculosi
also
alarm
call
urgent
discoveri
novel
class
compound
antimycobacteri
activ
capabl
overcom
resist
mycobacterium
strain
current
drug
mannich
base
among
novel
class
antimycobacteri
compound
recent
caught
attent
research
field
sever
exampl
paper
deal
antitubercular
keton
mannich
base
avail
thu
dimethylamin
mannich
base
fig
report
mic
valu
mgml
mgml
mycobacterium
tuberculosi
h
rv
candid
n
r
r
h
candid
n
r
f
r
h
respect
approxim
effici
refer
drug
rifampin
microorgan
addit
abil
candid
inhibit
growth
mycobacterium
avium
concentr
mgml
rang
howev
signific
correl
structur
pattern
mannich
base
eg
presenc
absenc
cinnamoyl
doubl
bond
substitut
pattern
phenyl
ring
electron
hydrophob
steric
properti
substitu
aromat
ring
antimycobacteri
activ
could
establish
mannich
base
n
r
och
r
h
emerg
seri
viabl
hit
compound
mic
valu
mgml
ic
valu
vero
cell
mgml
compound
present
therefor
greater
toxic
toward
mycobacterium
normal
mammalian
cell
tent
explain
abil
affect
respir
isol
rat
liver
mitochondria
mic
valu
sever
drugresist
strain
mycobacterium
similar
ident
valu
determin
h
rv
strain
isocitr
lyas
enzym
glyoxyl
cycl
catalyz
cleavag
isocitr
succin
glyoxyl
togeth
malat
synthas
bypass
two
decarboxyl
step
tricarboxyl
acid
cycl
glyoxyl
cycl
essenti
surviv
pathogen
includ
tuberculosi
insid
host
isocitr
lyas
identifi
bacteria
fungi
plant
analog
enzym
document
human
therefor
isocitr
lyas
pursu
promis
target
develop
novel
antimycobacteri
agent
highthroughput
screen
larg
librari
keton
mannich
base
enzym
led
identif
candid
fig
potent
inhibitori
activ
ic
mgml
compound
activ
tuberculosi
actual
evalu
phenol
mannich
base
fig
deriv
hydrazon
gener
isoniazid
hydroxyacetophenon
screen
tuberculosi
h
rv
found
inhibit
growth
mic
valu
rang
mm
six
compound
seri
potent
isoniazid
mic
mm
potent
candid
nr
shown
equipot
isoniazid
decreas
bacteri
load
lung
infect
mice
dose
mgkg
antimycobacterium
activ
novobiocin
mannich
base
fig
evalu
two
candid
nr
nacetoxyacetylnmethyl
nacetaminoacetylnmethyl
show
increas
potenc
novobiocin
although
comparison
establish
antimycobacteri
drug
provid
phenol
mannich
base
deriv
allomaltol
piperazin
fig
good
activ
mycobacterium
smegmati
mic
valu
mgml
although
growth
inhibit
mycobacterium
candid
librari
moder
good
mic
valu
mgml
mannich
base
deriv
analogu
substitut
halogen
aromat
ring
among
potent
compound
seri
departur
substitut
piperazin
candid
bulki
aromat
ring
directli
link
gener
led
decreas
potenc
mycobacterium
although
substitu
tbutoxycarbonyl
ethoxycarbonyl
cyclohexyl
benzoyl
furfuryl
dimethylamino
ethyl
appear
toler
better
other
eg
isopropyl
allyl
phenethyl
benzyl
extens
studi
aim
evalu
tuberculosi
h
rv
librari
mannich
base
type
fig
obtain
replac
piperazin
compound
piperidin
led
valuabl
insight
sar
particular
type
compound
inspect
sar
subset
mannich
base
suggest
posit
substitu
lesser
extent
natur
substitu
play
import
role
antimycobacteri
activ
potent
candid
subset
gener
substitut
posit
piperidin
ring
replac
allomaltol
chlorokoj
acid
substrat
afford
piperazin
mannich
base
r
fig
analog
compar
antimycobacteri
activ
mic
valu
mani
paper
report
antimycobacteri
activ
mannich
base
pyrrol
deriv
publish
last
decad
intens
research
field
stem
discoveri
italian
research
universit
la
sapienza
rome
fig
potent
agent
sever
collect
strain
clinic
isol
tuberculosi
also
nontuberculosi
mycobacteri
strain
drugresist
mycobacteria
mic
valu
compar
refer
drug
isoniazid
streptomycin
although
quest
potent
antimycobacteri
agent
systemat
modif
lead
compound
success
first
provid
experiment
proof
import
presenc
natur
substitu
posit
pyrrol
ring
subsequ
novel
pyrrol
mannich
base
analog
fig
deriv
also
thiomorpholin
amin
reagent
either
chlorin
chlorin
fluorin
substitu
phenyl
ring
posit
pyrrol
synthes
two
candid
r
f
r
h
r
h
r
f
show
improv
activ
mic
valu
mgml
tuberculosi
mannich
base
mic
mgml
investig
structureeantimycobacteri
activ
relationship
analogu
pursu
view
optim
structur
candid
thu
synthesi
novel
mannich
base
pyrrol
use
iter
introduct
lipophil
moieti
either
one
posit
pyrrol
ring
lead
compound
recombin
shuffl
substitu
employ
far
phenyl
ring
two
posit
pyrrol
ring
undertaken
studi
confirm
superior
antimycobacteri
activ
mannich
base
contain
thiomorpholinyl
moieti
compar
activ
correspond
analogu
moieti
evidenc
import
fluorin
substitut
especi
posit
phenyl
ring
antimycobacteri
activ
prove
decreas
activ
introduct
moieti
structur
lead
compound
unfortun
novel
candid
potent
mannich
base
identifi
investig
howev
replac
one
halogen
structur
lead
compound
lipophil
substitu
methyl
ethyl
npropyl
ipropyl
afford
candid
improv
antimycobacteri
activ
mic
valu
mgml
even
refer
drug
streptomycin
order
increas
lipophil
replac
methyl
group
posit
pyrrol
ring
ethyl
also
examin
novel
mannich
base
x
nch
fig
gener
less
activ
sever
tuberculosi
strain
methylsubstitut
analogu
although
cytotox
toward
normal
cell
lower
methylsubstitut
counterpart
explor
relationship
natur
substitu
phenyl
ring
posit
pyrrol
ring
antimycobacteri
activ
pyrrol
mannich
base
led
identif
novel
lead
compound
fig
high
activ
toward
tuberculosi
h
rv
strain
mic
mgml
antimycobacteri
activ
mannich
base
compar
refer
drug
streptomycin
rifampin
candid
demonstr
low
cytotox
toward
normal
cell
select
index
ic
mic
subsequ
seri
morpholin
deriv
design
synthes
view
lower
clearanc
rate
mous
microsom
fraction
associ
presenc
thiomorpholin
although
replac
thiomorpholin
morpholin
gener
result
decreas
potenc
candid
fig
found
equipot
lead
compound
show
improv
microsom
clearanc
lower
cytotox
normal
cell
ultim
select
vivo
pharmacokinet
efficaci
studi
acut
murin
tuberculosi
infect
model
mannich
base
efficaci
dose
result
colonyform
unit
reduct
lung
mgkg
within
rang
commonli
employ
tuberculosi
drug
recent
studi
show
mutat
gene
mycobacterium
strain
respons
resist
suggest
product
gene
cellular
target
make
member
mmpl
mycobacteri
membran
protein
larg
famili
new
potenti
druggabl
target
treatment
tuberculosi
point
mutat
gene
confer
resist
analog
pyrrol
mannich
base
later
identifi
sever
mycobacterium
mutant
larg
number
antimycobacteri
pyrrol
mannich
base
also
employ
obtain
final
multiprob
qsar
model
shown
offer
good
predict
antimycobacteri
activ
extern
unrel
test
set
compound
account
variou
stage
endeavor
concern
synthesi
pyrrol
mannich
base
antimycobacteri
agent
along
relat
biolog
result
obtain
italian
research
also
made
object
sever
author
review
along
year
patent
claim
antimycobacteri
activ
pyrrol
mannich
base
deriv
also
worth
mention
hand
attempt
make
drastic
departur
alreadi
establish
structur
featur
antimycobacteri
pyrrol
mannich
base
introduct
oxazolidinon
moieti
remind
antibacteri
linezolid
led
seri
compound
x
acetamido
hetero
fig
best
less
potent
mannich
base
addit
pyrrol
mannich
base
fig
shown
act
inhibitor
ic
valu
rang
mm
mycobacterium
protein
tyrosin
phosphatas
b
enzym
essenti
surviv
bacteria
host
vitro
evalu
use
mycobacterium
strain
perform
mannich
base
isatin
deriv
evalu
antimycobacteri
agent
well
sever
isatin
mannich
base
fig
contain
semicarbazid
moieti
equipot
mic
mgml
isoniazid
tuberculosi
two
candid
potent
vitro
either
isoniazid
rifampicin
multidrugresist
mycobacterium
strain
mic
mgml
schiff
base
obtain
isatin
r
f
cl
f
lamivudin
aminomethyl
use
fluoroquinolon
r
ethyl
cyclopropyl
r
h
ch
amin
reagent
result
mannich
base
fig
show
growth
inhibit
tuberculosi
h
rv
concentr
mgml
inhibit
one
select
schiff
base
lamivudin
alon
inhibit
growth
mycobacterium
strain
given
concentr
sever
morpholin
mannich
base
thiosemicarbazon
r
cc
h
h
h
h
fig
potent
antimycobacteri
agent
mic
valu
mgml
replac
trifluoromethoxi
group
nitro
led
slight
decreas
potenc
becam
drastic
fluorin
replac
trifluoromethoxi
group
wherea
substitut
morpholin
piperidin
gener
decreas
antimycobacteri
activ
candid
use
fluoroquinolon
gatifloxacin
amin
reagent
sixteen
mannich
base
deriv
isatin
isatin
semicarbazon
isatin
thiosemicarbazon
isatin
hydrazon
isoniazid
isatin
schiff
base
sulfadiazin
prepar
test
antimycobacteri
activ
mic
valu
record
growth
inhibit
mycobacterium
compound
rang
mgml
ngml
wherea
mic
valu
mgml
determin
multidrugresist
strain
promis
result
obtain
potent
compound
seri
test
murin
model
dose
mgkg
analysi
data
inhibit
tuberculosi
dna
gyras
suggest
enzym
could
target
isatinefluoroquinolon
hybrid
good
result
obtain
evalu
antimycobacteri
agent
mannich
base
obtain
isatin
semicarbazon
thiosemicarbazon
substrat
ciprofloxacin
amin
reagent
mic
valu
nm
mannich
base
gener
isatin
correspond
semicarbazon
thiosemicarbazon
oxim
ether
use
amin
reagent
compar
potenc
analog
mannich
base
deriv
moxifloxacin
amin
reagent
also
potent
mic
valu
mgml
tuberculosi
mgml
multidrugresist
mycobacterium
strain
isatinemoxifloxacin
conjug
gener
less
potent
antimycobacteri
parent
fluoroquinolon
evalu
antimycobacteri
agent
aminomethyl
led
interest
result
direct
comparison
mannich
base
x
mannich
base
x
fig
substitu
posit
azol
ring
deriv
cyclic
secondari
aliphat
amin
show
former
significantli
potent
isoniazidsensit
tuberculosi
h
rv
strain
latter
thu
suggest
presenc
oxygen
crucial
antimycobacteri
activ
type
compound
continu
initi
studi
search
better
antimycobacteri
agent
restrict
mannich
base
varieti
amin
reagent
employ
aminomethyl
expand
includ
n
substitut
benzyl
methylamin
structur
modif
preserv
good
activ
candid
mic
valu
mgml
howev
replac
substitu
posit
mannich
base
x
phenyl
pyrazinyl
result
significantli
decreas
antimycobacteri
activ
wherea
replac
gener
affect
activ
candid
bismannich
base
fig
deriv
dapson
amin
reagent
benzaldehyd
aldehyd
reagent
various
substrat
excel
antimycobacteri
activ
isoniazidsensit
isoniazidresist
strain
tuberculosi
potent
isoniazid
sensit
strain
potent
isoniazid
resist
strain
studi
allow
anoth
direct
comparison
time
mannich
base
tabl
mannich
base
tabl
substitu
posit
aforement
azol
candid
potent
potent
mannich
base
tuberculosi
h
rv
strain
still
less
potent
isoniazid
hand
mannich
base
r
h
oh
r
c
h
ch
ch
ch
c
h
h
r
ch
c
h
c
h
substitut
phenyl
deriv
fig
low
antimycobacteri
activ
mic
valu
mgml
major
mannich
base
deriv
either
moieti
posit
triazol
ring
potent
antimycobacteri
mic
mgml
refer
drug
streptomycin
smegmati
addit
mannich
base
nr
fig
equipot
refer
drug
streptomycin
mic
mgml
smegmati
mannich
base
imidazo
deriv
fig
screen
antimycobacteri
activ
evalu
librari
mannich
base
r
cc
h
r
h
br
nr
tuberculosi
h
rv
show
candid
mic
mgml
second
collect
aminomethyl
imidazo
deriv
r
nc
h
cc
h
r
cl
ch
och
nr
consist
mannich
base
good
antimycobacteri
activ
growth
inhibit
concentr
mgml
amongst
mannich
base
r
oc
h
ch
pyrrolidinecontain
deriv
consist
best
agent
tuberculosi
h
rv
also
compound
nr
fig
moder
antimycobacteri
activ
mic
mgml
addit
type
substrat
present
far
miscellan
substrat
subject
mannich
reaction
view
synthes
compound
antimycobacteri
activ
aminomethyl
amid
function
tetracyclin
use
fluoroquinolon
amin
reagent
afford
mannich
base
fig
excel
activ
tuberculosi
mic
valu
mgml
pyrazinamid
also
aminomethyl
amid
function
use
piperazin
includ
four
fluoroquinolon
amin
reagent
result
mannich
base
fig
least
potent
refer
drug
pyrazinamid
tuberculosi
show
significantli
improv
antimycobacteri
activ
pyrazinamid
multidrugresist
mycobacterium
strain
antihiv
drug
efavirenz
aminomethyl
use
either
common
piperazin
piperazinecontain
fluoroquinolon
amin
reagent
afford
hybrid
fig
mannich
base
deriv
fluoroquinolon
good
activ
tuberculosi
comparison
standard
antimycobateri
drug
avail
though
investig
antimycobacteri
activ
small
number
indol
mannich
base
obtain
fig
uncov
candid
inhibit
growth
tuberculosi
h
rv
almost
complet
concentr
mgml
fig
good
antimycobacteri
activ
mic
mgml
mannich
base
fig
moder
activ
tuberculosi
h
rv
final
pyrazolon
mannich
base
nr
nhcoc
h
fig
potent
refer
drug
ethambutol
ciprofloxacin
inferior
isoniazid
tuberculosi
h
rv
incid
fungal
infect
varieti
steadili
increas
last
decad
becom
one
main
caus
morbid
mortal
especi
patient
compromis
immun
system
develop
resist
currentlyinus
antifung
drug
also
repres
major
concern
discoveri
novel
antifung
agent
prefer
outsid
six
major
class
present
avail
treatment
one
highest
prioriti
pharmaceut
industri
latest
advanc
evalu
mannich
base
variou
structur
potenti
antifung
present
section
first
report
antifung
activ
keton
mannich
base
rel
recent
monomannich
base
type
fig
doubl
mannich
base
fig
acetophenon
r
r
h
nr
dimethylamino
shown
weak
antifung
activ
correspond
methiodid
potent
refer
drug
amphotericin
b
yeast
saccharomyc
cerevisia
candida
krusei
dermatophyt
trichophyton
mentagrophyt
trichophyton
rubrum
microsporum
cani
thu
quatern
nitrogen
atom
mannich
base
type
appear
chemic
modif
lead
effici
antifung
variou
substitut
pattern
phenyl
ring
keton
mannich
base
also
improv
significantli
antifung
activ
compound
bismannich
base
r
c
h
deriv
variou
acetophenon
fig
activ
aspergillu
fumigatu
antifung
activ
relat
piperidinol
r
c
h
fig
broader
slightli
potent
compar
correspond
monomannich
base
bismannich
base
especi
dermatophyt
rubrum
cani
howev
later
studi
show
minor
modif
replac
ethyl
methyl
substitu
nitrogen
increas
antifung
activ
bismannich
base
r
ch
decreas
potenc
piperidinol
r
ch
rubrum
cani
use
phenethylamin
amin
reagent
mannich
reaction
variou
acetophenon
afford
secondari
keton
monomannich
base
r
ch
ch
c
h
fig
along
piperidinol
r
ch
ch
c
h
compound
relev
activ
mic
valu
either
mgml
cani
dermatophyt
whose
growth
inhibit
refer
drug
nystatin
concentr
rang
use
studi
member
librari
mannich
base
enon
antifung
effect
potent
amphotericin
b
least
one
mani
select
plant
fungi
keton
mannich
base
deriv
arylamin
amin
reagent
also
report
antifung
effect
thu
mannich
base
r
r
h
f
fig
almost
twofold
potent
refer
drug
ampicillin
candida
albican
wherea
candid
r
f
cl
deriv
r
cl
n
ch
deriv
fig
mic
valu
compar
refer
drug
fluconazol
aspergillu
flavu
chrysosporium
keratinophilum
c
albican
evalu
mannich
base
fig
deriv
cyclic
keton
n
show
compound
good
anticandida
antisaccharomyc
activ
less
potent
aspergillu
strain
none
compound
potent
refer
drug
amphotericin
b
anticandida
potenc
candid
gener
diminish
increas
size
ring
substitut
pattern
aromat
ring
natur
amin
aminomethyl
moieti
influenc
antifung
activ
consider
addit
bunsatur
keton
system
structur
requir
antifung
activ
mannich
base
amino
alcohol
obtain
reduct
carbonyl
group
mostli
inact
toward
fungi
use
studi
inhibit
ergosterol
synthesi
appear
mechan
mannich
base
exert
anticandida
activ
although
abl
influenc
develop
pseudohypha
induc
notic
chang
protein
composit
c
albican
inspect
sar
disclos
previou
studi
also
prove
valid
mannich
base
deriv
cyclic
keton
fuse
aromat
ring
fig
except
mic
valu
compound
consist
better
mannich
base
transcript
profil
c
albican
cell
treat
candid
n
nr
show
transcript
respons
typic
oxid
stress
similar
c
albican
transcript
activ
suggest
abil
mannich
base
directli
trigger
oxid
stress
may
least
part
reason
antifung
activ
mannich
base
fig
obtain
either
secondari
aliphat
amin
primari
arylamin
good
activ
sever
type
fungi
two
candid
nr
r
n
ch
r
r
potent
refer
drug
ketoconazol
fungi
investig
studi
antifung
activ
doubl
mannich
base
fig
sever
fungi
also
good
although
potenc
compound
c
albican
moder
sever
studi
report
antifung
activ
phenol
mannich
base
avail
hydrazon
obtain
salicylaldehyd
aminomethyl
use
variou
secondari
amin
give
mannich
base
fig
potent
anticandida
candid
nr
diphenylamino
weaker
refer
drug
clotrimazol
wherea
growth
aspergillu
niger
inhibit
potent
compound
mic
valu
rang
mgml
aminomethyl
fig
along
copper
ii
complex
signific
antifung
activ
radial
inhibit
myceli
growth
sever
plant
pathogen
fungi
compar
even
higher
sever
case
refer
drug
nystatin
terbinafin
even
concentr
greater
refer
drug
voriconazol
three
mannich
base
nr
r
fig
bare
show
anticandida
activ
compar
voriconazol
aminomethyl
mulundocandin
antifung
lipopeptid
belong
echinocandin
antifung
undertaken
view
improv
solubl
water
result
mixtur
mannich
base
r
ch
nr
r
h
doubl
mannich
base
r
r
ch
nr
fig
separ
antifung
activ
compound
evalu
vitro
one
candid
show
good
inhibit
c
albican
fumigatu
nonetheless
vivo
test
collect
promis
mani
compound
show
anticandida
activ
compar
parent
mulundocandin
signific
improv
anticandida
activ
compar
mulundocandin
observ
monomannich
base
r
r
h
equipot
fluconazol
three
member
collect
r
ch
r
r
h
r
fig
inhibit
zone
niger
compar
refer
drug
fluconazol
benzoxazin
well
naphthoxazin
fig
either
inact
weak
activ
candida
spp
fumigatu
cryptococcu
neoforman
compound
librari
moder
activ
sporothrix
schenckii
mentagrophyt
contrast
naphtho
r
h
oc
h
potent
refer
drug
griseofulvin
c
albican
wherea
naphtho
r
oc
h
equipot
griseofulvin
niger
exampl
mannich
base
phenol
fuse
heterocycl
ring
investig
antifung
activ
includ
compound
fig
moder
weak
activ
niger
penicillium
spp
compar
refer
drug
griseofulvin
compound
fig
effici
aspergillu
spp
c
albican
concentr
high
mgml
mannich
base
chlorokoj
acid
fig
good
anticandida
activ
mic
valu
mgml
antifung
activ
dermatophyt
slightli
poorer
contrast
mannich
base
fig
deriv
allomaltol
piperazin
poor
antifung
activ
c
albican
candida
parapsilosi
compar
refer
drug
fluconazol
member
librari
equipot
fluconazol
c
krusei
antifung
activ
variou
mannich
base
isatin
deriv
examin
jointli
antibacteri
activ
mannich
base
fig
obtain
isatin
semicarbazon
substrat
hetero
arylamin
amin
reagent
good
anticandida
activ
activ
refer
drug
fluconazol
wherea
mannich
base
r
secondari
aliphat
amin
fig
moder
antifung
activ
aspergillu
spp
consist
lower
refer
drug
fluconazol
activ
mannich
base
r
r
antifung
potenc
c
albican
niger
potenc
refer
drug
griseofulvin
coupl
mannich
base
r
substitut
phenyl
fig
moder
activ
niger
activ
c
albican
penicillium
notatum
gener
poor
mannich
base
r
fig
moder
potent
c
albican
niger
compar
refer
drug
fluconazol
final
evalu
niger
mannich
base
ar
c
h
fig
equipot
refer
drug
ketoconazol
fumigatu
wherea
mannich
base
ar
c
h
n
ch
twofold
potent
ketoconazol
three
analogu
equipot
ketoconazol
evalu
mannich
base
tabl
antifung
agent
report
conjunct
antibacteri
activ
seri
mannich
base
except
candid
r
c
h
nr
nhc
h
f
whose
anticandida
activ
refer
drug
clotrimazol
compound
inact
mannich
base
investig
studi
compar
refer
drug
fluconazol
activ
mannich
base
less
potent
c
albican
cerevisia
mannich
base
either
inact
show
low
antifung
activ
wherea
mannich
base
inact
c
albican
cerevisia
mannich
base
lack
anticandida
activ
mannich
base
mannich
base
major
mannich
base
equipot
refer
drug
fluconazol
c
albican
small
number
candid
moder
activ
fungu
wherea
rest
inact
mannich
base
moder
activ
aspergillu
spp
c
albican
penicillium
marneffei
two
candid
r
h
c
h
deriv
amin
reagent
equipot
refer
drug
ciclopiroxolamin
sever
mannich
base
also
equipot
refer
drug
fluconazol
aspergillu
spp
mentagrophyt
p
marneffei
neither
compound
candid
fig
exhibit
anticandida
activ
wherea
mannich
base
weak
moder
activ
candida
tropicali
cerevisia
niger
antifung
activ
mannich
base
aspergillu
spp
penicillium
spp
moder
good
mannich
base
x
ch
r
c
h
potent
refer
drug
fluconazol
c
albican
mannich
base
also
show
good
antifung
activ
c
albican
fusarium
solani
best
anticandida
activ
seri
mannich
base
record
candid
r
c
h
och
inhibit
zone
refer
drug
fluconazol
addit
fig
synthes
doubl
mannich
reaction
start
thion
primari
aliphat
aromat
amin
compound
good
antifung
activ
chrysosponium
tropicum
rubrum
complet
inact
fumigatu
flavu
microsporum
nanum
mix
result
obtain
fungi
candid
potent
refer
drug
clotrimazol
niger
moder
potent
c
albican
fusarium
oxysporum
wherea
rest
compound
seri
total
inact
three
fungi
far
aminomethyl
deriv
concern
candid
fig
activ
c
albican
cerevisia
wherea
seri
mannich
base
featur
imidazol
moieti
fig
candid
nr
twofold
potent
cerevisia
twofold
less
potent
c
albican
refer
drug
fluconazol
antifung
activ
aminomethyl
tabl
report
studi
deal
compound
antibacteri
activ
sever
mannich
base
equipot
refer
drug
ciclopiroxolamin
mentagrophyt
flavu
fumigatu
mic
mgml
p
marneffei
mannich
base
deriv
either
morpholin
show
high
activ
p
marneffei
mentagrophyt
flavu
fumigatu
compar
refer
drug
ciclopiroxolamin
wherea
deriv
primari
aromat
amin
weak
antifung
activ
mannich
base
deriv
piperazin
moder
anticandida
activ
rest
collect
inact
oxadiazolethion
mannich
base
posit
oxadiazol
ring
either
pyridin
quinolin
moieti
notic
anticandida
activ
activ
mannich
base
cerevisia
c
tropicali
niger
moder
best
mannich
base
weak
antifung
activ
c
albican
niger
aspergillu
clavatu
one
candid
nr
nhc
h
och
potent
refer
drug
ketoconazol
first
two
fungi
almost
equipot
ketoconazol
last
fungu
sever
mannich
base
similar
mic
valu
refer
drug
amphotericin
b
c
albican
fumigatu
rubrum
mentagrophyt
imidazolecontain
mannich
base
exhibit
better
antifung
activ
c
albican
rubrum
mentagrophyt
refer
drug
fluconazol
compound
report
studi
includ
mannich
base
claim
exhibit
signific
antifung
activ
c
albican
lack
access
origin
inform
provid
onlin
edit
supplement
materi
miss
make
data
assess
imposs
three
mannich
base
moder
activ
aspergillu
spp
curvularia
lunata
mannich
base
anticandida
activ
mannich
base
show
antifung
activ
c
albican
cerevisia
addit
sever
aminomethyl
potent
refer
drug
nystatin
fungal
plant
pathogen
aspergillu
spp
anticandida
activ
cmannich
base
thiazolidinon
fig
found
weaker
refer
drug
terbinafin
three
mannich
base
moder
activ
c
albican
flavu
one
candid
r
c
h
nr
n
c
h
fig
show
latter
fungu
growth
inhibit
potenc
mic
mgml
half
determin
refer
drug
fluconazol
also
aminomethyl
thiazolidinon
fig
moder
activ
aspergillu
spp
c
albican
compar
refer
drug
ketoconazol
pyrimidin
deriv
aminomethyl
view
evalu
antifung
activ
result
mannich
base
includ
thio
barbitur
acid
doubl
nmannich
base
x
fig
anticandida
activ
clotrimazolecontain
commerci
drug
imidil
cmannich
base
thio
barbitur
acid
fig
obtain
use
aldehyd
compon
amin
reagent
mannich
reaction
show
good
activ
aspergillu
spp
compar
refer
drug
salicyl
acid
antifung
evalu
mannich
base
miscellan
substrat
belong
previous
mention
class
topic
sever
studi
pmannich
base
fig
show
good
activ
c
albican
cerevisia
mic
mgml
compar
refer
drug
amphotericin
b
mic
mgml
variou
mannich
base
type
fig
deriv
imid
present
antiaspergillu
activ
rang
weak
good
correl
structur
activ
small
number
compound
seri
could
establish
anticandida
activ
potent
mannich
base
fig
half
activ
refer
drug
fluconazol
aminomethyl
hydrazidon
r
c
h
deriv
isonicotin
acid
hydrazid
fig
good
anticandida
activ
analogu
r
nc
h
less
activ
activ
niger
even
poorer
sever
dimethylamin
mannich
base
deriv
substitut
aryl
imidazo
pyridin
fig
activ
aspergillu
spp
c
albican
refer
drug
griseofulvin
evalu
fungi
mannich
base
r
ch
sydnon
fig
consist
less
activ
refer
drug
griseofulvin
nystatin
major
mannich
base
r
och
behav
similarli
except
candid
r
och
nr
potent
refer
drug
fluconazol
nystatin
c
albican
mannich
base
deriv
one
fig
inact
aspergillu
spp
c
albican
aminomethyl
pyrazolin
fig
anticandida
activ
mic
mgml
compar
even
better
refer
drug
clotrimazol
mic
mgml
sever
acetylen
mannich
base
fig
equipot
refer
drug
ketoconazol
c
albican
mannich
base
deriv
hydantoin
fig
gener
moder
growth
inhibitor
c
albican
niger
phenothiazin
mannich
base
fig
activ
niger
size
inhibit
zone
mm
antifung
activ
mannich
base
fig
dion
mgdisc
c
albican
niger
superior
refer
drug
clotrimazol
mgdisc
antifung
activ
mannich
base
one
fig
equipot
refer
drug
fluconazol
c
albican
mic
mgml
much
world
popul
live
area
high
risk
contract
malaria
million
peopl
suffer
acut
malaria
year
approxim
half
million
die
diseas
malaria
larg
erad
mani
part
world
total
number
record
case
still
rise
one
caus
grave
situat
prolifer
malaria
parasit
rapidli
becom
resist
antimalari
drug
especi
frequent
use
chloroquin
develop
novel
antimalari
stagnat
sinc
owe
lack
interest
develop
countri
topic
limit
market
potenti
drug
initi
numer
program
support
public
fund
led
surg
interest
drug
neglect
diseas
antimalari
certainli
amongst
drug
use
mannich
reaction
synthesi
antimalari
long
rich
histori
quest
aminomethyl
substrat
treatment
malaria
start
amodiaquin
fig
first
mannich
base
use
treat
malaria
mani
earli
studi
focus
deriv
sar
within
class
antimalari
suggest
chlorin
atom
posit
quinolin
scaffold
phenol
mannich
base
moieti
structur
featur
essenti
antimalari
activ
compound
nowaday
use
amodiaquin
declin
owe
consider
toxic
result
vivo
convers
reactiv
quinoneimin
metabolit
cytochrom
therefor
hypothes
swap
phenol
hydroxyl
aminomethyl
side
chain
amodiaquin
prevent
format
toxic
metabolit
help
circumv
advers
side
effect
associ
use
amodiaquin
hypothesi
led
design
synthesi
sever
amodiaquin
analogu
retain
antimalari
activ
lack
potenti
form
quinoneimin
deriv
analogu
mannich
base
isom
amodiaquin
henceforth
name
isoquin
fig
express
vitro
activ
chloroquin
sensit
strain
highli
chloroquineresist
strain
plasmodium
falciparum
nm
time
potent
chloroquin
isoquin
diphosph
salt
subsequ
test
vitro
murin
plasmodium
yoelii
ns
strain
found
potent
amodiaquin
administ
oral
moreov
toxic
metabolit
excess
accumul
isoquin
notic
anim
model
unaccept
high
first
pass
metabol
isoquin
ndealkyl
metabolit
four
anim
speci
compromis
isoquin
activ
parasit
complic
develop
process
isoquin
market
drug
novel
candid
ntertbutyl
isoquin
fig
identifi
use
isoquin
lead
shown
exhibit
low
nm
activ
chloroquineresist
sensit
parasit
well
vivo
oral
activ
equival
amodiaquin
significantli
improv
antimalari
exposur
profil
addit
ntertbutyl
isoquin
better
overal
preclin
safeti
profil
chloroquin
amodiaquin
synthes
scalabl
costeffect
way
studi
disposit
candid
show
isoquin
undergo
vivo
oxid
ndealkyl
desethylisoquin
metabolit
improv
blood
clearanc
isoquin
unfortun
desethylisoquin
also
potent
inhibitori
action
isoquin
hand
ntertbutyl
isoquin
human
plasma
protein
bind
abil
inhibit
similar
isoquin
desethylisoquin
reduc
rate
ndealkyl
higher
oral
bioavail
compar
isoquin
desethylisoquin
properti
made
ntertbutyl
isoquin
better
candid
isoquin
develop
studi
vitro
activ
isoquin
p
falciparum
clinic
isol
collect
kenya
relat
amino
acid
chang
pfcrt
two
gene
associ
resist
show
isoquin
possess
high
activ
field
isol
ic
nm
compar
nm
chloroquin
nm
amodiaquin
isoquin
activ
could
correl
polymorph
pfcrt
start
ntertbutyl
isoquin
templat
three
benzoxazin
r
c
h
nc
h
ch
c
h
fig
design
gener
doubl
mannich
reaction
despit
good
antiplasmodium
activ
chloroquinesensit
ic
nm
chloroquineresist
ic
nm
strain
rapid
ring
open
benzoxazin
low
ph
make
unsuit
develop
novel
analogu
nr
aliphat
primari
secondari
amin
aromat
primari
secondari
amin
amodiaquin
test
vitro
chloroquinesensit
strain
p
falciparum
compound
activ
mannich
base
nr
fig
show
good
activ
mic
ngml
compar
chloroquin
mic
ngml
antimalari
activ
analogu
isoquin
fig
also
evalu
regardless
natur
amin
aminomethyl
moieti
activ
consider
lower
refer
drug
chloroquin
use
primari
amin
deriv
bicycl
scaffold
synthesi
novel
isoquin
analogu
led
discoveri
fig
approxim
twofold
potent
either
chloroquin
isoquin
chloroquinesensit
resist
p
falciparum
strain
seri
isotebuquin
analogu
r
cl
cf
r
h
correspond
doubl
mannich
base
r
ch
nhc
ch
well
noxid
deriv
monomannich
base
doubl
mannich
base
type
fig
also
evalu
chloroquinesensit
resist
p
falciparum
strain
candid
potent
chloroquin
chloroquinesensit
strain
major
mannich
base
potent
chloroquin
chloroquineresist
strain
mannich
base
one
aminomethyl
function
gener
potent
doubl
mannich
base
pyronaridin
fig
anoth
exampl
antimalari
drug
featur
phenol
mannich
base
moieti
structur
aminoquinolin
scaffold
typic
amodiaquin
congen
replac
pyronaridin
naphthyridin
ring
system
pyronaridin
first
synthes
chines
institut
parasit
diseas
use
sole
china
treatment
malaria
good
result
year
besid
difficultli
access
literatur
chines
sever
recent
studi
provid
inform
physicochem
properti
adm
properti
rat
interact
antimalari
potenti
use
combin
therapi
artesun
mechan
action
base
inhibit
bhematin
format
subsequ
glutathionedepend
hematin
degrad
process
base
observ
substitut
quinolin
scaffold
amodiaquin
napthyridin
ring
system
pyronaridin
preserv
antimalari
action
orlitz
initi
ambiti
synthet
program
aim
explor
effect
antimalari
properti
replac
quinolin
quinolinebas
antimalari
fuse
heterocycl
system
contain
one
pyridin
ring
thu
singl
r
h
doubl
mannich
base
r
ch
nr
structur
relat
amodiaquin
pyronaridin
respect
featur
pyrido
compound
x
nh
benzofuro
compound
moieti
synthes
evalu
chloroquinesensit
resist
p
falciparum
strain
fig
expect
mannich
base
present
studi
exhibit
good
antimalari
activ
doubl
mannich
base
gener
potent
singl
mannich
base
howev
spite
varieti
fuse
heterocycl
system
investig
compound
antimalari
activ
least
compar
chloroquin
emerg
except
one
pyronaridin
analogu
x
nh
r
ch
nr
nr
candid
ic
nm
chloroquinesensit
strain
ic
nm
chloroquineresist
strain
evalu
plasmodium
winckei
murin
malaria
model
intraperiton
dosag
mgkg
show
intact
parasit
could
notic
three
day
treatment
phenol
mannich
base
moieti
previous
mention
antimalari
agent
also
found
candid
design
incorpor
hybrid
dual
mode
action
thu
combin
tetraoxan
phenol
mannich
base
moieti
afford
hybrid
call
mannoxan
fig
activ
low
nanomolar
concentr
surpass
abil
artesun
tetraoxan
rka
peroxideamodiaquin
combin
cure
malaria
mice
mgkg
hybrid
artemisin
phenol
mannich
base
moieti
led
candid
fig
time
potent
artemisin
p
yoelii
nigeriensi
could
easili
convert
water
solubl
form
administ
oral
presum
good
bioavail
lack
capabl
form
neurotox
metabolit
dihydroartemisinin
hybrid
fig
structur
similar
shown
activ
sodium
artesun
chloroquinesensit
chloroquineresist
p
falciparum
strain
screen
collect
compound
contain
motif
structur
inhibit
parasit
growth
red
blood
cell
infect
chloroquinesensit
p
falciparum
strain
identifi
hit
compound
whose
elabor
led
sever
hybrid
featur
sever
type
phenol
mannich
moieti
second
pharmacophor
evalu
strain
strain
rodent
parasit
plasmodium
berghei
show
introduct
phenol
mannich
base
moieti
result
candid
potent
parasit
h
assay
exampl
compound
fig
design
hybrid
dual
mode
action
also
broaden
includ
pyrrol
mannich
base
thu
hybrid
pyrrol
mannich
base
fig
evalu
chloroquinesensit
chloroquineresist
p
falciparum
strain
less
potent
isoquin
strain
howev
candid
r
h
nr
n
c
h
equipot
chloroquin
strain
four
candid
also
potent
chloroquin
strain
sever
candid
small
librari
mannich
base
r
h
ch
pyrrol
analogu
artemisin
fig
antimalari
activ
superior
artemisin
chloroquin
chloroquinesensit
p
falciparum
strain
select
mannich
base
librari
potent
aforement
refer
drug
chloroquineresist
p
falciparum
strain
compound
test
display
good
activ
peter
day
suppress
test
use
mgkg
day
postinfect
candid
show
complet
elimin
parasit
three
mannich
base
investig
vivo
effect
dose
mgkg
elimin
p
berghei
mice
wherea
candid
r
ch
nr
reach
clearanc
parasitemia
h
last
treatment
increas
mous
surviv
day
biolog
profil
render
superior
clinic
use
sodium
artesun
phenol
mannich
base
chalcon
analogu
fig
claim
possess
antimalari
activ
chloroquinesensit
p
falciparum
strain
concentr
rang
mgml
take
account
structur
similar
phenol
mannich
base
keton
mannich
base
bunsatur
keton
possibl
mechan
action
compound
could
inhibit
thioredoxin
fig
antimalari
phenol
mannich
base
deriv
miscellan
substrat
reductas
p
falciparum
phenol
mannich
base
thiosemicarbazon
semicarbazon
fig
well
relat
quinolinecontain
deriv
fig
screen
chloroquineresist
p
falciparum
strain
candid
deriv
piperazin
antimalari
activ
remain
mannich
base
inact
candid
potent
antimalari
agent
mannich
base
nr
featur
two
quinolin
motif
structur
potent
ic
nm
imin
pyridon
r
r
h
ch
fig
phenol
mannich
base
moieti
activ
chloroquineresist
p
falciparum
strain
ic
valu
mm
atovaquoneresist
p
falciparum
strain
ic
valu
low
mm
potenc
lower
refer
drug
chloroquin
atovaquon
addit
aminoalkyl
lawson
use
variou
aldehyd
nalkylferrocenylmethylamin
afford
mannich
base
r
alkyl
fig
structur
resembl
antimalari
drug
atovaquon
evalu
three
candid
r
nc
h
nc
h
nc
h
p
falciparum
show
less
potent
atovaquon
selflimit
natur
viral
diseas
except
caus
human
immunodefici
viru
hiv
requir
specif
therapi
although
treatment
use
bring
condit
symptom
end
quickli
current
avail
drug
design
target
four
main
group
virus
name
herp
virus
hepat
virus
influenza
virus
hiv
recent
investig
antivir
activ
mannich
base
deal
mostli
aminomethyl
phenol
aminomethyl
isatin
although
exampl
mannich
base
antivir
properti
deriv
type
substrat
avail
literatur
phenol
mannich
base
arbidol
fig
broadspectrum
antivir
agent
commonli
use
russia
treat
acut
respiratori
viral
infect
act
inhibit
virusmedi
fusion
target
membran
subsequ
blockag
viru
entri
target
cell
use
arbidol
lead
compound
group
shenyang
pharmaceut
univers
led
gong
initi
program
aim
investig
structureeantihepat
b
relationship
seri
phenol
mannich
base
deriv
variou
heterocycl
ring
system
first
report
topic
chines
research
present
seri
analogu
arbidol
x
r
ch
cc
h
r
br
fig
variou
substitu
r
aromat
sulfoxid
moieti
present
amino
residu
differ
origin
dimethylamino
group
arbidol
eg
secondari
aliphat
amin
nhazol
belong
imidazol
aminomethyl
function
posit
sar
investig
base
abil
compound
inhibit
replic
hepat
b
viru
hbv
product
surfac
antigen
hepat
b
viru
hbsag
extracellular
form
hepat
b
core
antigen
hbeag
cell
infect
hbv
show
half
mannich
base
exhibit
inhibitori
effect
hbv
superior
refer
drug
lamivudin
replac
origin
methyl
group
cyclopropyl
led
increas
antivir
activ
enhanc
cytotox
candid
well
wherea
presenc
fluorin
chlorin
substitu
aromat
sulfoxid
moieti
result
improv
antihbv
activ
departur
origin
phenylmercapto
function
arbidol
reduc
cytotox
mannich
base
x
leav
time
antihbv
activ
practic
unchang
also
natur
amino
group
aminomethyl
function
appear
littl
effect
antihbv
activ
mannich
base
report
studi
relationship
presenc
linker
contain
two
three
atom
sulfur
atom
side
chain
phenyl
moieti
antihbv
activ
mannich
base
x
soch
ch
ch
null
r
ch
r
br
also
explor
candid
phenethyl
residu
prove
inact
wherea
candid
residu
present
remark
antihbv
activ
subsequ
studi
antihbv
activ
arbidol
analogu
x
r
ch
cc
h
r
h
unsubstitut
posit
indol
scaffold
claim
natur
amino
function
play
import
role
pyrrolidineand
imidazolecontain
candid
exhibit
better
antihbv
activ
candid
differ
amino
residu
anoth
set
mannich
base
x
r
ch
r
h
author
suggest
presenc
residu
amino
moieti
rather
afford
potent
antihvb
agent
replac
sulfinyl
group
side
chain
sulfonyl
appear
enhanc
antivir
activ
reduc
cellular
toxic
mannich
base
although
result
later
studi
support
opposit
conclus
substitut
indol
scaffold
quinolin
mannich
base
x
fig
result
potent
inhibit
hbv
dna
replic
compar
refer
drug
lamivudin
analysi
sar
compound
reveal
presenc
moieti
link
sulfur
side
chain
posit
quinolin
scaffold
conjunct
amin
moieti
fig
phenol
mannich
base
inspir
arbidol
use
antihepat
b
agent
methylpiperazinyl
morpholinyl
aminomethyl
function
requir
good
antihbv
activ
evalu
mannich
base
fig
deriv
tetracycl
ring
system
compris
quinolin
scaffold
fuse
benzothiopyran
ring
system
variou
substitut
pattern
aromat
ring
identifi
signific
number
candid
good
inhibit
hbv
replic
search
antihbv
agent
similar
structur
continu
evalu
seri
phenol
mannich
base
r
ch
c
h
ch
ch
r
h
f
x
substitut
posit
residu
fig
compound
exhibit
inhibitori
effect
secret
hbsag
superior
refer
drug
lamivudin
lack
abil
inhibit
replic
hbv
dna
cell
concentr
inferior
correspond
cytotox
presenc
fluorin
posit
benzimidazol
scaffold
presenc
sulfinyl
function
appear
critic
inhibit
hbsag
secret
mannich
base
evalu
anoth
seri
mannich
base
x
r
h
fig
show
thioether
seri
inhibit
replic
hbv
dna
candid
amino
moieti
good
inhibitor
secret
hbsag
inhibitori
effect
significantli
decreas
upon
oxid
sulfur
thioether
sulfinyl
sulfonyl
phenol
mannich
base
r
h
deriv
fig
especi
moieti
aminomethyl
function
inhibit
replic
hbv
dna
inhibitori
effect
secret
hbsag
hbeag
natur
substitu
arylmercapto
residu
modul
antihbv
activ
decreas
bulki
substitu
bromin
fluorin
exampl
presenc
lipophil
substitu
eg
methyl
group
enhanc
inhibit
replic
hbv
dna
wherea
presenc
group
increas
activ
phenol
mannich
base
deriv
chlorokoj
acid
fig
evalu
herp
simplex
viru
viru
amongst
candid
report
one
studi
two
mannich
base
inhibitori
concentr
rang
mgml
wherea
compound
activ
variou
degre
mannich
base
deriv
amin
reagent
inhibit
one
candid
r
potent
refer
drug
acyclovir
addit
candid
r
present
remark
activ
mgml
aminomethyl
deriv
variou
phenol
substrat
test
differ
virus
one
phenol
mannich
base
r
nhch
norvisnagin
fig
moder
activ
evalu
aminomethyl
deriv
fig
flavivirida
virus
led
mix
result
phenol
mannich
base
r
h
r
h
ch
gener
inact
bovin
viral
diarrhea
viru
bvdv
yellow
fever
viru
yfv
respiratori
syncyti
viru
rsv
candid
activ
bvdv
yfw
also
cytotox
oalkyl
phenol
mannich
base
r
nc
h
r
h
ch
especi
candid
methyl
group
posit
coumarin
ring
system
activ
bvdv
inact
yfv
rsv
oacyl
phenol
mannich
base
r
coc
h
r
h
ch
gener
inact
three
virus
one
candid
r
coc
h
r
h
nr
remark
activ
rsv
compar
refer
drug
also
low
toxic
compound
activ
panel
virus
compris
coxsackieviru
strain
marek
diseas
viru
vesicular
stomat
viru
reoviru
addit
screen
extens
librari
compound
identifi
mannich
base
fig
reactiv
latent
could
prove
help
erad
latent
reservoir
rest
memori
cell
either
alon
combin
treatment
antivir
activ
mannich
base
isatin
deriv
topic
sever
investig
screen
twelv
mannich
base
deriv
semithiocarbazon
fig
panel
virus
afford
compound
antivir
properti
except
candid
x
r
allyl
weak
activ
yfv
strain
subtox
concentr
candid
potent
refer
drug
ribavirin
also
cytotox
base
result
molecular
studi
aim
design
inhibitor
hiv
revers
transcriptas
seri
mannich
base
fig
synthes
candid
secondari
aliphat
amino
moieti
aminomethyl
function
show
inhibit
enzym
wherea
mannich
base
nr
nhc
h
show
inhibit
aminomethyl
schiff
base
obtain
isatin
r
f
cl
f
lamivudin
use
fluoroquinolon
r
ethyl
cyclopropyl
r
h
ch
amin
reagent
gave
mannich
base
fig
less
potent
hiv
parent
schiff
base
potent
candid
r
f
also
less
potent
lamivudin
hiv
start
schiff
base
trimethoprim
mannich
base
fig
obtain
use
fluoroquinolon
amin
reagent
evalu
hiv
hepat
c
viru
hcv
show
mannich
base
r
cl
inhibit
replic
hiv
cell
effect
concentr
ec
rang
mgml
compound
activ
hcv
rna
replic
inhibit
mgml
mannich
base
r
ch
nr
three
mannich
base
r
ch
deriv
fluoroquinolon
amin
reagent
show
inhibit
replic
hiv
cell
ec
rang
mgml
addit
compound
r
ch
activ
hcv
rna
replic
inhibit
mgml
furthermor
studi
report
candid
r
h
nr
inhibitor
japanes
enceph
viru
west
nile
viru
vitro
remark
inhibitor
japanes
enceph
viru
murin
model
investig
antivir
activ
mannich
base
deriv
substrat
phenol
isatin
avail
literatur
well
major
mannich
base
r
cl
och
fig
obtain
naminomethyl
morpholin
piperidin
various
piperazin
show
activ
sever
acut
respiratori
syndrom
sar
coronaviru
also
mannich
base
antivir
activ
type
b
influenza
viru
viru
inhibit
occur
almost
cytotox
concentr
aminomethyl
amid
function
tetracyclin
use
fluoroquinolon
amin
reagent
afford
mannich
base
fig
four
candid
deriv
tetracyclin
one
deriv
minocyclin
found
inhibit
hiv
replic
ec
valu
mm
toxic
mock
infect
cem
cell
line
greater
mm
addit
mannich
base
show
moder
inhibit
process
strand
transfer
step
integras
evalu
efavirenz
mannich
base
fig
led
discoveri
three
candid
least
potent
parent
compound
hiv
larg
number
indol
mannich
base
r
aminomethyl
fig
deriv
pentacycl
core
along
sever
acetylen
mannich
base
core
claim
activ
hcv
member
flavivirida
famili
virus
none
mannich
base
fig
deriv
indophenazin
substrat
sulfonamid
anthranil
acid
amin
reagent
either
show
activ
hiv
cytotox
concentr
present
weak
activ
hsv
vsv
vaccinia
viru
anticonvuls
drug
use
treatment
seizur
epilepsi
common
chronic
neurolog
disord
affect
around
million
peopl
age
worldwid
discoveri
novel
antiepilept
drug
reli
either
ration
design
base
use
wellknown
pharmacophor
eg
imid
random
screen
librari
compound
keton
mannich
base
r
aryloxi
arylthio
r
h
nr
n
c
h
r
r
h
nr
dimethylamino
fig
relat
piperidinol
r
aryloxi
r
c
h
fig
examin
anticonvuls
activ
maxim
electroshock
me
subcutan
pentylenetetrazol
scptz
screen
none
compound
provid
protect
scptz
screen
sever
candid
demonstr
anticonvuls
activ
me
screen
neurotox
level
mgkg
four
keton
mannich
base
type
deriv
acetophenon
substrat
common
secondari
aliphat
amin
amin
reagent
well
correspond
azin
fig
assess
anticonvuls
use
two
test
result
show
anticonvuls
activ
candid
superior
azin
compound
deriv
activ
dose
mgkg
me
test
candid
show
anticonvuls
activ
cptz
test
bismannich
base
r
h
r
c
h
correspond
piperidinol
protect
me
test
mgkg
andor
candid
r
r
c
h
protect
scmet
test
mgkg
h
presenc
moieti
appear
import
anticonvuls
activ
compound
analogu
moieti
identifi
good
anticonvuls
agent
previou
studi
anticonvuls
activ
phenol
mannich
base
investig
extens
aytemir
group
screen
deriv
allomaltol
group
fig
use
me
scptz
test
show
candid
r
c
h
provid
excel
protect
pentylenetetrazoleinduc
seizur
neurotox
high
dose
mgkg
candid
r
h
high
anticonvuls
activ
me
test
dose
min
without
neurotox
evalu
anoth
seri
mannich
base
allomaltol
reveal
candid
r
ch
c
h
activ
scptz
test
mgkg
h
along
candid
r
h
activ
me
test
mgkg
h
although
mannich
base
allomaltol
obtain
use
morpholin
piperidin
amin
reagent
anticonvuls
activ
subsequ
studi
deal
novel
mannich
base
gener
piperidin
amin
reagent
report
candid
r
r
r
ch
r
h
r
h
ch
r
h
fig
protect
scptz
test
candid
r
ch
r
h
provid
protect
me
test
mgkg
use
piperidin
amin
reagent
mannich
reaction
allomaltol
substrat
led
candid
r
un
substitut
phenyl
r
oh
cn
coch
two
mannich
base
r
h
r
oh
r
h
r
oh
activ
scptz
test
mgkg
h
activ
me
test
either
h
h
contrast
allomaltol
replac
kojic
acid
substrat
mannich
reaction
piperidin
use
mine
reagent
result
candid
nr
piperidin
fig
activ
scptz
test
either
h
h
two
r
h
r
oh
r
h
r
oh
activ
me
test
mgkg
h
one
candid
r
c
h
r
coch
activ
dose
h
mannich
base
nr
piperazin
kojic
acid
substrat
piperazin
amin
reagent
gener
better
anticonvuls
analog
mannich
base
allomaltol
mannich
base
deriv
kojic
acid
piperidin
author
tent
explain
enhanc
anticonvuls
activ
mannich
base
kojic
acid
compar
activ
mannich
base
allomaltol
possibl
format
extra
hydrogen
bond
former
compound
howev
mannich
base
deriv
chlorokoj
acid
also
good
anticonvuls
present
like
mannich
base
allomaltol
one
hydrogen
bond
structur
hydantoin
repres
core
structur
old
gener
antiepilept
drug
phenytoin
substitut
aminomethyl
moieti
shown
improv
activ
me
seizur
mice
evalu
librari
nmannich
base
fig
deriv
piperazin
aminomethyl
function
show
major
candid
effect
me
orand
scptz
screen
quantit
studi
rat
oral
administr
show
three
mannich
base
r
h
r
c
h
c
h
ch
c
h
ch
potent
phenytoin
me
test
result
anoth
studi
show
candid
gener
activ
me
test
scptz
screen
chlorinesubstitut
mannich
base
r
cl
gener
less
activ
unsubstitut
aromat
ring
r
h
wherea
candid
deriv
amin
reagent
mannich
reaction
less
potent
deriv
morpholin
piperazin
compar
candid
obtain
arylpiperazin
amin
reagent
mannich
base
alkylen
alkenylen
carbonyl
ester
linker
piperazin
moieti
phenyl
ring
present
enhanc
anticonvuls
protect
pentylenetetrazoleinduc
seizur
notic
h
h
well
take
account
establish
anticonvuls
properti
mani
spirohydantoin
mannich
base
x
nh
spirohydantoin
fig
synthes
evalu
anticonvuls
effect
me
scptz
screen
potent
refer
drug
phenytoin
high
neurotox
preclud
test
besid
hydantoin
succinimid
present
structur
requir
core
structur
good
anticonvuls
agent
name
nitrogencontain
heteroatom
system
least
one
carbonyl
group
wellestablish
drug
ethosuximid
exampl
class
antiepilept
drug
group
obniska
develop
novel
anticonvuls
long
time
mannich
base
deriv
various
substitut
succinimid
one
class
compound
provid
interest
result
report
research
base
signific
number
candid
synthes
aminomethyl
deriv
fig
gener
show
protect
me
screen
also
effect
scptz
screen
moreov
candid
present
activ
h
administr
also
h
indic
quick
onset
long
durat
anticonvuls
activ
mannich
base
deriv
secondari
aliphat
amin
morpholin
gener
effect
screen
despit
larg
number
compound
evalu
studi
consist
sar
could
establish
compound
good
anticonvuls
properti
emerg
almost
studi
none
anticonvuls
mannich
base
deem
suffici
promis
advanc
clinic
studi
aminomethyl
spirosuccinimid
also
investig
anticonvuls
candid
x
ch
deriv
piperazin
piperazin
amin
reagent
mannich
reaction
potent
anticonvuls
seri
me
test
replac
substitut
aryl
render
candid
activ
test
activ
mannich
base
simpler
spirosuccinimid
fig
appear
depend
candid
n
deriv
piperazin
devoid
anticonvuls
activ
hand
mannich
base
n
obtain
piperazin
amin
reagent
effici
me
screen
scptz
screen
evalu
anticonvuls
agent
mannich
base
succinimid
ident
fig
also
topic
sever
recent
paper
gener
mannich
base
obtain
potent
obtain
turn
potent
mannich
base
deriv
actual
inact
case
candid
gener
amin
reagent
mannich
reaction
effici
me
test
natur
posit
substitu
aromat
ring
attach
piperazin
modul
anticonvuls
activ
compound
howev
mannich
base
deriv
piperazin
effici
screen
effect
mannich
base
potent
anticonvuls
activ
na
v
sodium
channel
current
also
investig
potenti
mechan
action
compound
result
show
anticonvuls
activ
candid
correl
nice
effect
sodium
channel
blocker
addit
direct
correl
anticonvuls
properti
andor
serotonin
receptor
affin
besid
hydantoin
succinimid
substrat
featur
ureido
motif
structur
aminomethyl
view
obtain
anticonvuls
agent
barbitur
acid
thio
analogu
subject
mannich
reaction
two
amin
reagent
quinazolinon
moieti
result
candid
x
r
fig
provid
good
protect
respect
me
scptz
screen
dose
mgkg
lack
neurotox
sed
hypnot
effect
mannich
base
one
fig
show
signific
anticonvuls
activ
me
test
candid
afford
result
compar
obtain
refer
drug
phenytoin
sever
studi
concern
anticonvuls
activ
fuse
sevenmemb
ring
system
contain
two
heteroatom
avail
literatur
aminomethyl
fig
provid
protect
me
test
rang
dose
mgkg
candid
r
r
equipot
refer
drug
phenytoin
lamotrigin
me
screen
also
equipot
refer
drug
valproat
scptz
screen
anoth
studi
allow
direct
comparison
anticonvuls
activ
analog
aminomethyl
x
x
fig
dose
mg
kg
latter
provid
protect
me
test
former
mannich
base
x
r
r
och
activ
compound
seri
keton
mannich
base
r
h
cl
r
er
r
er
ch
r
r
r
ch
r
h
scaffold
amino
moieti
fig
evalu
use
model
seizur
induc
chemic
compound
provid
protect
h
wherea
candid
deriv
acetophenon
r
h
provid
protect
h
inflamm
part
complex
nonspecif
immun
respons
vascular
tissu
occur
reaction
type
injuri
pathogen
irrit
damag
cell
etc
initi
respons
bodi
harm
stimuli
initi
cell
alreadi
present
tissu
achiev
increas
movement
plasma
leukocyt
especi
granulocyt
blood
injur
tissu
releas
seri
cellderiv
mediat
trigger
afterward
cascad
biochem
event
propag
inflammatori
respons
nonsteroid
antiinflammatori
drug
nsaid
commonli
use
treatment
inflamm
along
symptom
fever
pain
swell
present
signific
side
effect
longterm
usag
gastrointestin
lesion
kidney
injuri
cardiovascular
risk
along
mani
class
compound
mannich
base
variou
structur
investig
part
ongo
search
novel
antiinflammatori
drug
keton
mannich
base
r
h
ch
ch
deriv
aromat
amin
fig
evalu
use
xyleneinduc
ear
swell
test
carrageenaninduc
paw
edema
candid
r
h
superior
refer
drug
ibuprofen
test
wherea
sever
candid
r
ch
less
effici
still
effect
ibuprofen
test
administr
keton
mannich
base
fig
rat
chronic
inflammatori
process
induc
insert
cotton
pellet
led
increas
phagocyt
capac
peripher
neutrophil
enhanc
activ
serum
complement
system
higher
catalas
activ
slightli
decreas
activ
superoxid
dismutas
observ
doubl
mannich
base
one
fig
inhibit
product
proinflammatori
cytokin
tnfa
concentr
mm
cytotox
refer
drug
dexamethason
compar
effect
candid
product
cytokin
mm
investig
antiinflammatori
activ
mannich
base
r
h
f
cl
br
r
och
oc
h
n
amino
acid
isoleucin
methionin
amin
moieti
fig
perform
use
carrageenaninduc
paw
edema
model
pelletinduc
granuloma
model
result
discoveri
two
antiinflammatori
agent
r
och
oc
h
n
r
ch
ch
sch
deriv
methionin
dose
mgkg
two
mannich
base
respect
effici
refer
drug
diclofenac
dose
mgkg
reduct
paw
swell
dose
two
candid
also
show
respect
activ
refer
drug
indomethacin
dose
mgkg
chronic
inflamm
continu
studi
undertaken
view
broaden
natur
amino
acid
cystein
threonin
methionin
isoleucin
asparagin
glutamin
amin
moieti
mannich
base
also
natur
alkoxi
substitu
aromat
ring
novel
candid
antiinflammatori
activ
mgkg
except
two
candid
r
oc
h
r
ch
sh
ch
conh
display
mild
activ
acut
inflamm
model
one
exampl
mannich
base
obtain
simpl
phenol
potenti
antiinflammatori
agent
avail
recent
literatur
thu
evalu
four
phenol
mannich
base
fig
use
formalininduc
acut
inflamm
model
mice
reveal
one
candid
reliabl
activ
upon
parenter
administr
mgkg
wherea
refer
drug
diclofenac
sodium
exhibit
twothird
activ
albeit
mgkg
phenol
mannich
base
resveratrol
analogu
contain
pyridinyl
moieti
either
one
two
three
aminomethyl
residu
fig
test
use
xyleneinduc
ear
edema
mice
mgkg
two
effici
refer
drug
ibuprofen
wherea
remain
candid
less
potent
antiinflammatori
activ
mannich
base
polyhydroxyl
phenol
also
investig
dose
mgkg
two
candid
nr
r
deriv
fig
slightli
lower
activ
refer
drug
indomethacin
carrageenaninduc
paw
edema
three
candid
r
nr
r
nr
fig
effici
inhibit
product
tnfa
concentr
mm
refer
drug
dexamethason
mm
experiment
condit
mannich
base
studi
also
effici
inhibit
product
dexamethason
research
also
investig
action
enzym
involv
inflamm
cyclooxygenas
cox
trypsin
bglucuronidas
phenol
mannich
base
r
chalcon
analogu
fig
substitut
pattern
ring
candid
one
except
none
candid
inhibit
activ
trypsin
wherea
mannich
base
studi
inhibit
activ
bglucuronidas
candid
deriv
chalcon
analogu
halogen
posit
b
ring
gener
potent
deriv
chalcon
analogu
halogen
posit
b
ring
addit
mannich
base
poor
inhibitor
excel
inhibitor
major
candid
effici
inhibit
refer
drug
aspirin
differ
studi
two
four
phenol
mannich
base
chalcon
analogu
found
reduc
rat
paw
edema
induc
carrageenan
although
compound
found
good
inhibitor
trypsin
time
satisfactori
correl
antioxid
free
radic
scaveng
lipooxygenas
inhibit
could
establish
induc
nitric
oxid
synthas
ino
gener
high
level
nitric
oxid
modul
inflamm
multipl
pathway
inhibit
enzym
phenol
mannich
base
heterocycl
analogu
chalcon
variou
structur
also
investig
type
phenol
mannich
base
found
strongli
inhibit
product
ic
valu
rang
mm
benzoxazin
fig
easili
obtain
doubl
mannich
reaction
inhibit
swell
rat
paw
variou
degre
administ
oral
dose
equimolar
mgkg
indomethacin
compar
indomethacin
one
candid
r
effici
anoth
candid
r
equipot
chalcon
analogu
r
deriv
benzoxazin
fig
pronounc
antiinflammatori
activ
compar
candid
display
effici
refer
drug
indomethacin
phenol
mannich
base
naturallyoccur
benzopyranon
also
test
antiinflammatori
agent
mannich
base
deriv
fig
superior
refer
drug
indomethacin
reduc
rat
paw
edema
induc
carrageenan
two
candid
nr
time
effici
indomethacin
mm
without
signific
inhibit
irisolidon
isoflavon
isol
pueraria
spp
found
exert
antiinflammatori
action
suppress
ino
gene
express
proinflammatori
cytokin
activ
microglia
chemic
modif
irisolidon
mean
mannich
reaction
use
primari
aliphat
aromat
amin
amin
reagent
led
candid
fig
enhanc
abil
inhibit
nitric
oxid
product
compar
parent
irisolidon
antiinflammatori
activ
mannich
base
also
investig
sever
candid
tabl
evalu
use
carrageenan
induc
rat
paw
edema
model
activ
one
r
c
h
nr
compar
refer
drug
ibuprofen
mannich
base
secondari
aliphat
amino
moieti
dimethylamino
diethylamino
aminomethyl
function
effici
refer
drug
celecoxib
reduc
rat
paw
edema
h
h
also
lower
ic
valu
around
nm
inhibit
compar
celecoxib
nm
far
tabl
concern
major
mannich
base
upon
administr
either
mgkg
mgkg
lower
antiinflammatori
activ
carrageenaninduc
rat
paw
edema
model
refer
drug
indomethacin
mgkg
although
one
candid
r
c
h
nr
inhibit
edema
format
higher
dose
almost
effici
indomethacin
start
ibuprofen
two
separ
studi
report
synthesi
antiinflammatori
activ
mannich
base
differ
arylideneamino
moieti
posit
scaffold
fig
potent
compound
seri
either
residu
aminomethyl
function
common
benzaldehyd
r
h
c
h
h
c
h
use
gener
azomethin
moieti
sever
candid
antiinflammatori
activ
compar
refer
drug
diclofenac
gener
effici
ibuprofen
everi
time
interv
h
also
potent
compound
seri
either
residu
aminomethyl
function
hand
use
gener
azomethin
moieti
result
mannich
base
consist
potent
analogu
previous
mention
seri
compound
candid
less
effici
refer
drug
indomethacin
reduc
rat
paw
edema
sever
mannich
base
show
peak
antiinflammatori
activ
h
postinject
edema
inhibit
compar
indomethacin
wherea
antiinflammatori
activ
candid
peak
h
postinject
edema
inhibit
compar
indomethacin
mannich
base
fig
moder
antiinflammatori
activ
potent
compound
seri
show
approxim
effici
refer
drug
indomethacin
mannich
base
structur
relat
aminomethyl
fig
reduc
significantli
inflammatori
respons
maximum
inhibit
compar
refer
drug
diclofenac
inhibit
present
fast
onset
antiinflammatori
action
other
longlast
antiinflammatori
effect
antiinflammatori
activ
mannich
base
scarc
examin
sever
mannich
base
tabl
especi
deriv
ibuprofen
start
materi
substrat
gener
amin
reagent
aminomethyl
step
effici
refer
drug
diclofenac
reduc
rat
paw
edema
also
mannich
base
fig
antiinflammatori
activ
compar
refer
drug
indomethacin
carrageenaninduc
rat
paw
edema
test
sever
paper
publish
okhan
group
report
antiinflammatori
activ
mannich
base
one
studi
show
candid
r
ch
r
h
co
acyl
moieti
posit
benzoxazolidinon
scaffold
potent
analogu
r
h
co
r
h
acyl
group
posit
fig
addit
antiinflammatori
activ
two
candid
equipot
refer
drug
indomethacin
substitut
fluorin
phenyl
ring
acyl
moieti
appear
less
favor
antiinflammatori
activ
candid
r
h
r
difluorobenzoyl
mannich
base
r
ch
r
h
residu
aminomethyl
function
less
potent
refer
drug
indomethacin
carrageenaninduc
rat
paw
edema
test
result
suggest
natur
substitu
aryl
group
piperazin
play
import
role
antiinflammatori
activ
compound
mannich
base
r
r
h
antiinflammatori
effect
compar
refer
drug
indomethacin
h
administr
effici
reduc
swell
reach
plateau
afterward
wherea
indomethacin
continu
increas
time
two
studi
report
antiinflammatori
activ
mannich
base
isatin
aminomethyl
deriv
thiosemicarbazon
afford
mannich
base
r
r
h
ch
nr
secondari
aliphat
amin
fig
show
moder
antiinflammatori
activ
inhibit
edema
dose
mgkg
compar
refer
drug
diclofenac
inhibit
edema
dose
mgkg
sever
mannich
base
fig
obtain
deriv
isatin
hydrazon
antiinflammatori
activ
compar
refer
drug
diclofenac
highest
level
activ
observ
h
correl
seri
antiinflammatori
activ
natur
amino
moieti
aminomethyl
function
notic
activ
decreas
increas
lipophil
amino
group
seri
nmannich
base
benzimidazol
deriv
fig
evalu
antiinflammatori
agent
use
formalininduc
paw
edema
method
compar
refer
drug
diclofenac
mgkg
caus
signific
reduct
paw
edema
albeit
differ
dose
mgkg
mannich
base
r
h
ch
mgkg
mannich
base
also
sever
mannich
base
r
c
h
deriv
secondari
aliphat
amin
primari
arylamin
show
moder
antiinflammatori
activ
h
administr
activ
refer
drug
aspirin
dose
mgkg
mannich
base
obtain
substrat
mention
far
examin
antiinflammatori
agent
well
thu
nmannich
base
nr
pyrimido
azepin
deriv
fig
moder
activ
reduct
edema
compar
record
refer
drug
diclofenac
wherea
nmannich
base
tricycl
system
deriv
pyrimido
azepin
fig
less
potent
antiinflammatori
activ
approxim
diclofenac
two
aminomethyl
pyridazinon
bear
thiophen
ring
name
compound
fig
show
reduct
rat
paw
edema
respect
compar
refer
drug
indomethacin
even
administ
higher
dose
rel
refer
drug
none
mannich
base
r
h
ch
och
cl
x
ch
deriv
isoxazolin
fig
effici
indomethacin
reduc
rat
paw
edema
two
acetylen
mannich
base
x
ch
betulon
acid
scaffold
fig
investig
antiinflammatori
agent
piperidin
deriv
almost
effici
refer
drug
indomethacin
reduc
rat
paw
edema
morpholin
analogu
half
activ
piperidin
mannich
base
pain
symptom
inflamm
antiinflammatori
analges
activ
novel
candid
usual
evalu
time
therefor
surpris
mani
studi
report
antiinflammatori
activ
mannich
base
also
offer
inform
analges
potenti
sever
keton
mannich
base
r
h
ch
ch
deriv
aromat
amin
fig
equipot
refer
drug
ibuprofen
acet
acidinduc
writh
test
hot
plate
test
one
potent
candid
compound
r
r
h
deriv
ptoluidin
mannich
base
deriv
cyclohexanon
also
effici
pain
reliev
phenol
mannich
base
substitut
either
ring
naphthalen
system
variou
function
synthes
use
preform
aminomethyl
reagent
eg
imonium
salt
obtain
aromat
aldehyd
secondari
aliphat
amin
claim
analges
activ
claim
difficult
assess
two
candid
evalu
comparison
establish
analges
provid
addit
candid
x
ch
fig
effici
inhibit
writh
reaction
second
candid
x
offer
modest
protect
pain
inhibit
writh
reaction
mannich
base
analges
activ
report
sever
studi
candid
r
c
h
nr
r
oc
h
nr
tabl
good
antiinflammatori
activ
also
test
analges
activ
effici
determin
use
tail
flick
method
albino
rat
compar
refer
drug
ibuprofen
sever
mannich
base
fig
show
analges
activ
tail
flick
latenc
compar
refer
drug
pentazocin
tail
flick
latenc
rest
compound
moder
activ
mannich
base
fig
less
effici
tail
flick
test
reaction
time
potent
compound
seri
approxim
latenc
provid
refer
drug
pentazocin
two
candid
tabl
deriv
ibuprofen
start
materi
substrat
gener
use
either
ethyl
piperazin
amin
reagent
aminomethyl
step
effici
analges
refer
drug
diclofenac
hot
plate
test
mannich
base
fig
equipot
refer
drug
diclofenac
acet
acidinduc
writh
test
analges
activ
mannich
base
also
determin
candid
investig
antiinflammatori
activ
librari
mannich
base
deriv
fig
carri
benzoyl
moieti
aromat
ring
r
r
substitut
benzoyl
signific
differ
analges
activ
analogu
could
observ
although
candid
provid
moder
low
protect
either
test
use
determin
analges
activ
name
acet
acidinduc
writh
test
pbenzoquinoneinduc
abdomin
constrict
test
two
mannich
base
deriv
substitut
benzoyl
found
effici
refer
drug
aspirin
thu
analges
activ
mannich
base
r
h
r
c
h
co
nr
equipot
aspirin
analges
activ
mannich
base
r
ch
r
h
co
nr
slightli
poorer
aspirin
seri
mannich
base
deriv
sever
compound
show
better
analges
activ
compar
refer
drug
aspirin
analges
activ
compound
consist
higher
antiinflammatori
activ
suggest
mannich
base
might
exert
analges
activ
central
two
mannich
base
deriv
also
found
possess
analges
activ
compar
aspirin
mannich
base
deriv
thiosemicarbazon
fig
moder
effici
protect
prevent
acet
acidinduc
writh
mice
dose
mgkg
refer
drug
diclofenac
provid
protect
test
dose
mgkg
mannich
base
isatin
hydrazon
fig
carri
quinazolin
moieti
deriv
acycl
secondari
aliphat
amin
dimethylamin
diethylamin
potent
analges
effect
superior
compar
refer
drug
diclofenac
h
administr
decreas
rapidli
afterward
nmannich
base
fig
obtain
benzimidazol
use
dimethylamin
diethylamin
amin
reagent
found
moder
analges
dose
mgkg
rel
paracetamol
mgkg
mannich
base
deriv
substrat
diphenylamin
amin
reagent
poor
analges
candid
owe
toxic
mannich
base
deriv
administ
lower
dose
mgkg
analges
activ
rang
moder
nr
good
nr
diethylamino
compar
paracetamol
nmannich
base
analges
activ
compar
refer
drug
pentazocin
administ
dose
time
greater
pentazocin
mannich
base
deriv
benzimidazol
r
ch
nhnhc
h
h
also
show
moder
good
analges
activ
aceticacidinduc
writh
test
analges
activ
diclofenac
dose
evalu
first
seri
nmannich
base
deriv
pyridin
fig
led
identif
weak
moder
analges
agent
amongst
candid
deriv
phenyl
piperazin
amin
moieti
effici
analges
writh
hot
plate
test
second
seri
mannich
base
subsequ
synthes
candid
display
signific
activ
writh
test
analges
activ
time
potent
aspirin
time
weaker
morphin
use
refer
drug
studi
excess
reactiv
oxygen
speci
produc
live
organ
caus
oxid
stress
damag
cell
initi
chain
reaction
lead
lipid
peroxid
dna
damag
protein
oxid
besid
complex
system
antioxid
metabolit
enzym
natur
prevent
cell
damag
exogen
antioxid
may
sometim
requir
keep
reactiv
oxygen
speci
optimum
level
use
mannich
reaction
gener
novel
chemic
entiti
capabl
act
antioxid
present
section
keton
mannich
base
fig
obtain
arylamin
amin
reagent
substrat
respect
test
antioxid
activ
evalu
abil
scaveng
dpph
radic
effici
candid
seri
name
r
h
r
n
ch
show
moder
potenc
scaveng
dpph
radic
approxim
compar
standard
butyl
hydroxytoluen
substitut
aromat
ring
electronwithdraw
group
appear
reduc
antioxid
abil
mannich
base
larg
number
phenol
mannich
base
report
literatur
potenti
antioxid
antioxid
activ
two
phenol
mannich
base
deriv
thymol
fig
assess
mean
xanthin
oxidas
inhibit
test
cellfre
system
inhibit
lipid
peroxid
use
ratliv
homogen
candid
especi
mannich
base
morpholin
amin
moieti
present
enhanc
antioxid
activ
test
compar
parent
thymol
three
phenol
mannich
base
nr
r
oc
h
nh
deriv
fig
design
primarili
antiinflammatori
agent
also
evalu
abil
inhibit
lipid
peroxid
result
show
candid
effici
indomethacin
prevent
lipid
peroxid
antioxid
activ
may
correl
ulcerogen
activ
three
mannich
base
fig
piperidin
amin
moieti
nr
show
moder
high
abil
scaveng
dpph
radic
dpph
scaveng
abil
standard
gallic
acid
rest
candid
either
poor
scaveng
dpph
radic
fail
react
dpph
radic
although
phenol
mannich
base
show
effici
antioxid
variou
degre
candid
nr
diphenylamino
fig
potent
scaveng
hydrogen
peroxid
activ
compar
standard
ascorb
acid
inferior
standard
butyl
hydroxyanisol
select
hybrid
fig
develop
primarili
agent
treatment
alzheim
diseas
exhibit
also
potent
peroxyl
radic
absorb
capac
trolox
equivalentsmmol
mannich
base
determin
mean
oracfl
method
oxygen
radic
absorb
capac
fluoresc
phenol
mannich
base
natur
flavanon
design
synthes
view
improv
antioxid
effici
bioavail
water
solubl
parent
flavanon
three
mannich
base
r
oh
r
h
r
diethylamino
diisopropylamino
apigenin
fig
exhibit
antioxid
activ
greater
apigenin
rest
candid
present
antioxid
activ
compar
apigenin
antioxid
activ
apigenin
deriv
concentrationdepend
dpph
radic
scaveng
abil
potent
mannich
base
almost
standard
ascorb
acid
concentr
mgml
scutellarein
also
aminomethyl
give
mannich
base
r
r
oh
r
aminomethyl
abil
scaveng
dpph
radic
sampl
concentr
rang
mm
comparison
wellestablish
antioxid
provid
studi
monoand
bismannich
base
fig
synthes
evalu
inhibitor
photooxid
pigment
lipofuscin
retin
pigment
cell
thought
play
role
macular
degener
candid
show
suffici
antioxid
abil
inhibit
noncellular
intracellular
photooxid
superior
antioxid
quercetin
hand
phenol
mannich
base
obtain
known
antioxid
sesamol
ineffect
inhibitor
photooxid
mm
phenol
mannich
base
chalcon
analogu
candid
r
fig
modest
poor
scaveng
dpph
radic
reduct
dpph
absorpt
compar
standard
quercetin
reduct
dpph
absorpt
result
dpph
scaveng
abil
phenol
mannich
base
deriv
chalcon
analogu
obtain
differ
studi
also
line
antioxid
data
record
mannich
base
greatest
reduct
dpph
absorpt
concentr
high
mm
mannich
base
howev
one
candid
seri
scaveng
superoxid
radic
effici
anoth
candid
potent
inhibitor
heme
depend
lipid
peroxid
sever
mannich
base
deriv
tabl
effici
antioxid
standard
ascorb
acid
reduct
dpph
radic
show
enhanc
antioxid
activ
parent
seri
mannich
base
nr
substitut
primari
arylamin
tabl
design
antioxid
agent
evalu
use
scaveng
dpph
radic
assay
scaveng
azinobi
acid
radic
cation
abt
assay
ferric
reduc
antioxid
power
assay
half
mannich
base
show
greater
dpph
radic
scaveng
abil
butyl
hydroxytoluen
ic
mm
seven
exhibit
greater
antioxid
activ
trolox
ic
mm
assay
candid
high
dpph
scaveng
activ
along
mannich
base
also
good
scaveng
abt
radic
cation
activ
greater
trolox
ferric
reduc
antioxid
power
assay
three
mannich
base
show
better
activ
trolox
seven
potent
butyl
hydroxytoluen
mannich
base
nr
c
h
compound
exhibit
high
potenc
three
assay
also
effici
trolox
inhibit
lipid
peroxid
mice
liver
microsom
homogen
nmannich
base
succinimid
r
h
phenyl
nr
nhc
h
fig
nmannich
base
phthalimid
show
moder
dpph
scaveng
activ
compar
standard
vitamin
c
vitamin
e
abil
inhibit
peroxid
linol
acid
moder
weak
also
sever
nmannich
base
saccharin
fig
antioxid
potent
standard
ascorb
acid
abt
assay
potent
antioxid
saccharin
nmannich
base
deriv
pyrazolin
fig
dpph
scaveng
nitric
oxid
scaveng
activ
compar
standard
antioxid
ascorb
acid
rutin
presenc
phenol
hydroxyl
group
could
respons
antioxid
activ
compound
final
antioxid
activ
two
cmannich
base
uracil
fig
determin
mean
measur
rate
oxid
addit
compound
reaction
mixtur
reduc
rate
oxid
level
compar
rate
oxid
presenc
butyl
hydroxytoluen
small
number
studi
deal
investig
mannich
base
antihypertens
agent
phenol
mannich
base
appear
particularli
remark
blood
pressurelow
substanc
sever
singl
doubl
mannich
base
variou
phenol
thiomorpholin
amin
moieti
show
gradual
effect
systol
diastol
mean
arteri
pressur
start
dose
mgkg
case
refer
drug
captopril
losartan
omapatrilat
effect
notic
mgkg
manner
similar
aforement
refer
drug
phenol
mannich
base
also
induc
gradual
signific
reduct
heart
rate
anesthet
mice
doubl
mannich
base
fig
emerg
valuabl
candid
one
lowest
effect
dosag
collect
exhibit
highest
antihypertens
activ
consciou
spontan
hypertens
rat
model
research
examin
antihypertens
effect
doubl
mannich
base
moieti
structur
fig
result
show
activ
candid
inferior
doubl
mannich
base
presum
due
chang
bulki
substitu
para
phenol
hydroxyl
presenc
two
aminomethyl
function
structur
may
essenti
preserv
antihypertens
activ
candid
reason
level
replac
thiomorpholin
morpholin
could
also
caus
poorer
antihypertens
properti
candid
rel
mannich
base
attempt
synthes
aminomethyl
naphthyloxi
butano
acid
eg
compound
obtain
butano
acid
subject
aminomethyl
concentr
mg
kg
candid
nr
lower
blood
pressur
anesthet
cat
similarli
propranolol
compound
nr
superior
propanolol
dose
fall
blood
pressur
mm
hg
durat
effect
min
also
worth
mention
antihypertens
effect
cmannich
base
name
fig
mannich
base
agent
blood
pressur
regul
fig
report
earlier
public
larg
collect
mannich
base
r
h
ch
c
h
ch
ch
ch
c
h
och
cl
fig
evalu
antihypertens
activ
noninvas
tail
cuff
method
sever
candid
found
significantli
reduc
mean
arteri
blood
pressur
albeit
higher
dose
refer
drug
hydralazin
presenc
alkyl
group
substitu
r
seem
favor
antihypertens
activ
wherea
natur
amin
moieti
appear
influenc
activ
sever
mannich
base
r
ch
c
h
nc
h
ch
c
h
r
ch
c
h
imidazo
benzimidazol
fig
found
reduc
arteri
blood
pressur
anesthet
rat
dose
lower
dose
refer
drug
dibazol
produc
effect
mgkg
analog
aminomethyl
imidazo
benzimidazol
r
ch
nc
h
ch
c
h
fig
effici
antihypertens
agent
mannich
base
reduc
arteri
blood
pressur
dose
lower
record
candid
sever
octahydroquinazolin
deriv
r
h
fig
obtain
doubl
mannich
reaction
start
arylamin
shown
produc
insignific
chang
arteri
blood
pressur
heart
rate
dose
mgkg
howev
deriv
r
och
conhn
chc
h
r
r
h
candid
initi
seri
afford
signific
decreas
systol
diastol
arteri
blood
pressur
rapid
onset
action
min
minor
decreas
heart
rate
anesthet
male
adult
albino
rat
hand
candid
r
produc
timedepend
signific
increas
systol
diastol
arteri
blood
pressur
without
caus
tachycardia
min
make
compound
use
treatment
hypotens
small
number
studi
report
activ
mannich
base
parasit
plasmodium
spp
among
parasit
caus
parasit
infect
especi
develop
countri
differ
speci
trypanosomatida
famili
pathogen
human
caus
african
trypanosomiasi
sleep
sick
trypanosoma
brucei
american
trypanosomiasi
chaga
diseas
trypanosoma
cruzi
leishmaniasi
leishmania
spp
addit
one
studi
investig
activ
mannich
base
entamoeba
histolytica
one
studi
report
antischistosoma
activ
mannich
base
deriv
praziquantel
parasit
protozoa
belong
trypanosoma
spp
uniqu
thiol
metabol
base
flavoenzym
trypanothion
reductas
enzym
could
therefor
consid
promis
target
ration
drug
design
african
sleep
sick
chaga
diseas
differ
form
leishmaniasi
owe
absenc
mammalian
host
structur
differ
relat
host
enzym
essenti
role
parasit
surviv
unsatur
keton
mannich
base
react
readili
thiol
sever
compound
shown
effici
mechanismbas
inhibitor
p
falciparum
thioredoxin
reductas
studi
concern
abil
compound
interact
trypanothion
reductas
free
trypanothion
undertaken
candid
nr
dimethylamino
fig
inactiv
trypanothion
reductas
presenc
nadph
suggest
reduct
enzym
prior
interact
mannich
base
essenti
divinyl
keton
aris
deamin
candid
actual
inhibitor
activ
trypanothion
reductas
higher
parent
mannich
base
unfortun
divinyl
keton
also
reactiv
consid
drug
candid
mannich
base
display
modest
activ
strain
intracellular
parasit
may
explain
reaction
glutathion
present
millimolar
concentr
cytosol
mammalian
host
cell
nonetheless
show
signific
effect
extracellular
b
rhodesiens
might
least
partial
due
high
reactiv
toward
trypanothion
reductas
trypanothion
trypanothion
reductas
valid
drug
target
trypanosomiasi
design
synthesi
novel
unsatur
mannich
base
base
melaminophenyl
arsen
drug
melarsoprol
subsequ
pursu
candid
r
cl
h
ch
fig
effici
vitro
trypanothion
reductas
inhibitor
display
signific
activ
cellbas
assay
cruzi
activ
toward
brucei
presenc
melamin
residu
para
enon
motif
result
improv
trypanocid
potenc
r
cl
compar
hit
compound
howev
presenc
melamin
residu
meta
enon
motif
significantli
lower
ic
human
cell
line
use
studi
indic
compound
high
cytotox
hand
phenol
mannich
base
fig
basic
inact
toward
parasit
mannich
base
taken
effect
cell
despit
absenc
carrier
suggest
main
rout
entri
compound
aminopurin
transport
stem
observ
heterocycl
pyrazolopyridin
ring
system
consid
analog
quinolin
aminoquinolin
deriv
effici
antimalari
sever
deriv
featur
pyrazolopyridin
scaffold
design
test
leishmania
amazonensi
evolut
form
promastigot
thu
mannich
base
r
c
h
r
ch
c
h
fig
activ
antileishmani
agent
ic
valu
nm
wherea
aminoquinolin
deriv
amodiaquin
ic
nm
structureeact
point
view
result
suggest
pyrazolopyridin
ring
system
bioisoster
quinolin
presenc
carbethoxi
group
structur
candid
influenc
significantli
biolog
activ
amebiasi
contagi
diseas
human
gastrointestin
tract
caus
parasit
protozoa
e
histolytica
candid
small
librari
piperazin
mannich
base
tabl
activ
imss
strain
e
histolytica
three
potent
refer
drug
metronidazol
ic
mm
amin
residu
aminomethyl
function
activ
mannich
base
ic
nm
ic
nm
ic
mm
addit
cytotox
antiamoeb
candid
low
concentr
rang
mm
four
newli
synthes
mannich
base
praziquantel
fig
two
candid
nr
n
c
h
n
nhch
ch
oh
exhibit
signific
vitro
antischistosoma
activ
worm
kill
mm
mm
respect
effici
praziquantel
worm
kill
mm
platelet
crucial
hemostasi
connect
one
anoth
receptor
bridg
form
aggreg
final
plug
tear
interrupt
endothelium
howev
aggreg
platelet
lead
format
clot
also
trigger
irregular
vessel
wall
result
abnorm
clot
format
primari
factor
develop
thrombot
disord
unstabl
angina
myocardi
infarct
stroke
peripher
vascular
diseas
especi
occur
coronari
arteri
platelet
aggreg
also
initi
endogen
substanc
collagen
thrombin
prostaglandin
endoperoxid
thromboxan
arachidon
acid
adenosin
diphosph
adp
etc
inhibit
platelet
aggreg
repres
promis
strategi
treatment
thrombot
diseas
sever
studi
report
activ
mannich
base
inhibitor
platelet
aggreg
sever
type
phenol
mannich
base
repres
structur
fig
also
evalu
inhibitor
platelet
aggreg
induc
adp
collagen
concentr
mm
mgml
respect
numer
candid
variou
structur
show
good
inhibitori
effect
potent
refer
drug
clopidogrel
wherea
nine
compound
collect
exhibit
inhibitori
activ
rang
model
good
platelet
aggreg
inhibitori
activ
associ
presenc
pyridyl
moieti
ring
b
structur
chalcon
analogu
also
presenc
ring
hydroxi
group
meta
carbonyl
function
phenol
mannich
base
r
r
oh
r
aminomethyl
scutellarein
fig
investig
thrombin
inhibitor
influenc
sever
paramet
prothrombin
time
activ
partial
thromboplastin
time
thrombin
time
fibrinogen
determin
candid
show
greater
thrombin
inhibitori
activ
compar
parent
scutellarein
mannich
base
deriv
scutellarein
contain
morpholinyl
residu
aminomethyl
function
potent
subsequ
select
molecular
dock
experi
thrombin
experi
reveal
morpholinylmethyl
group
occupi
deep
pocket
thrombin
bind
site
wherea
scutellarein
part
inhibitor
molecul
anchor
three
hydrogen
bond
within
activ
site
effect
mannich
base
r
ch
c
h
nc
h
ch
c
h
r
ch
c
h
r
ch
nc
h
ch
c
h
fig
adpinduc
aggreg
rabbit
thrombocyt
studi
vitro
sever
candid
candid
found
lower
effect
concentr
ec
decreas
degre
aggreg
half
refer
drug
acetylsalicyl
acid
cellular
effect
thrombin
includ
platelet
aggreg
mediat
activ
thrombin
receptor
belong
famili
four
gproteincoupl
receptor
call
proteaseactiv
receptor
becom
attract
drug
discoveri
target
peptidemimet
small
organ
molecul
antagonist
properti
alreadi
design
synthes
indol
mannich
base
motif
incorpor
structur
seri
novel
peptidemimet
r
oc
h
ch
c
h
ch
fig
capabl
bind
abil
candid
inhibit
platelet
aggreg
test
measur
degre
aggreg
human
platelet
also
establish
degre
inhibit
contract
aortic
ring
compound
r
oc
h
ch
c
h
ch
belong
seri
deriv
potent
candid
valu
inhibitori
concentr
time
lower
refer
compound
inhibit
platelet
aggreg
addit
result
confirm
enhanc
inhibitori
activ
two
candid
contract
aorta
ring
compar
activ
effect
becam
evid
increas
dose
candid
seri
deriv
found
inact
weak
inhibitor
assay
antiulc
agent
class
drug
use
treat
ulcer
stomach
upper
part
small
intestin
acid
peptic
diseas
chronic
patholog
affect
million
peopl
worldwid
estim
world
popul
develop
condit
lifetim
imbal
aggress
factor
gastric
acid
helicobact
pylori
infect
excess
intak
antiinflammatori
drug
immoder
consumpt
alcohol
high
concentr
reactiv
oxygen
speci
one
hand
protect
factor
eg
mucu
bicarbon
anion
prostaglandin
good
blood
flow
effici
cellular
repair
endogen
exogen
antioxid
hand
consid
caus
ulcer
treatment
ulcer
symptom
reli
pain
reliev
antiacid
cytoprotect
agent
allow
heal
ulcer
agent
prevent
recurr
ulcer
proton
pump
inhibitor
muscarin
antagonist
pirenzepin
receptor
antagonist
cimetidin
abil
mannich
base
act
antiulc
agent
report
small
number
studi
antiulc
activ
saminomethyl
deriv
gener
fig
substrat
secondari
aliphat
amin
amin
reagent
mannich
reaction
evalu
vivo
use
aspirininduc
ulcer
model
albino
rat
base
ulcer
score
mean
ulcer
index
degre
protect
calcul
compar
refer
drug
omeprazol
five
candid
r
h
r
c
h
oc
h
offer
protect
five
mannich
base
r
h
r
h
c
h
h
c
nc
h
moder
antiulc
activ
approxim
protect
compar
omeprazol
protect
aminomethyl
sulfanilamid
amin
reagent
afford
mannich
base
fig
whose
abil
reduc
volum
acid
secret
determin
pylor
ligat
method
three
candid
r
oc
h
h
present
good
antiulc
activ
ulcer
indic
rang
dose
mgkg
refer
drug
omeprazol
ulcer
index
dose
mgkg
small
number
furo
flavon
type
r
c
h
h
r
h
ch
r
c
h
fig
aminomethyl
either
posit
evalu
gastroprotect
agent
use
ethanolinduc
gastric
ulcer
model
rat
mean
valu
protect
index
mannich
base
rang
comparison
antiulc
refer
drug
provid
studi
best
three
candid
r
r
ch
nr
r
r
och
nr
r
c
h
r
h
nr
methoxi
group
posit
common
structur
featur
correspond
mannich
base
hydroxyl
group
instead
methoxi
significantli
less
activ
mental
disord
compris
broad
rang
problem
differ
symptom
gener
character
combin
abnorm
thought
emot
behavior
relationship
other
common
neurolog
condit
label
mental
disord
includ
depress
anxieti
schizophrenia
bipolar
disord
stand
mental
disord
sever
disabl
untreat
mental
neurolog
substanc
use
disord
exact
high
toll
account
total
global
burden
diseas
unipolar
depress
disord
third
lead
caus
diseas
burden
account
global
burden
diseas
current
predict
indic
depress
lead
caus
diseas
burden
global
rang
differ
type
treatment
mental
disord
avail
suitabl
treatment
depend
disord
individu
major
option
mani
mental
disord
psychotherapi
anoth
option
psychiatr
medic
amongst
sever
group
drug
current
employ
psychiatr
medic
antidepress
treat
clinic
depress
well
anxieti
rang
disord
anxiolyt
includ
sed
use
anxieti
disord
relat
problem
insomnia
mood
stabil
use
primarili
bipolar
disord
antipsychot
use
psychot
disord
notabl
posit
symptom
schizophrenia
select
serotonin
reuptak
inhibitor
ssri
play
import
role
pharmacotherapeut
treatment
depress
attempt
modifi
gener
ssri
structur
motif
gphenoxypropylamin
two
keton
mannich
base
r
cl
br
fig
deriv
substrat
amin
reagent
synthes
carbonyl
function
amino
keton
subsequ
reduc
result
secondari
hydroxyl
convert
ether
group
reaction
although
design
ssri
analogu
target
studi
show
antidepress
activ
intermedi
keton
mannich
base
effect
refer
drug
fluoxetin
sertralin
imipramin
similar
dosag
valid
experiment
model
depress
mice
forc
swim
test
innov
computerassist
approach
base
predict
activ
spectra
substanc
pass
appli
discoveri
new
anxiolyt
initi
databas
compris
structur
gener
virtual
combinatori
design
highli
divers
chemic
compound
includ
differ
type
heterocycl
thiazol
pyrazol
isatin
fuse
imidazol
view
increas
probabl
find
new
chemic
entiti
anxiolyt
eight
hit
obtain
databas
four
candid
mannich
base
keton
mannich
base
mannich
base
deriv
imidazo
benzo
thiazol
two
mannich
base
r
f
r
ch
r
r
c
h
deriv
imidazo
pyridin
fig
synthes
test
potenti
anxiolyt
use
conflict
situat
test
candid
show
anxiolyt
effect
compar
greater
refer
drug
medazepam
mannich
base
r
r
c
h
potent
anxiolyt
studi
two
time
potent
medazepam
collect
compound
share
benzoxepin
scaffold
common
structur
featur
evalu
sedativeehypnot
effect
use
phenobarbitalinduc
sleep
test
among
compound
three
keton
mannich
base
nr
fig
decreas
onset
phenobarbitalinduc
sleep
prolong
durat
hypnosi
administ
dose
equimolar
refer
drug
phenobarbit
hypnot
activ
candid
nr
compar
phenobarbit
mannich
base
nr
dimethylamino
exhibit
moder
activ
mannich
base
nr
virtual
inact
therefor
natur
amino
residu
mannich
base
seem
signific
impact
hypnot
activ
addit
biolog
activ
mannich
base
present
far
isol
studi
found
report
variou
biolog
activ
mannich
base
singular
result
cover
section
without
attempt
arrang
systemat
order
two
phenol
mannich
base
deriv
substrat
dimethylamin
amin
reagent
evalu
hepatoprotect
agent
experiment
toxic
hepat
induc
tetrachloromethan
degre
liver
damag
evalu
term
alanin
aminotransferas
activ
blood
serum
malon
dialdehyd
content
liver
homogen
even
dose
correspond
ld
abil
two
candid
diminish
hepatotox
action
tetrachloromethan
superior
refer
compound
emoxypin
addit
assay
use
tetrachloromethaneinduc
hepat
model
two
acetylen
mannich
base
x
ch
betulon
acid
scaffold
fig
shown
decreas
alkalin
phosphatas
activ
lower
alanin
aminotransferas
aspart
aminotransferas
activ
blood
serum
compar
control
acetylen
mannich
base
fig
test
guinea
pig
spontan
beat
atria
view
evalu
neg
chronotrop
activ
potenc
candid
approxim
four
time
lower
bradycard
agent
zatebradin
therefor
exclud
subsequ
test
blocker
hyperpolarizationactiv
current
ondansetron
analogu
r
ch
piperazin
moieti
instead
imidazol
fig
synthes
evalu
antiemet
agent
use
retch
model
candid
effect
extent
administ
dose
mgkg
mannich
base
r
antiemet
activ
compar
refer
drug
ondansetron
low
dosag
mgkg
sever
bthujaplicin
analogu
fig
test
oxid
stressinduc
death
cell
follow
exposur
glutam
piperazinecontain
mannich
base
potent
parent
bthujaplicin
protect
glutamatechalleng
cell
ec
valu
rang
mm
potent
candid
chroman
moieti
substitu
piperazin
residu
high
vitro
neuroprotect
activ
mannich
base
may
due
potent
antioxid
effect
impart
chroman
moieti
analog
morpholin
mannich
base
also
activ
protect
cell
oxytosi
less
activ
piperazinecontain
bthujaplicin
deriv
presenc
isopropyl
group
also
seem
import
neuroprotect
activ
compound
sinc
analog
mannich
base
deriv
tropolon
activ
estrogen
defici
menopaus
one
common
caus
osteoporosi
hormon
replac
therapi
wide
use
prevent
bone
loss
although
present
potenti
drawback
increas
risk
uterin
bleed
andor
hyperplasia
increas
risk
endometri
breast
ovarian
cancer
higher
occurr
myocardi
infarct
cardiovascular
diseas
etc
conjug
iminodiacet
acid
fig
design
estrogencontain
boneseek
agent
could
prevent
bone
loss
lesser
side
effect
subsequ
synthes
mean
mannich
reaction
mannich
base
show
signific
affin
bone
lower
affin
ovari
uteru
maintain
affin
osteoblast
estrogen
receptor
candid
induc
uterin
hypertrophi
lower
level
biochem
marker
bone
turnov
eg
osteocalcin
alkalin
phosphatas
ctermin
telopeptid
fragment
type
collagen
cterminu
found
group
rat
treat
ovariectom
rat
suggest
decreas
bone
turnov
administr
candid
improv
bone
miner
densiti
trabecular
architectur
ovariectomi
suppress
bodi
weight
increas
result
suggest
compound
effect
prevent
ovariectomyinduc
bone
loss
exhibit
exhibit
fewer
advers
side
effect
make
mannich
base
better
choic
prevent
postmenopaus
osteoporosi
three
bispmannich
base
r
r
ch
r
er
ch
r
er
ch
fig
deriv
diethyl
phosphit
substrat
amino
acid
amin
reagent
mannich
reaction
use
investig
induct
adipogen
osteogen
differenti
mesenchym
stem
cell
isol
human
adipos
tissu
hmad
cell
candid
affect
adipocyt
differenti
induc
inhibit
osteoblast
format
without
detect
cytotox
effect
wherea
refer
drug
sodium
alendron
elicit
cytotox
effect
even
lowest
concentr
use
studi
therapeut
efficaci
toxic
profil
keton
doubl
mannich
base
fig
put
immunosuppress
preferenti
inhibit
oppos
sever
kinas
examin
candid
block
activ
downstream
substrat
fail
inhibit
sever
enzym
includ
growth
factor
receptor
tyrosin
kinas
src
famili
member
serinethreonin
protein
kinas
mannich
base
alon
prolong
kidney
allograft
surviv
induc
transplant
toler
combin
cyclosporin
present
therapeut
synerg
candid
show
nephrotox
affect
hematopoiesi
lipid
metabol
metabol
cytochrom
isoform
therefor
mannich
base
prolong
allograft
surviv
without
sever
toxic
effect
associ
current
immunosuppress
drug
may
provid
signific
clinic
benefit
transplant
patient
import
number
studi
report
activ
mannich
base
enzym
inhibitor
although
studi
cover
section
usual
valid
import
topic
ration
evidencesupport
connect
enzym
scrutini
certain
medic
condit
examin
action
mannich
base
enzym
inhibitor
provid
experiment
evid
mannich
base
could
actual
use
agent
treatment
specif
medic
condit
start
tacrin
first
drug
approv
treatment
alzheim
diseas
potent
inhibitor
acetylcholinesteras
ach
butyrylcholinesteras
buch
multifunct
compound
fig
combin
neuroprotect
antioxid
metalbind
properti
dual
inhibit
ach
buch
singl
small
molecul
design
synthes
mannich
reaction
hybrid
potent
inhibitor
ach
buch
bovin
origin
ic
rang
submicromolar
nanomolar
concentr
candid
contain
unsubstitut
moieti
methylen
tether
carbon
atom
potent
inhibitori
activ
select
mannich
base
evalu
inhibitor
human
cholinesteras
exhibit
ic
valu
rang
nm
ach
rang
nm
buch
mannich
base
r
r
h
n
potent
dual
inhibitor
human
ach
buch
librari
mannich
base
hybrid
fig
design
dual
bind
site
inhibitor
ach
combin
tacrin
recogn
inhibitor
catalyt
bind
site
ach
indanon
moieti
donepezil
known
respons
bind
drug
peripher
site
ach
evalu
inhibitor
ach
bovin
erythrocyt
buch
human
serum
use
ellman
method
show
activ
two
candid
modest
third
candid
z
h
r
och
x
ch
exhibit
moder
activ
ach
nm
good
activ
buch
nm
appar
differ
activ
candid
due
lengthen
one
methylen
group
alkyl
chain
link
tacrin
indanon
moieti
monomannich
base
fig
deriv
secondari
aliphat
amin
primari
arylamin
bismannich
base
deriv
either
primari
aliphat
amin
x
nr
r
c
h
r
c
h
ch
ch
r
h
ch
piperazin
evalu
ach
inhibitori
activ
use
ellman
method
degre
inhibit
rang
concentr
mm
decreas
mm
wherea
degre
ach
inhibit
tacrin
virtual
concentr
greater
potent
inhibitor
seri
concentr
bismannich
base
deriv
piperazin
inhibitori
activ
ach
buch
phenol
mannich
base
r
h
ch
allyl
prenyl
nr
n
ch
n
c
h
xanthon
deriv
fig
found
moder
good
compar
refer
drug
galantamin
candid
deriv
diethylamin
amin
reagent
mannich
reaction
gener
potent
inhibitor
enzym
natur
alkyl
moieti
r
modul
select
inhibitor
toward
one
enzym
thu
potent
inhibitor
ach
featur
methyl
group
r
wherea
increas
bulki
substitu
appear
favor
inhibit
buch
mannich
base
r
prenyl
nr
n
c
h
potent
dual
inhibitor
seri
molecular
dock
studi
perform
view
garner
inform
bind
mode
inhibitor
enzym
sever
phenol
mannich
base
natur
occur
flavanon
oroxylin
fig
potent
inhibitor
intestin
aglucosidas
parent
oroxylin
candid
less
potent
oroxylin
yeast
aglucosidas
nonetheless
potent
inhibitor
intestin
aglucosidas
seri
still
less
potent
refer
drug
acarbos
candid
fail
inhibit
enzym
deriv
acycl
secondari
amin
amin
reagent
mannich
reaction
alicycl
natur
secondari
amin
may
respons
good
inhibitori
activ
aglucosidas
seri
keton
mannich
base
deriv
nabumeton
fig
possess
modest
inhibitori
activ
intestin
aglucosidas
approxim
mm
addit
modest
inhibitori
activ
anoth
therapeut
target
type
diabet
mellitu
obes
relat
state
insulin
resist
name
proteintyrosin
phosphatas
howev
two
mannich
base
r
h
good
agonist
peroxisom
proliferatoractiv
receptor
major
regul
lipid
glucos
metabol
novel
seri
inhibitor
design
retain
nabumeton
moieti
sulfanilamid
serv
amin
reagent
synthesi
keton
mannich
base
type
respect
fig
candid
gener
potent
inhibitor
aglucosidas
analog
suggest
sulfonamid
moieti
potent
pharmacophor
aminoisoxazol
mannich
base
r
inhibit
aglucosidas
activ
dose
mgml
replac
sulfonamid
moieti
acid
view
mimic
acid
hydrophil
part
molecul
known
antidiabet
activ
led
novel
seri
mannich
base
r
h
second
seri
candid
r
c
h
fig
also
evalu
aglucosidas
inhibitor
activ
gener
poorer
mannich
base
r
h
deriv
acid
exampl
potent
aglucosidas
inhibitor
inhibit
seri
deriv
acid
candid
purin
nucleosid
phosphorylas
pnp
catalyz
phosphorolyt
cleavag
inosin
guanosin
deoxi
analogu
deoxi
ribos
hypoxanthin
guanin
genet
defici
pnp
lead
complet
tcell
defici
earli
life
eventu
death
infant
viru
infect
pnp
identifi
target
treatment
tcell
lymphoma
rheumatoid
arthriti
psoriasi
multipl
sclerosi
tcell
mediat
disord
transit
state
analogu
compound
occupi
catalyt
site
enzym
induc
slow
conform
chang
would
normal
occur
place
catalyt
site
appropri
geometri
search
would
locat
transit
state
normal
substrat
enzym
schramm
et
al
develop
seri
mannich
base
transit
state
analogu
purin
nucleosid
phosphorylas
inhibit
gener
call
immucilin
although
aminomethyl
purin
analogu
present
within
firstand
secondgener
pnp
inhibitor
obtain
reduct
amin
direct
mannich
reaction
expediti
synthesi
secondgener
pnp
inhibitor
mean
mannich
reaction
later
develop
third
gener
inhibitor
includ
sever
exampl
mannich
base
fig
obtain
direct
aminomethyl
substrat
amino
alcohol
ethanolamin
diethanolamin
amin
reagent
unfortun
candid
obtain
direct
aminomethyl
prove
modest
poor
inhibitor
pnp
dissoci
constant
k
rang
pm
compar
mannich
base
previous
investig
dadmeimmucilinh
k
pm
fig
mannich
base
inhibitor
aglucosidas
dadmeimmucil
k
pm
fig
nonetheless
studi
identifi
two
acycl
simplifi
altern
immucilin
analogu
name
k
pm
openchain
amino
alcohol
two
asymmetr
carbon
atom
k
pm
deriv
achir
dihydroxyaminoalcohol
seramid
fig
potent
inhibitor
pnp
enantiom
immucilinh
dadmeimmucilinh
shown
pnp
bind
properti
differ
consider
sinc
access
enantiomer
pure
start
azasugar
employ
gener
requir
suitabl
enzymebas
rout
discoveri
two
simpler
mannich
base
repres
signific
step
forward
develop
clinic
use
pnp
inhibitor
sulfurcontain
transit
state
analogu
develop
well
origin
specif
inhibitor
pnp
p
falciparum
later
shown
sulfurcontain
candid
analog
dadmeimmucilinh
mannich
base
also
bind
human
nativ
pnp
although
human
pnp
toler
substitut
hydroxyl
transit
state
analogu
alkylthio
arylthio
group
slowonset
natur
inhibit
lost
inhibitor
dissoci
constant
increas
two
three
order
magnitud
fluorinecontain
analogu
fig
dadmeimmucilinh
also
evalu
human
pnp
inhibitor
enantiom
exhibit
slowonset
bind
constant
pm
nm
addit
direct
mannich
reaction
use
gener
similar
fashion
potent
transit
state
inhibitor
enzym
methylthioadenosin
phosphorylas
methylthioadenosin
nucleosidas
purin
specif
nucleosid
hydrolas
larg
librari
band
gamino
keton
screen
view
discov
inhibitor
transglutaminas
bamino
keton
keton
mannich
base
strongli
inhibit
enzym
mannich
base
deriv
aliphat
keton
substrat
deriv
alkyl
aryl
keton
substrat
primari
amin
amin
reagent
weak
inhibitor
ic
mm
transglutaminas
potent
transglutaminas
inhibitori
activ
resid
keton
mannich
base
deriv
alkyl
aryl
keton
substrat
secondari
aliphat
amin
amin
reagent
natur
aryl
moieti
substrat
natur
alkyl
group
attach
nitrogen
atom
influenc
transglutaminas
inhibitori
activ
candid
gener
heteroarylsubstitut
substrat
pyridinyl
pyrazinyl
fare
better
substrat
aryl
moieti
phenyl
naphthyl
tbutyl
isopropyl
benzyl
group
phenyl
alkyl
substitu
nitrogen
afford
potent
transglutaminas
inhibitor
candid
ic
nm
fig
disulfid
wellknown
transglutaminas
inhibitor
novel
seri
bamino
keton
r
h
n
r
cooch
n
r
cooch
n
fig
deriv
cystamin
dimethyl
cystin
ester
dimethyl
homocystin
ester
amin
reagent
mannich
reaction
synthes
found
approxim
time
activ
start
disulfid
mannich
base
deriv
potent
inhibitor
seri
natur
disulfidecontain
amin
moieti
significantli
influenc
activ
candid
heterocycl
carbocycl
moieti
r
mannich
base
deriv
fig
evalu
vitro
inhibitor
two
human
carbon
anhydras
hca
ec
isozym
ii
use
hydratas
esteras
assay
respect
two
candid
exhibit
weak
hca
ii
inhibitori
effect
esteras
activ
wherea
two
mannich
base
could
use
carbon
anhydras
activ
phenol
mannich
base
deriv
quercetin
fig
deriv
baicalein
deriv
fig
screen
inhibit
cyclindepend
kinas
use
biochem
assay
method
base
fluoresc
reson
energi
transfer
candid
essenti
devoid
inhibitori
activ
cyclindepend
kinas
hand
baicalein
mannich
base
time
potent
parent
flavon
suggest
presenc
nitrogen
atom
crucial
inhibit
cyclindepend
kinas
presenc
second
heteroatom
amin
moieti
eg
oxygen
morpholin
sulfur
thiomorpholin
nitrogen
nmethylpiperazin
increas
potenc
candid
virtual
screen
commerci
librari
contain
drug
druglik
molecul
model
heparanas
led
identif
sever
candid
high
score
bind
affin
subsequ
test
nmr
competit
inhibit
experi
use
suramin
known
heparanas
inhibitor
one
candid
amodiaquin
fig
subset
fourteen
repres
compound
retain
characterist
scaffold
amodiaquin
present
differ
function
group
phenylamino
moieti
select
nmr
competit
inhibit
experi
although
candid
improv
heparanas
inhibitori
activ
amodiaquin
emerg
subset
sever
structur
requir
bind
inhibitor
activ
site
enzym
obtain
four
mannich
base
nitroxolin
fig
found
inhibit
effici
activ
methionin
burkholderia
pseudomallei
valu
rang
low
micromolar
nm
candid
seri
also
show
vitro
growth
inhibit
burkholderia
thailandensi
hexacycl
indol
mannich
base
r
h
ch
nr
n
c
h
r
ch
nr
deriv
annel
maleimidoindolodiazepin
fig
test
panel
human
protein
kinas
inact
test
enzym
micromolar
concentr
four
synthes
acetylen
mannich
base
nr
n
c
h
nallylnmethyl
n
nmethyl
deriv
fig
three
inhibitor
squalenehopen
cyclas
candid
nr
nallylnmethyl
half
potent
hoffmanela
roch
anticholesterem
drug
ro
effect
inhibitor
squaleneand
oxidosqualen
cyclas
featur
secondari
amino
group
structur
thiazolidinon
cmannich
base
r
c
h
c
h
ch
c
h
nr
n
c
h
fig
evalu
inhibitor
schistosoma
mansoni
cercari
elastas
inact
oxadiazolethion
nmannich
base
residu
fig
activ
mushroom
tyrosinas
time
potent
refer
compound
kojic
acid
presenc
thion
group
abl
chelat
copper
abil
cyclic
secondari
amin
form
extens
hydrophob
contact
within
bind
site
tyrosinas
appear
respons
activ
anoth
oxadiazolethion
nmannich
base
name
tabl
present
moder
inhibitori
activ
ureas
within
seri
compound
investig
comparison
activ
wellestablish
ureas
inhibitor
provid
ligand
receptor
receptor
receptor
also
known
serotonin
receptor
belong
group
g
proteincoupl
receptor
except
ligandg
ion
channel
found
central
peripher
nervou
system
function
mediat
excitatori
inhibitori
neurotransmiss
receptor
activ
natur
ligand
neurotransmitt
serotonin
mannich
base
n
fig
evalu
ligand
type
receptor
could
involv
mediat
anticonvuls
effect
compound
candid
exhibit
moder
low
affin
k
nm
receptor
k
nm
natur
spiran
cycloalkyl
group
influenc
serotonin
receptor
affin
significantli
although
cyclohexylsubstitut
candid
slightli
activ
cyclopentylsubstitut
analogu
natur
substitu
aryl
moieti
piperazin
ring
modul
select
toward
one
receptor
thu
mannich
base
r
show
highest
affin
receptor
lowest
affin
receptor
highest
receptor
affin
shown
mannich
base
r
addit
computeraid
design
novel
mannich
base
led
identif
sever
compound
potenti
dual
affin
receptor
serotonin
transport
whose
synthesi
evalu
final
led
candid
r
h
f
fig
desir
pharmacolog
profil
seri
nsubstitut
phenol
mannich
base
moieti
either
one
two
aminomethyl
function
synthes
test
receptor
antagonist
activ
longitudin
musclemyenter
plexu
prepar
guinea
pig
ileum
agonist
candid
r
cl
fig
exhibit
mild
moder
antagonist
activ
doubl
mannich
base
gener
less
potent
monomannich
base
counterpart
mannich
base
r
cl
r
h
nr
receptor
antagonist
activ
compar
refer
compound
ondansetron
replac
chlorin
methoxi
led
less
potent
candid
r
och
wherea
candid
ethoxi
group
posit
quinoxalin
ring
even
less
potent
presenc
piperazin
aminomethyl
moieti
candid
seem
favor
receptor
antagonist
activ
presenc
cyclic
secondari
amin
dopamin
receptor
g
proteincoupl
receptor
wide
distribut
brain
whose
primari
endogen
ligand
neurotransmitt
dopamin
least
five
subtyp
dopamin
receptor
receptor
subtyp
usual
predomin
time
numer
subtyp
discoveri
fauc
fig
potent
select
receptor
ligand
fuel
search
novel
chemic
entiti
abil
bind
dopamin
receptor
base
observ
two
ligand
mani
dopamin
receptor
ligand
featur
methylen
bridg
piperazin
ring
hetero
aromat
part
molecul
variou
analogu
design
synthes
howev
major
analogu
obtain
either
nucleophil
displac
appropri
substitut
piperazin
halogen
atom
halomethyl
deriv
select
hetero
aromat
substrat
reduct
amin
formylsubstitut
hetero
aromat
substrat
presenc
piperazin
literatur
search
reveal
exampl
mannich
reaction
employ
synthes
ligand
evalu
dopamin
receptor
bind
abil
addit
pyrrolo
pyridin
pyrazolo
pyridin
ring
system
use
gener
ligand
imidazo
pyridin
anoth
exampl
azaindol
ring
system
aminomethyl
yield
mannich
base
fig
receptor
bind
profil
candid
sever
monomannich
base
deriv
pyrrol
fig
determin
vitro
measur
abil
compet
h
spiperon
clone
human
dopamin
receptor
subtyp
long
short
receptor
affin
measur
employ
assay
use
select
ligand
h
sch
porcin
striatal
membran
mannich
base
select
ligand
receptor
subtyp
candid
imidazo
pyridin
scaffold
potent
counterpart
pyrrol
ring
potent
mannich
base
r
h
show
affin
dopamin
receptor
low
nanomolar
rang
select
receptor
subtyp
exceed
refer
drug
clozapin
sever
small
seri
candid
compris
mannich
base
r
h
cl
pyrrolo
pyrimidin
scaffold
fig
design
evalu
ligand
dopamin
receptor
subtyp
long
short
appreci
affin
dopamin
receptor
test
strongest
bind
seri
record
candid
r
r
h
r
dopamin
receptor
k
valu
nm
respect
novel
heteroaromat
scaffold
employ
synthesi
mannich
base
fig
potenti
receptor
ligand
candid
deriv
pyrrolo
pyridin
ring
system
bound
select
receptor
k
nm
evalu
mannich
base
gener
imidazo
pyrimidin
variou
substitu
posit
led
differ
result
depend
natur
number
substitu
thu
mannich
base
r
r
r
h
deriv
unsubstitut
scaffold
mannich
base
r
ch
r
r
h
obtain
pyrimidin
effect
dopamin
receptor
result
bind
assay
mannich
base
deriv
dimethylsubstitut
imidazo
pyrimidin
show
candid
r
r
ch
r
h
bind
affin
dopamin
receptor
rang
refer
drug
clozapin
candid
r
r
ch
r
h
weak
ligand
modif
introduct
carbethoxi
group
structur
candid
r
r
ch
r
cooc
h
two
methoxi
group
mannich
base
r
r
och
r
h
led
compound
without
affin
dopamin
receptor
seri
mannich
base
deriv
pyrimidin
candid
r
r
r
ch
r
good
bind
properti
dopamin
receptor
wherea
anoth
candid
r
r
r
ch
r
exhibit
slight
select
dopamin
receptor
use
pyrrolo
pyrimidin
scaffold
led
potent
ligand
dopamin
receptor
studi
k
valu
nm
natur
amino
group
posit
pyrrolo
pyrimidin
scaffold
modul
activ
thu
mannich
base
nr
good
affin
dopamin
receptor
replac
pyrrolidin
morpholin
result
signific
loss
dopamin
receptor
bind
affin
two
novel
indol
mannich
base
r
h
oc
h
c
h
fig
synthes
direct
aminomethyl
evalu
ligand
sever
dopamin
receptor
subtyp
along
heteroarylmethylpiperazin
candid
potent
select
dopamin
receptor
ligand
mannich
base
r
h
oc
h
potent
compound
librari
k
nm
addit
mannich
base
r
c
h
potent
candid
piperazin
moieti
suggest
import
indol
hetero
aromat
moieti
type
dopamin
receptor
ligand
effect
affin
dopamin
receptor
subtyp
replac
mannich
base
monocycl
bicycl
amin
residu
also
investig
mannich
base
x
ch
n
fig
deriv
amin
reagent
mannich
reaction
modest
affin
moder
select
dopamin
receptor
subtyp
compar
receptor
subtyp
pyrrolidinol
analogu
x
ch
n
fig
poor
bind
affin
subtyp
dopamin
receptor
homopiperazin
analogu
fig
moder
bind
affin
dopamin
receptor
subtyp
k
nm
candid
deriv
nonan
ring
system
amin
reagent
mannich
reaction
fig
bound
poorli
type
dopamin
receptor
investig
studi
although
candid
fig
deriv
heptan
ring
system
amin
reagent
mannich
reaction
highest
receptor
affin
compound
test
paper
k
nm
also
poor
select
toward
k
nm
k
nm
mannich
base
deriv
piperazin
fig
modest
bind
affin
dopamin
receptor
subtyp
k
nm
good
select
subtyp
thyroid
receptor
nuclear
receptor
belong
superfamili
whose
member
function
hormon
activ
transcript
factor
regul
transcript
thyroid
receptor
control
natur
ligand
thyroid
hormon
unligand
ligand
thyroid
receptor
bind
regul
gene
control
thyroid
respons
element
ligand
thyroid
receptor
complex
also
recruit
particular
coactiv
protein
mani
avail
view
steer
cours
transcript
regul
highthroughput
screen
librari
compound
identifi
number
hit
inhibitor
interact
thyroid
receptor
coactiv
steroid
receptor
coactiv
two
hit
compound
keton
mannich
base
fig
candid
repres
new
class
thyroid
receptor
antagonist
except
select
toward
b
isoform
activ
presenc
thyroid
hormon
abl
silenc
signal
mannich
base
like
coval
bound
thyroid
receptor
result
alkyl
process
thu
inhibit
hormoneinduc
gene
transcript
subsequ
preliminari
sar
show
hydrophob
moieti
para
keton
function
keton
mannich
base
analog
import
structur
featur
potent
inhibitor
thyroid
receptorecoactiv
interact
second
seri
candid
explor
effect
natur
amino
group
keton
mannich
base
analog
deriv
interact
coregulatori
protein
isoform
thyroid
receptor
synthes
candid
inhibit
interact
low
micromolar
rang
roughli
select
toward
isoform
b
keton
mannich
base
like
function
prodrug
true
activ
speci
name
bunsatur
keton
result
deamin
therefor
collect
enon
variou
substitu
carbonecarbon
doubl
bond
also
test
view
provid
insight
mechan
action
keton
mannich
base
inhibitor
interact
result
show
inhibit
interact
thyroid
receptor
coactiv
protein
depend
strongli
substitut
pattern
carbonecarbon
doubl
bond
bunsatur
keton
potent
unsubstitut
enon
fig
formal
aris
deamin
wherea
substitut
enon
weaker
inhibitor
subsequ
investig
confirm
enon
actual
inhibitor
compound
gener
within
bind
site
remain
bound
react
one
local
cystein
residu
addit
attempt
examin
complex
thyroid
receptor
b
mannich
base
xray
crystallographi
led
detect
activ
cleft
thyroid
receptor
b
enon
instead
mannich
base
although
enon
react
rapidli
thyroid
hormon
posit
close
sever
cystein
residu
sever
experi
show
form
enon
slowli
alkyl
nearbi
residu
occlud
activ
pocket
thyroid
receptor
b
signific
improv
pharmacolog
properti
especi
potenc
therapeut
index
inhibitor
thyroid
hormon
receptor
coactiv
bind
base
keton
mannich
base
achiev
seri
novel
candid
aromat
ring
electron
withdraw
substitu
associ
high
efficaci
sulfonyl
group
reduc
cytotox
also
piperazinon
use
prefer
amin
moieti
view
minim
ion
channel
activ
inhibitor
potent
compound
r
fig
show
outstand
thyroid
hormon
receptor
coactiv
interact
inhibitori
potenc
good
therapeut
index
inhibit
kclstimul
depolar
cell
observ
mannich
base
androgen
receptor
ligandregul
transcript
factor
nuclear
receptor
superfamili
receptor
repres
import
molecular
target
treatment
prostat
cancer
activ
bind
two
natur
endogen
ligand
testosteron
subsequ
activ
androgenrespons
gene
block
androgen
receptor
antagonist
competit
inhibit
highthroughput
screen
structur
divers
chemic
librari
compris
synthet
natur
compound
led
identif
hit
compound
exhibit
competit
inhibit
bind
androgen
receptor
mannich
base
r
r
ch
r
c
h
fig
select
develop
owe
consist
androgen
receptor
antagonist
activ
cellbas
assay
use
monkey
kidney
fibroblast
cell
fortynin
analogu
design
base
bamino
keton
core
structur
nine
analogu
show
higher
bind
affin
androgen
receptor
evalu
enantiom
candid
r
r
cl
r
show
androgen
receptormodul
activ
bind
resid
dextrorotatori
isom
sar
within
librari
keton
mannich
base
reveal
presenc
chlorin
substitu
r
prefer
para
amino
group
import
androgen
receptor
antagonist
effect
presenc
electronwithdraw
group
substitu
r
crucial
highaffin
bind
receptor
good
androgen
fig
mannich
base
inhibitor
interact
thyroid
receptor
coregul
receptor
bind
activ
found
among
analogu
phenyl
substitu
r
mannich
base
heteroaryl
moieti
exhibit
less
cytotox
toward
hela
cell
mannich
base
r
substitut
phenyl
candid
r
r
cl
r
inhibit
growth
cell
mous
mammari
cell
line
respond
well
androgen
effect
prolifer
cell
human
prostat
cancer
cell
line
lack
measur
androgen
receptor
weak
mannich
base
type
subsequ
disclos
select
nonsteroid
antagonist
anoth
member
nuclear
receptor
superfamili
name
progesteron
receptor
sar
within
collect
mannich
base
show
coordin
effect
substitu
r
r
modul
potenc
select
progesteron
receptor
androgen
receptor
mannich
base
modul
activ
acetylcholin
receptor
topic
two
recent
studi
two
quaternari
salt
r
ch
allyl
deriv
bisaminomethyl
pyrazinodiindol
fig
synthes
order
probe
bind
alloster
bind
domain
muscarin
receptor
quaternari
salt
show
slightli
higher
bind
affin
muscarin
receptor
subtyp
correspond
parent
doubl
mannich
base
turn
exhibit
rel
poor
alloster
potenc
due
structur
similar
candid
neuromuscularblock
agent
bind
affin
muscletyp
nicotin
acetylcholin
receptor
also
determin
thu
compound
r
ch
higher
affin
muscl
type
nicotin
acetylcholin
receptor
alloster
site
receptor
doubl
mannich
base
nr
deriv
phthalamid
fig
competit
antagonist
effect
acetylcholin
isol
guinea
pig
ileum
poorer
refer
compound
atropin
behav
noncompetit
antagonist
higher
concentr
addit
candid
nr
antagon
motor
effect
oxotremorin
mice
mannich
base
nr
inact
test
indol
mannich
base
r
phenethyl
fig
moder
bind
affin
k
nm
k
nm
receptor
consid
potent
nonselect
ligand
sigma
receptor
keton
mannich
base
fig
deriv
cyclic
keton
atetralon
x
ch
ch
chromanon
x
och
indanon
x
ch
benzosuberon
x
ch
substrat
either
z
ch
z
n
amin
reagent
mannich
reaction
also
evalu
affin
toward
receptor
gener
mannich
base
higheraffin
sigma
receptor
ligand
correspond
analogu
compar
alkylpiperidin
alkylpiperazin
evalu
studi
keton
mannich
base
moder
affin
sigma
receptor
presenc
carbonyl
group
structur
appear
detriment
especi
affin
receptor
bind
affin
seem
influenc
size
satur
ring
fuse
aromat
ring
thu
sixmemb
candid
potent
mannich
base
deriv
indanon
benzosuberon
howev
candid
x
ch
ch
z
ch
one
select
compound
studi
select
toward
receptor
approxim
k
nm
k
nm
contrast
mannich
base
deriv
consist
better
ligand
receptor
mannich
base
indol
substitut
carbocycl
ring
carboxamid
group
evalu
human
histamin
h
receptor
antagonist
preliminari
analysi
bind
affin
candid
r
ic
h
cc
h
x
ch
nc
h
nc
h
c
fig
human
h
receptor
respect
differ
posit
isom
within
seri
establish
correl
pattern
good
human
h
receptor
affin
pattern
least
favor
h
receptor
bind
affin
presenc
piperidin
morpholin
aminomethyl
group
led
compound
excel
histamin
h
receptor
affin
wherea
presenc
piperazin
aminomethyl
group
well
toler
sever
mannich
base
indol
pattern
also
present
reason
potenc
human
h
antagonist
case
presenc
cyclobutyl
residu
piperazin
ring
carboxamid
group
seem
favor
human
histamin
h
bind
affin
substitut
isopropyl
residu
search
new
ligand
abl
discrimin
among
three
adrenerg
receptor
subtyp
seri
mannich
base
r
ch
nc
h
ch
c
h
ch
c
h
c
c
h
deriv
fig
structur
relat
potent
adrenerg
receptor
antagonist
heat
synthes
evalu
gener
trend
candid
show
lower
affin
heat
three
adrenerg
receptor
subtyp
replac
tyramin
phenyl
piperazin
enhanc
affin
toward
subtyp
particular
addit
mannich
base
deriv
amin
fig
design
open
chain
analogu
candid
evalu
show
slight
improv
affin
three
adrenerg
receptor
subtyp
start
hit
obtain
screen
larg
librari
compound
employ
subsequ
stepwis
refin
structur
featur
seri
mannich
base
r
substitut
phenyl
pyrazolon
fig
design
ligand
cc
chemokin
receptor
potenti
molecular
target
treatment
allerg
asthma
evalu
bind
human
receptor
candid
show
compound
display
ic
valu
around
nm
two
mannich
base
r
h
bound
tightli
initi
hit
compound
ic
nm
lead
compound
r
h
ic
nm
suffer
poor
water
solubl
metabol
stabil
less
lipophil
analogu
prepar
introduct
ioniz
group
differ
part
molecul
replac
structur
r
h
moieti
pyridinyl
moieti
well
substitut
moieti
pyridinyl
pyridinylnoxid
led
second
seri
pyrazolon
mannich
base
fig
improv
solubl
water
enhanc
metabol
stabil
although
structur
modul
r
moieti
gener
decreas
bind
affin
candid
modif
r
part
afford
potent
compound
ic
nm
two
nmannich
base
r
h
f
pyrazol
deriv
fig
report
studi
examin
interact
seri
neurokinin
receptor
inact
k
mm
throughout
last
decad
larg
number
novel
mannich
base
synthes
evalu
potenti
treatment
multitud
diseas
medic
condit
prodrug
molecul
elicit
respons
biolog
target
vast
amount
data
concern
structureeact
relationship
mannich
base
deriv
structur
divers
substrat
ad
previou
knowledg
thu
allow
better
insight
design
effect
drug
candid
base
aminomethyl
reaction
futur
tremend
progress
made
field
anticanc
agent
antimicrobi
last
decad
wit
chemic
modif
mani
biologicallyact
naturallyoccur
substrat
well
establish
drug
mean
mannich
reaction
view
improv
biolog
activ
mannich
reaction
earn
right
place
power
tool
medicin
chemistri
synthesi
novel
chemic
entiti
endow
variou
interest
biolog
properti
modif
physicochem
properti
candid
ultim
influenc
candid
biodispon
perform
pharmacolog
activ
drug
